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Generation	and	Application	of	Antibodies	for	Detection	of	
Prostate	Cancer	Biomarker	
Abstract	
Julia	Zapatero-Rodríguez.	
Prostate	 cancer	 is	 one	 of	 the	 main	 health	 problems	 in	 men–over	 3,300	 new	 cases	 are	
diagnosed	 each	 year	 in	 Ireland	 alone.	 Serum	 Prostate	 Specific	 Antigen	 (PSA)	 is	 the	 main	
biomarker	 used	 to	 aid	 in	 the	 early	 detection	 of	 prostate	 cancer.	 However,	 its	 use	 has	
resulted	 in	 a	 high	 rate	 of	 overdiagnosis	 and	 overtreatment.	 Finding	 alternative,	 more	
sensitive	 and	 specific	 biomarkers/biomarker	 panels	 is	 now	 a	 priority.	 HER2	 is	 a	 promising	
candidate	biomarker	for	this	panel,	as	it	is	related	with	cancer	progression	and	survival.	
This	research	describes	the	construction	of	an	avian-derived	HER2-specific	scFv	library,	from	
which	 highly	 specific	 antibodies	 were	 isolated	 and	 characterised.	 After	 extensive	
optimization	of	assay	conditions,	a	competitive	ELISA	for	HER2	detection	was	developed,	but	
the	 sensitivity	 required	 to	 detect	 HER2	 within	 the	 clinical-relevant	 range	 could	 not	 be	
achieved.	To	circumvent	this,	 fluorescence-based	HER2	detection	was	 investigated,	but	did	
not	 resulted	 in	 an	 improved	 sensitivity.	 Thus,	 an	 electrochemical	 impedance	 spectroscopy	
(EIS)-based	 immunosensor	 was	 designed	 for	 highly	 sensitive	 detection	 of	 HER2.	
Nanomaterial-based	 electrochemical	 detection	 exhibited	 great	 sensitivity	 for	 HER2	 from	
serum	samples,	with	a	LOD	of	0.01	ng/mL.	
‘In-house’-generated	 anti-HER2	 and	 anti-fPSA	 scFv	 antibodies	were	 also	 incorporated	 in	 a	
centrifugal	microfluidic	‘lab-on-a-disc’	platform	for	the	simultaneous	detection	of	a	panel	of	
prostate	cancer	biomarkers.	ELISA-based	detection	of	HER2	and	fPSA	was	demonstrated	on	
a	compact,	automated	and	robust	CD-like	device	that	employs	purely	rotational	fluidic	flow	
control	for	the	entire	assay	protocol,	from	plasma	separation	to	signal	production.	This	work	
provides	an	insight	about	the	potential	of	microfluidic	technologies	for	multi-marker	assay-
based	detection.		
Finally,	the	application	of	a	magneto-immunoassay	for	the	detection	of	fPSA	was	explored	in	
collaboration	with	The	Gwent	Group	Ltd.	Anti-fPSA	scAb	antibodies	were	immobilised	on	
magnetic	beads	for	the	capture	and	easy	separation	of	this	antigen	from	the	sample.	A	
‘proof-of-concept’	amperometric	magneto-immunosensor	for	the	detection	of	fPSA	within	
the	clinical-relevant	ranges	(0.5–10	ng/mL)	was	developed.	
		 1	
Chapter	1	
	
Introduction	
		 2	
1.1	PROSENSE	-	THE	MARIE	CURIE	INITIAL	TRAINING	NETWORK			
In	order	 to	 increase	 the	understanding	of	 the	 clinical	 relevance	of	prostate	 cancer	
biomarkers	 and	 improve	 the	 sensitivity,	 robustness	 and	 speed	 of	 biosensing	
technologies	 for	 the	 simultaneus	 screening	 of	 such	 biomakers,	 the	 European	
Commission	 funded	 a	 new	 initiative	 in	October	 2012,	 	 the	Marie	 Curie	 Sklowdska	
Innovative	 Training	 	 Network	 (ITN)	 “Cancer	 Diagnosis:	 Parallel	 Sensing	 of	 Prostate	
Cancer	Biomarkers”	(PROSENSE).	This	was	an	interdisciplinary	network	with	the	aim	
of	 developing	 improved	 devices	 for	 prostate	 cancer	 diagnosis,	 prognosis	 and	
treatment.	 PROSENSE	 is	 an	 amalgamation	 of	 various	 scientific	 disciplines	 involving	
university	 groups,	 R&D	 sections	 of	 small	 and	 medium	 enterprises,	 research	
institutes,	hospitals	and	the	R&D	section	of	a	large	enterprise	in	the	biomedical	field.	
The	project	is	coordinated	by	Dr.	Pedro	Estrela	from	the	Department	of	Electronic	&	
Electrical	Engineering,	University	of	Bath.	The	multidisciplinary	group	include	teams	
from	the	UK	(University	of	Bath,	Cardiff	University),	Portugal	(INESC-Microsistemas	e	
Nanotecnologias),	Ireland	(School	of	Biotechnology,	Dublin	City	University),	Germany	
(University	 of	 Applied	 Sciences	 Kaiserslautern),	 Slovakia	 (Institute	 of	 Chemistry,	
Slovak	 Academy	 of	 Sciences),	 Switzerland	 (Integrated	 Systems	 Laboratory,	 École	
Polytechnique	 Fédérale	 De	 Lausanne).	 PROSENSE	 involves	 two	 SMEs	 (Applied	
Enzyme	 Technology	 Ltd.,	 UK	 and	 Xeptagen	 Ltd.,	 Italy)	 and	 one	 big	 company	
(Euroimmun,	 Germany).	 The	 associated	 members	 are	 the	 University	 Hospital	 of	
Wales,	Bristol	Urological	 Institute,	Royal	United	Hospital	Bath,	Avacta	Life	Sciences	
(UK),	and	the	University	of	the	West	of	England	(Faculty	of	Health	and	Life	Sciences	
and	Institute	of	Bio-Sensing	Technology).		
	
The	 focus	 area	 in	 my	 project	 (Early-stage	 researcher	 3	 [ESR3]:	 Generation	 and	
applications	 of	 antibodies	 to	 biomarkers	 of	 prostate	 cancer)	 includes	 the		
development	and	study	of	potential	prostate	cancer	biomarkers	and	generation	of	
highly-specific	 recombinant	 antibodies	 to	 these	 biomarkers.	 As	 part	 of	 PROSENSE	
ITN	 requirements,	 I	 visited	 other	 host	 organisations	 for	 secondments	 or	 training	
workshops	and	I	established	collaborations	with	multiple	fellows	within	the	network.		
		 3	
1.2	THESIS	SUMMARY	
	
The	clinical	utility	of	current	prostate	specific	antigen	(PSA)	tests	for	prostate	cancer	
diagnosis	 is	 severely	 limited.	 It	 is	 commonly	agreed	 that,	due	 to	 the	 complexity	of	
prostate	cancer,	a	single	biomarker	may	be	insufficient	for	early	diagnosis.		
	
This	thesis	describes	the	generation,	characterisation	and	application	of	recombinant	
antibodies	to	prostate	cancer	biomarkers	for	improved	diagnosis	of	prostate	cancer.	
In	 this	 study,	 the	construction	of	a	 single-chain	antibody	 fragment	 (scFv)	 library	 to	
HER2,	 a	 potential	 prostate	 cancer	 biomarker,	 is	 described.	 The	 applications	 of	
recombinant	 antibodies	 to	 PSA	 (scAb)	 and	 HER2	 (scFv)	 in	 impedimetric	 and	
amperometric	 biosensors	 and	 in	 a	 microfluidic	 ‘lab-on-a-disc’	 device	 are	 also	
investigated.	 General	 approaches	 for	 recombinant	 antibody	 generation	 are	
described	 in	 detail	 and	 different	 examples	 for	 their	 use	 in	 biosensors	 are	
demonstrated.	
	
1.3	INTRODUCTION	TO	PROSTATE	CANCER			
	
The	 prostate	 is	 a	 small	 exocrine	 gland	 in	 the	 reproductive	 system	 in	 men	 that	
secretes	 prostatic	 fluid,	 which	 accounts	 for	 30	%	 of	 the	 semen	 fluid	 (which	 also	
contains	seminal	 fluid	and	spermatozoa)	 (Lilja	et	al.,	1989).	The	prostate	 is	 located	
beneath	the	bladder	and	surrounds	the	urethra,	the	duct	that	connects	the	bladder	
to	the	urinary	meatus	and	conducts	urine	and	semen	outside	the	body	(Rizzo,	2015).		
Prostate	cancer	(PCa)	is	the	most	commonly	diagnosed	cancer	in	men	in	Europe	and	
the	 third	 most	 frequent	 cancer	 in	 the	 entire	 European	 population	 (Ferlay	 et	 al.	
2013).	More	than	90	%	of	prostate	cancers	are	acinar	adenocarcinomas,	where	the	
tumour	 arises	 from	 the	 secretory	 prostatic	 acinar	 cells.	 Prostate	 cancer	 can	 be	
detected	at	early	stages	by	digital	rectal	examination	(DRE)	or	PSA	test	(Heidenreich	
et	 al.,	 2011),	 although	 controversy	 has	 arisen	 related	 to	 the	 low	 specificty	 of	 this	
biomarker.	During	 the	DRE	a	doctor	 inserts	a	gloved	 finger	 into	 the	 rectum	to	 feel	
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the	 prostate	 surface	 for	 swelling,	 harder	 areas	 or	 lumps	 that	 can	 indicate	 the	
presence	of	a	 tumour.	PSA	blood	test	measures	 the	 levels	of	 this	protein	 in	blood.	
PSA	 levels	under	4	ng/mL	are	considered	 ‘normal’,	 levels	between	4	and	10	ng/mL	
are	considered	 ‘intermediate’	 (within	 the	diagnostic	 ‘grey	zone’,	 in	which	cancer	 is	
present	 in	25	%	of	patients)	and	PSA	levels	over	10	ng/mL	are	considered	‘high’	(in	
which	 50	%	 of	 the	 patients	 will	 have	 advanced	 disease)	 (Catalona	 et	 al.,	 1994;	
Ezenwa	 et	 al.,	 2012).	 DRE	 and	 PSA	 test	 are	 only	 indicators	 of	 cancer	 risk	 and	 if	
abnormal	 results	 are	 obtained	 in	 these	 tests,	 a	 biopsy	 is	 often	 recommended	 to	
examine	 prostate	 tissue	 samples	 for	 cancer	 cells.	 If	 cancer	 cells	 are	 present,	 the	
pathologist	 will	 assign	 a	 Gleason	 score–on	 a	 scale	 of	 2	 to	 10–based	 on	 the	
appearance	of	cancer	cells	compared	to	normal	cells,	to	help	evaluate	the	prognosis	
of	patients	with	prostate	cancer	(Table	1.1).		
Staging	of	 prostate	 cancer	provides	 information	about	 the	extent	of	 the	 cancer	 to	
help	medical	personnel	predict	prognosis	and	decide	how	it	should	be	treated.	The	
most	widely	used	staging	system	is	the	American	Joint	Committee	on	Cancer	(AJCC)	
TNM	(tumour,	 lymph	node,	metastasis)	 system	 (Table	1.1).	 	Overall	 staging	can	be	
achieved	by	combining	the	TNM	status,	with	the	Gleason	score	and	PSA	level	(Table	
1.1)	as	described	in	Table	1.2	(Harisinghani	et	al.,	2003).	
The	 majority	 of	 prostate	 cancers	 are	 slow	 growing	 and	 organ-confined,	 and	 the	
relative	5-year	survival	rate	(based	on	patients	diagnosed	more	than	5	years	ago)	is	
98.8	%,	 according	 with	 the	 SEER	 (surveillance,	 epidemiology,	 and	 end	 results)	
program	 2005-2011	 (Howlader	 et	 al.,	 2015).	 This	 is	 the	 reason	 why	 active	
surveillance	(regular	monitoring	of	the	disease)	is	a	viable	treatment	option	for	men	
with	 low-risk,	 low-stage	 prostate	 cancer.	 Other	 treatment	 options	 include	
prostatectomy	 (surgery	 to	 remove	 the	 prostate	 gland),	 androgen-deprivation	
therapy	(to	stop	the	release	of	testosterone,	which	promotes	the	growth	of	prostate	
cells),	radiotherapy	or	chemotherapy	(Heidenreich	et	al.,	2011).	
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Table	1.1	Prostate	cancer	staging	factors	in	clinical	practice.	Taken	from	Sharma	et	al.,	2016.		
Staging	strategy	 Factor	to	be	
considered	
Classification	 Description	
TNM	staging	 Extent	of	
primary	
tumour	(T)	
TX	 Primary	tumour	not	assessed.	
T1	(a–c)	 Clinically	insignificant	(it	cannot	be	felt	
during	DRE	or	seen	on	scans	(e.g.	TRUS).	
T2	(a–c)	 Tumour	confined	to	the	prostate	gland.	
T3	(a–b)	 Tumour	spreads	outside	the	prostate	
(may	invade	seminal	vesicles).	
T4	 Extra-prostatic	growth	of	the	tumour	
into	tissues	other	than	seminal	vesicles.	
Spread	of	the	
tumour	to	
regional	lymph	
nodes	(N)	
NX	 Nearby	lymph	nodes	not	assessed.	
N0	 Tumour	has	not	spread	to	regional	
lymph	nodes.	
N1	 Tumour	has	spread	to	regional	lymph	
nodes.	
Distant	
metastasis	(M)	
PM1c	 More	than	one	site	of	metastasis	
present.	
MX	 Distant	metastasis	not	assessed	
M0	 Absence	of	distant	metastasis.	
M1	(a–c)	 Presence	of	distant	metastasis.	
Histopathologic	
grading	
Microscopic	
appearance	of	
cancer	cells–	
Gleason	Score	
(G)	
G	2–4:	lowly	
aggressive	
G	5–6:	mildly	
aggressive	
G	7:	moderately	
aggressive	
G	8–10:	highly	
aggressive	
Gleason	Grade	varies	from	1	to	5,	from	
well-differentiated	cells	to	poorly	
differentiated	cells	(marked	anaplasia).	
To	obtain	Gleason	Score,	the	most	
common	grade	(primary	grade)	and	the	
second	most	prominent	grade	
(secondary	grade)	found	in	a	biopsy	are	
added	together,	resulting	in	a	number	
between	2	and	10.	
PSA	levels	 PSA	at	
diagnosis	
<4	ng/mL	 ‘Normal’	PSA	serum	concentration	
4–10	ng/mL	 Diagnostic	‘grey	zone’.	%	fPSA	test	
recommended.	
>10ng/mL	 High	probability	of	prostate	cancer.	
Biopsy	recommended.	
DRE–Digital	rectal	examination;	fPSA–free	Prostate	Specific	Antigen;	TRUS–transrectal	ultrasound.	
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Table	 1.2	 Prostate	 cancer	 can	 be	 grouped	 in	 four	 stages	 combining	 the	 TNM	 system,	 the	 Gleason	
Score	and	the	PSA	levels.	Taken	from	Sharma	et	al.,	2016.	
	
Stage	 T	 N	 M	 Gleason	score	 PSA	(ng/mL)	
I	
T1	 N0	 M0	 ≤6	 ≤10	
T2a	 N0	 M0	 ≤6	 ≤10	
IIa	
T1	 N0	 M0	 =7	 <20	
T1	 N0	 M0	 ≤6	 10–20	
T2	(a/b)	 N0	 M0	 ≤7	 <20	
IIb	
T2c	 N0	 M0	 Any	 Any	
T1/T2	 N0	 M0	 Any	 ≥20	
T1/T2	 N0	 M0	 ≥8	 Any	
III	 T3	 N0	 M0	 Any	 Any	
IV	
T4	 N0	 M0	 Any	 Any	
Any	 N1	 M0	 Any	 Any	
Any	 Any	 M1	 Any	 Any	
												T–Tumour;	N–Node	;	M–Metastasis.	
	
1.4	BIOMARKERS	FOR	PROSTATE	CANCER	DIAGNOSIS:	LIMITATIONS	OF	SERUM	
PSA	AND	THE	SEARCH	FOR	NEW	BIOMARKERS	
	
The	 use	 of	 biomarkers	 for	 the	 diagnosis	 of	 prostate	 cancer	 has	 led	 to	 earlier	
detection	of	 the	disease.	PSA,	a	member	of	 the	kallikrein-related	peptidase	 family,	
(kallikrein-3),	 synthesized	 by	 the	 prostate	 tissue,	was	 the	 gold-standard	 biomarker	
for	the	detection	of	prostate	cancer	for	nearly	two	decades.	However,	PSA	screening	
has	 led	 to	 a	 high	 rate	 of	 over-diagnosis	 resulting	 in	 men	 with	 indolent	 disease	
undergoing	 unnecessary	 treatment	 (Etzioni	 et	 al.,	 2002)	 which	 is	 frequently	
accompanied	 by	 patient	 anxiety	 and	 side-effects	 such	 as	 erectile	 dysfunction	 or	
urinary	incontinence	(Mirza	et	al.	2011).	
	
Additionally,	 PSA	 is	 not	 specific	 to	 prostate	 cancer.	 It	 may	 also	 be	 present	 in	
increased	amounts	in	prostate	conditions	such	as	benign	prostatic	hyperplasia	(BPH),	
prostatic	intraepithelial	neoplasia	(PIN),	prostatitis	and	prostatic	infarction.	In	these	
conditions,	a	significant	increase	in	serum	PSA	is	observed	relative	to	the	normal	low	
levels	found	in	healthy	individuals	and,	consequently,	patients	with	high	serum	PSA	
levels	 do	 not	 necessarily	 suffer	 from	 prostate	 cancer.	 Furthermore,	 PSA	 levels	
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increase	with	age	and	vary	among	ethnic	groups	(Lilja	et	al.,	2008).	In	addition,	this	
biomarker	has	minimal	predictive	ability	 to	differentiate	prostate	cancer	 from	BPH	
and	to	determine	the	Gleason	score	and	cancer	stage	(Fan	et	al.,	2011).	Attempts	to	
increase	the	specificity	and	sensitivity	of	PSA	assays	by	using	different	PSA	isoforms	
(e.g.	 pro-PSA,	 free	 PSA	 and	 complex	 PSA)	 and	 altered	 PSA	 glycosylation	 patterns	
(discussed	in	Section	1.4.2)	have	considerably	improved	the	accuracy	of	PSA	testing.	
However,	this	has	not	solved	the	problem	of	distinguishing	between	significant	and	
insignificant	disease	(Gilgunn	et	al.,	2013).	In	2012,	the	U.S.	Preventive	Services	Task	
Force	(USPSTF)	published	a	recommendation	against	the	use	of	PSA	for	screening	of	
prostate	cancer,	considering	that	the	benefits	(early	detection,	which	can	avoid	0-1	
deaths	cancer	deaths	per	1000	men	screened)	do	not	outweigh	the	harms	(negative	
psychological	effects,	unnecessary	biopsies	or	overtreatment)		(Moyer	et	al.,	2012).	
Therefore,	 new	 diagnostic	 tools	 are	 required.	 For	 clinical	 diagnosis,	 non-invasive	
techniques	 using	 either	 serum	 or	 urine	 markers	 would	 be	 most	 suitable.	 These	
biological	 matrices	 should	 be	 focussed	 on	 to	 identify	 new,	 more	 sensitive	 and	
specific	biomarkers.	According	with	the	FDA	(U.S.	Food	and	Drug	Administration),	an	
ideal	biomarker	 should	be	 specific,	 sensitive,	quantifiable,	predictive	and	 robust.	A	
biomarker	should	also	bridge	pre-clinical	and	clinical	trials	and	be	easily	accesible	by	
non-invasive	 methods	 (Karley	 et	 al.,	 2011).	 Unfortunately,	 to	 date,	 no	 ideal	
biomarker	for	prostate	cancer	has	been	discovered.	
	
1.4.1	Candidate	protein	biomarkers	for	prostate	cancer		
A	wide	variety	of	potential	prostate	cancer	biomarkers	have	been	discovered	thanks	
to	advances	 in	proteomic	and	genomic	technologies.	Different	 types	of	biomarkers	
have	 been	 proposed,	 including	 genetic	 and	 protein	 markers,	 circulating	 miRNAs,	
autoantibodies	 (Figure	 1.1),	 microparticles	 (exosomes	 and	 prostasomes)	 and	
circulating	 tumour	 cells	 (CTCs).	 Among	 all	 of	 these,	 protein	 biomarkers	 have	 been	
widely	 researched	because	 they	 are	 abundant	 and	easily	 accessible	 in	body	 fluids.	
Table	 1.3	 summarizes	 some	 proposed	 biomarkers	 from	 the	 literature	 that	 could	
potentially	be	used	in	conjunction	with	PSA	for	diagnosis	and	monitoring	of	PCa.		
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Table	1.3.	Selected	prostate	cancer	protein	biomarkers.			
	
Biomarker	 Source	 Sensitivity	&	Specificity		(*)	
Correlation	with:				
G.S./		Bad		
prognosis	
Distinguish	
BPH	from	
PCa	
Reference	
PSA	 S	
Sensitivity:	24	%	
Specificity:	93	%	(PSA	
level	<	4	ng/ml)	
	N		 N	 N	 Lilja	et	al.	(2008)	
Hk2	 S	
Specificity:	13.7	%	(0.029	
ng/ml	cut-off)	Sensitivity:	
9	%	(0.245	ng/ml	cut-off)	
N	
	
Y	(if	
combined	
with	%	
fPSA)	
Y	(if	
combined	
with	%	
fPSA)	
Raaijmakers	
et	al.		(2007)	
PSMA	 S	 Sensitivity:	65.9	%	Specificity:	94.5	%	 UN	 Y	 Y	
Mhawech-
Fauceglia	et	
al.		(2007)	
EN-2	 U	
Sensitivity:	66	%		
Specificity:	88.2	%		(42.5	
ng/ml	cut-off)	
UN	 Y	 Y	 Morgan	et	al.		(2011)	
PRKC-ζ	 S	 PRKC-ζ-PrC	specific	for	PCa	 Y	 Y	
Y	(PKC-ζ-a	
and	PKC-ζ-
PrC)	
Yao	et	al.		
(2012)	
Her-2/neu	 S	 Low	specificity	(undefined)	 N	 Y	 N	
Ricciardelli		
et	al.		(2008)	
Topo2A	 S	 Low	specificity	(undefined)	 Y	 Y	 Y	
Willman	et	
al.		(2000)	
Mcm5	 U	 Sensitivity:	82	%	Specificity:	73-93	%	
Y	
	 N	 Y	
Dudderidge	
et	al.		(2010)	
ANXA3	 U	
Sensitivity:	50	%	
Specificity:	90	%				
(AUROC	of	0.755)	
Y	 Y	 Y	 Schostak	et	al.		(2009)	
MSP	 P/	SF	 Unknown	 N	 Y	 Y	 Bjartell	et	al.		(2009)	
Cav-1	 S	 High	sensitivity	and	specificity	(undefined)	 Y	 Y	 Y	
Corn	et	al.		
(2010)	
AMACR	 U/S	
Sensitivity:	70	%	
Specificity:	71	%										
(10.7	ng/ml	cut-off)	
N	 N	 Y	 Ouyang	et	al.		(2009)	
(*)	 In	 some	cases,	 sensitivity	and	specificity	as	 reported	by	 individual	 studies.	PSA–Prostate	specific	
antigen;	Hk2–Human	kallikrein	related	peptidase	2;	PSMA–Prostate	Specific	Membrane	Antigen;	EN-
2–Engrailed-2;	 PRKC-ζ–Protein	 kinase	 C-	 zeta;	 Her-2/neu–Receptor	 tyrosine-protein	 kinase	 erbB-2;	
Topo2A–DNA	 topoisomerase	 II-alpha;	 Mcm5–Minichromosome	 maintenance	 protein	 5;	 ANXA3–
Annexin	A3;	MSP–β-microseminoprotein;	Cav-1–Caveolin	1;	AMACR–alpha-methylacyl-CoA	racemase;	
EPCA–Early	 prostate	 cancer	 antigen;	 S–serum;	 U–Urine;	 P–plasma;	 SF–Seminal	 Fluid;	 N–No;	 Y–Yes;	
UN–Unknown;	G.S.–Gleason	Score;	BPH–Benign	prostatic	hyperplasia.		
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Further	investigation	of	the	complementarity	and	clinical	use	of	these	biomarkers	is	
needed	in	order	to	assemble	a	panel	of	biomarkers	with	the	necessary	performance	
characteristics	suitable	for	clinical	implementation.		
	
1.4.2	Next	generation	diagnostic	tools	for	Prostate	Cancer			
In	recent	years,	efforts	have	been	made	to	validate	biomarker	panels	with	associated	
use	of	appropriate	statistical	models	to	predict	high-risk	prostate	cancer	in	order	to	
avoid	unnecessary	biopsies	(Figure	1.1).	For	example,	the	4Kscore®	test	(OPKO	Lab,	
Nashville,	 TN)	 involves	 measurements	 of	 the	 plasma	 levels	 of	 a	 panel	 of	 four	
kallikrein	protein	biomarkers	(free	PSA,	intact	PSA,	total	PSA	and	hk2)	in	conjunction	
with	 collection	 of	 other	 clinical	 information	 (age,	 DRE	 and	 prior	 biopsy	 results).	
Furthermore,	 an	 algorithm	 is	 used	 to	predict	 risk	 (in	 terms	of	 probability)	 of	 high-
grade	 (Gleason	score	7	or	higher)	cancer	on	biopsy	 (Punnen	et	al.,	2015).	This	 test	
allows	for	individual	risk	prediction	to	aid	decisions	on	whether	or	not	to	perform	a	
prostate	biopsy.	Similarly,	the	biopsy-based	ProMark	(Metamark	Genetics)	prognosis	
test	uses	an	eight-protein	signature	(DEL2L1,	CUL2,	SMAD4,	PDSS2,	HSPA,	FUS,	pS6	
and	 YBOX1)	 for	 risk	 stratification	 in	 prostate	 cancer.	 Cutting-edge	 automated	
immunofluorescence	imaging	technology	allows	the	in	situ	measurement	of	multiple	
biomarkers	 in	 the	 ‘region	 of	 interest’	 (where	 these	 biomarkers	 are	 known	 to	 be	
altered	 as	 a	 result	 of	 prostate	 cancer)	 on	 tissue	 sections	 (Grönberg	 et	 al.,	 2015).	
Prostarix	(Metabolon	Inc.)	is	a	liquid	chromatography-mass	spectroscopy-based	test	
that	evaluates	 four	metabolites	 (sarcosine,	alanine,	glutamate	and	glycine)	 in	post-
DRE	urine.	The	test	allows	for	risk	stratification	and	aid	 in	the	decision	of	biopsy	 in	
patients	within	the	diagnostic	 ‘grey	zone’	 (PSA	values	2.5–10	ng/mL	and	suspicious	
DRE)	and	also	of	 re-biopsy	 in	men	with	prior	negative	biopsy	 (Sartori	et	al.,	2014).	
OurView	 Prognostic	 Panel	 (OPPP,	 from	OURLab)	 examines	 prostate	 cancer-related	
clinical	 (PSA,	 age,	 clinical	 stage	 and	 biopsy	 report),	morphological	 (Gleason	 grade)	
and	 biomolecular	 (PTEN,	 Ki67	 and	 DNA	 ploidy)	 factors	 in	 biopsy	 samples.	 OPPP	
scores	under	50	are	characteristic	of	less	aggressive	tumours	(Murphy	et	al.,	2015).	
Stockholm	3	(STHLM3)	is	a	recent	study	that	 incorporates	a	combination	of	plasma	
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protein	 biomarkers	 (PSA,	 intact	 PSA,	 free	 PSA,	 hk2,	 MSMB	 and	 MIC1),	 single	
nucleotide	polymorphisms	(232	SNP),	clinical	variables	and	prostate	examination	in	a	
multiple	 logistic	 regression	 model	 for	 the	 identification	 of	 clinically	 significant	
cancers.	The	STHLM3	model	has	shown	utility	in	the	detection	of	high-grade	cancer	
in	men	with	 low	PSA	levels	(1–3	ng/mL)	and	has	the	potential	of	reducing	prostate	
biopsies	by	one	third,	compared	with	PSA	screening	(Grönberg	et	al.,	2015).	
	
Genomic	 and	 transcriptome-based	 markers	 are	 also	 gaining	 prominence.	 The	
Oncotype	 DX	 Prostate	 Cancer	 Assay	 (Genomic	 Health,	 Inc.),	 a	 RT-PCR	 assay	 that	
measures	 a	 17-gene	 ‘signature’	 in	 prostate	 needle	 biopsies,	 provides	 information	
about	the	aggressiveness	of	recently	diagnosed	early-stage	prostate	cancer.	The	17-
gene	 panel	 includes	 genes	 involved	 in	 four	 tumorigenesis-related	 pathways:	 the	
androgen	pathway	(AZGP1,	KLK2,	SRD5A2,	and	FAM13C),	cellular	organization	(FLNC,	
GSN,	TPM2,	GSTM2),	stromal	response	(BGN,	COL1A1,	and	SFRP4)	and	proliferation	
(TPX2),	and	five	reference	genes.	Using	this	assay,	the	Genomic	Prostate	Score	(GPS)	
algorithm	 can	 be	 calculated	 to	 identify	 patients	 that	 can	 benefit	 from	 active	
surveillance	 (Knezevic	 et	 al.,	 2013).	 Also,	 for	 measuring	 prostate	 cancer	
aggressiveness,	the	Prolaris	test	analyses	the	activity	of	cell	cycle	progression	(CCP)	
genes	 in	 prostate	 cancer	 biopsy	 samples.	 The	 CCP	 score	 is	 calculated	 from	 the	
expression	levels	of	31	genes	to	predict	cancer	death	outcome	in	men	with	clinically	
localised	disease.	The	evidence	suggests	that	the	CCP	score	can	be	a	valuable	tool	to	
decide	treatment	options	and	has	the	potential	of	 reducing	the	number	of	surgery	
interventions	(Sommariva	et	al.,	2016).	The	Prostate	Core	Mitomic	Test	(MDNA	Life	
Sciences)	uses	a	different	approach	to	 find	cancer	 in	prostate	needle	core	samples	
from	negative	biopsies:	based	on	mitochondrial	DNA	(mtDNA)	deletions,	it	is	able	to	
identify	 malignant	 cells	 in	 appearing	 potential	 normal	 tissue	 (Parr	 et	 al.,	 2013;	
Kaisary	 et	 al.,	 2016),	 which	 could	 reduce	 the	 sampling	 error	 of	 prostate	 biopsies.	
Cancer-specific	epigenetic	status	of	prostate	cancer	gene	biomarkers	can	also	help	to	
detect	 prostate	 cancer.	 The	 Confirm	 MDx	 assay	 (MdxHealth)	 uses	 epigenetic	
multiplex	PCR	to	detect	aberrant	methylation	in	promoter	regions	of	GSTP1,	ACT	and	
RASSF1	 genes	 in	 biopsy	 specimens.	 This	 test	 has	 shown	 a	 sensitivity	 of	 68	%,	
specificity	of	64	%,	and	a	NPV	of	90	%	to	confirm	the	absence	of	cancer	in	men	with	
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suspicion	of	cancer	but	initial	negative	biopsy	(Stewart	et	al.,	2013).	This	proves	the	
utility	of	Confirm	MDx	assay	to	detect	occult	prostate	cancer	and	reduce	the	rate	of	
repeated	 biopsies	 (Wojno	 et	 al.,	 2014;	 Shindel,	 2016).	 Prosta	 Vysion	 (Bostwick	
Laboratories)	 is	 a	 panel	 of	 genetic	 biomarkers	 involved	 in	 prostate	 carcinogenesis:	
gene	fusion/translocation	analysis	of	 the	ERG	protein	and	the	 loss	of	PTEN	tumour	
suppressor	 gene.	 The	 Prosta	 Vysion	 Score	 provides	 information	 about	 the	
aggressiveness	and	prognosis	of	prostate	cancer	(Bostwick	Laboratories,	2011).		
	
Figure	 1.1.	 	 Commercial	 tests	 for	 the	management	 of	 prostate	 cancer,	 classified	 according	 to	 the	
clinical	application:	diagnostic	tests	to	aid	with	biopsy	recommendations	and	prognosis	tests	to	allow	
risk	 stratification	 following	 a	 positive	 biopsy	 result.	 Red:	 blood	 sample;	Green:	 urine	 sample;	Grey:	
tissue	sample.	Adapted	from	Murphy	et	al.	(2015).	
	
	
In	addition	to	this,	a	few	diagnostic	approaches	based	on	a	combination	of	multiple	
genomic	and/or	protein	biomarkers	have	already	received	FDA	approval	(Table	1.4).	
The	Progensa	PCA3	assay	is	RT-PCR-based	test	uses	PCA3	transcripts	normalised	by	
PSA	mRNA	in	post-DRE	urine	samples	and	it	may	allow	clinicians	to	decide	whether	
or	not	to	repeat	a	biopsy	in	men	with	a	previous	negative	result	(Capoluongo	et	al.,	
2014).	 The	 Prostate	 Health	 Index	 (phi)	 is	 a	 multiple	 biomarker	 immunoassay	 test	
based	 on	 an	 algorithm	 that	 combines	 serum	 total	 PSA,	 free	 PSA	 and	 [-2]	 proPSA.	
According	to	Loeb	and	Catalona	(2013),	PHI	outperforms	conventional	PSA	and	free-
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PSA	tests	and	has	clinical	utility	for	biopsy	decisions,	risk	stratification	and	treatment	
decision-making	(Loeb	et	al.,	2013).	The	Mi-Prostate	Score	(MiPS,	from	University	of	
Michigan	Health	 System)	 risk	model	 combines	 the	 analysis	 of	 T2-ERG	 gene	 fusion,	
PCA3,	and	serum	PSA	for	individualised	prostate	cancer	risk	assessment	(Tomlins	et	
al.,	2015).	
	
Table	1.4.	New	FDA-approved	tests	for	Prostate	Cancer	diagnosis.	
PCA3–Prostate	cancer	antigen	3;	PSA–Prostate	specific	antigen;	fPSA–free	PSA;	p2PSA–[-2]	proPSA;	
T2:ERG–Transmembrane	protease,	serine	2:ETS-related	gene	fusion.			
Another	 approach	 to	detect	 prostate	 cancer	 at	 early	 stages	 is	 taking	 advantage	of	
the	 body’s	 immune	 system.	 Autoantibodies	 (see	 Figure	 1.2)	 against	 a	 number	 of	
tumour-associated	antigens	(TAAs)	have	been	found	in	the	serum	of	prostate	cancer	
patients	 (Cho-Chung,	 2006;	Massoner	 et	 al.,	 2012;	 Ummanni	 et	 al.,	 2015).	 Due	 to	
their	 presence	 following	 any	 perturbation	 in	 the	 cellular	 microenvironment	 (e.g.	
protein	 mutation,	 degradation,	 overexpression	 or	 release	 from	 damaged	 tissue),	
they	 represent	 ideal	 candidates	 for	 early	 detection	 of	 cancer.	 An	 autoantibody	
signature	 in	 prostate	 cancer	 patients	 is	 also	 useful	 for	 the	 identification	 of	 new	
Test		and	FDA	
approval	year	
Biomarker	
and	type	of	
sample	
Potential	use	in	PCa	
diagnosis	 Advantages	 Reference	
Progensa®	
PCA3	Assay,	
2012	
PCA3	and	PSA	
RNA	in	post-
DRE	urine	
samples	
Determine	whether	to	
re-biopsy	previously	
biopsy-negative	
patients	for	prostate	
cancer	or	not.	
Negative	predictive	
value	of	90	%	
Capoluongo	
et	al.		(2014)	
The	Prostate	
Health	Index	
(phi),	2012	
Serum	PSA,	
fPSA	and	
p2PSA	
Identify	biopsy	
candidates	in	men	
older	than	50	with	PSA	
levels	between	4–10	
ng/mL	and	with	no	
suspicion	of	cancer.	
Predicts	clinically	
significant	PCa	
reducing	over-
detection	of	
indolent	PCa.	
Associated	with	
Gleason	Score.	
Sartori	et	al.		
(2014);	
Loeb	et	al.			
(2014)	
Mi-Prostate	
Score	(MiPS),	
2013	
Urine	T2:ERG	
gene	fusion	
and	a	snippet	
from	PCA3	
gene	
combined	
with	PSA	
levels	
Decide	after	PSA	
testing	whether	or	not	
to	monitor	PSA	levels	
or	perform	a	prostate	
biopsy.	
Can	predict	risk	of	
aggressive	PCa.	
T2:ERG	fusion	is	
ultra-specific	for	
PCa	
Young	et	al.		
(2012),	
Tomlins	et	
al.		(2015)	
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biomarkers.	 In	 a	 recent	 study,	 Schipper	 and	 co-workers	 identified	 a	 group	 of	 18	
potential	biomarkers	though	iterative	biopanning	(using	a	T7	phage-peptide	display	
library	derived	from	prostate	cancer	tissue)	against	biopsy	and	serum	samples	form	
healthy	and	prostate	 cancer	patients	 (Schipper	et	al.,	 2015).	 From	 these,	 a	 logistic	
regression	 model	 based	 on	 8	 biomarkers	 was	 developed.	 The	 score	 from	 this	
algorithm	can	be	used	to	identify	the	risk	of	prostate	cancer,	particularly	for	patients	
in	 the	 ‘gray	 zone’	 (Schipper	 et	 al.,	 2015).	 In	 addition	 to	 this,	 glycoprofiling	 of	
biomarkers	could	also	be	helpful	for	the	early	detection	of	prostate	cancer	(Belicky	
and	 Tkac,	 2015).	 Aberrant	 glycosylation	 patterns	 are	 typical	 of	 tumour	 cells	 and	
altered	glycan	structures	 in	PSA	have	been	reported	 in	prostate	cancer	 (Gilgunn	et	
al.,	 2013).	 A	 recent	 publication	 by	 Tkac’s	 group	 described	 the	 development	 of	 a	
lectin-based	 impedimetric	 biosensor	 for	 PSA	 quantification	 (down	 to	 4	 aM)	 and	
glycoprofiling	on	 the	 same	 interface.	Sambucus	 nigra	 (SNA)	 lectin	 (a	 sugar-binding	
protein)	 was	 used	 for	 ‘in-situ’	 glycoprofiling	 of	 PSA	 glycan,	 while	 simultaneously	
detecting	PSA	concentrations	down	to	aM	levels	(Pihíková	et	al.,	2016).	α-2,6-linked	
sialic	acid	 is	 lower	 in	 serum	PSA	 from	prostate	cancer	patients	 in	comparison	with	
BPH,	 while	 α2,3-linked	 sialic	 acid	 is	 more	 abundant	 in	 PSA	 from	 cancer	 patients	
(Meany	 et	 al.,	 2008).	 This	 could	 have	 a	 clinical	 value	 to	 differentiate	 BHP	 from	
prostate	cancer	at	the	time	of	diagnosis.	
	
	
Figure	1.2.	Production	of	autoantibodies	by	plasma	cells	 in	response	to	tumour	associated	antigens	
(TAAs).	Antigen-presenting	cells	(APCs)	take	up	TAAs	from	tumour	cells	and	present	them	to	T-cells.		
This	 results	 in	 the	 activation	 of	 the	 T-helper	 cells	 which	 interact	 with	 B-cells	 stimulating	 their	
maturation	into	plasma	cells	that	produce	autoantibodies	specific	to	the	initially	presented	TAA.				
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Though	PSA-based	testing	is	still	the	standard	practice	to	identify	patients	that	may	
be	 at	 risk	 for	 prostate	 cancer,	 and	 it	 is	 clearly	 evident	 from	 the	 level	 of	 recent	
research	 and	 development	 that	 clinicians,	 scientist	 and	 industries	 have	 a	 strong	
commitment	 towards	 developing	 new	 tools	 for	 better	 management	 of	 prostate	
cancer.	 The	 simultaneous	 detection	 of	 a	 panel	 of	 novel	 biomakers	 in	 a	 multiplex	
platform	may	help	to	answer	critical	clinical	questions	and	generate	novel	and	highly	
specific	 and	 sensitive	 devices	 in	 the	 future.	 A	 panel	 of	 biomarkers	 has	 already	
successfully	been	used	for	early	diagnosis	of	bowel	cancer	by	DCU	scientists	from	the	
Applied	Biochemistry	Group	(founded	by	Prof.	Richard	O’Kenendy),	 in	collaboration	
with	the	Irish	biotech	firm	Randox	(unpublished	data).		
	
1.5	ANTIBODIES	AND	RECOMBINANT	ANTIBODY	TECHNOLOGY	
1.5.1	Introduction	to	the	immune	system		
The	immune	system	is	a	protection	system	designed	to	detect	and	eliminate	foreign	
particles	and	infectious	organisms	that	enter	the	body.	This	defence	mechanism	can	
be	divided	in	two	categories:	innate	and	adaptive	immunity.	Innate	immunity	refers	
to	 non-specific	 mechanisms	 that	 act	 as	 the	 first	 line	 of	 defence	 against	 foreign	
molecules	 (antigen)	and	 include	physical	 (e.g.	 the	skin	or	mucous	membranes)	and	
chemical	 (e.g.	gastric	 juice)	barriers,	as	well	as	 cellular	 (phagocytosis	and	cell	 lysis)	
and	chemical	responses	(inflammation,	fever,	etc.).	The	adaptive	system	differs	from	
the	 innate	system	 in	 the	way	 it	 is	acquired	after	 the	antigen	 is	 first	processed	and	
recognised	 and	 it	 is	 able	 to	 create	 an	 ’immune	 memory‘	 to	 tailor	 an	 enhanced,	
specific	 response	against	 the	antigen	previously	encountered	 (Alberts	et	al.,	2002).	
Adaptive	immunity	is	mediated	by	different	types	of	lymphocytes	(B	cells	and	T	cells)	
that	 carry	 out	 two	 types	 of	 responses:	 antibody	 responses	 and	 cell-mediated	
responses.	 Once	 B-cells	 are	 activated,	 they	 differentiate	 into	 plasma	 cells,	 which	
produce	antibodies	that	are	released	into	the	blood	for	neutralisation	of	viruses	and	
toxins	 and	 marking	 out	 pathogens	 for	 destruction	 by	 phagocytic	 cells.	 In	 cell-
mediated	immune	responses,	activated	T-cells	respond	directly	against	antigens	that	
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are	 displayed	 on	 the	 surface	 of	 a	 host	 cell,	 inducing	 apoptosis	 in	 the	 infected	 cell	
(Alberts	et	al.,	2002).		
	
1.5.2	Antibody	overview	
	
Antibodies	are	soluble	glycoproteins	called	immunoglobulins	(Ig)	secreted	by	plasma	
cells	in	response	to	the	antigen.	The	basic	structure	of	an	immunoglobulin	consists	of	
four	polypeptide	chains–two	 identical	heavy	chains	 (with	a	molecular	weight	of	50	
kDa)	and	two	identical	light	chains	(25	kDa)–held	together	by	disulphide	bonds.	Both	
chains	 contain	 constant	 (C)	 and	 variable	 (V)	 domains.	 In	mammals,	 there	 are	 five	
different	antibody	isotypes,	based	on	the	type	of	heavy	chain	(α,	δ,	ε,	γ	and	μ)	that	is	
found	in	IgA,	IgD,	IgE,	IgG	and	IgM	antibodies,	respectively.	IgG	is	the	most	abundant	
antibody	 class	 found	 in	 serum	 and	 the	 most	 widely	 used	 for	 immune	 library	
construction	 and	 assay	 development.	 The	 basic	 structure	 of	 the	 IgG	 molecule	 is	
outlined	 in	 Figure	 1.3.	 The	 heavy	 (H)	 chain	 has	 a	 variable	 (VH)	 and	 three	 constant	
domains	(CH1,	CH2,	CH3),	while	the	light	(L)	chain	is	composed	of	single	variable	(VL)	
and	constant	 (CL)	domains	 (Conroy	et	al.,	2009).	The	 fragment	crystallisable	 (Fc)	of	
the	 immunoglobulin	 molecule	 is	 composed	 of	 the	 CH2	 and	 CH3	 domains	 and	 it	 is	
responsible	 of	 the	 antibody	 binding	 to	 effector	 molecules	 and	 cells.	 The	 antigen-
binding	 region	 of	 the	 molecule	 consists	 of	 two	 identical	 fragments	 termed	 the	
fragment	antigen-binding	(Fab).	Each	Fab	fragment	is	composed	of	one	constant	and	
one	variable	domain	of	each	of	the	heavy	and	light	chains,	and	each	of	these	variable	
domains	 contains	 three	 complementarity	 determining	 regions	 (CDRs),	 that	 are	
hyper-variable	regions	that	are	crucial	for	the	specific	binding	to	antigens	(Janeway	
et	 al.,	 2001).	 The	 third	 heavy-chain	 CDR	 (CDRH3)	 shows	 the	 greatest	 variation	 in	
terms	 of	 length	 and	 sequence,	 and	 is	 considered	 to	 be	 the	 key	 determinant	 of	
antibody	specificity	(Xu	et	al.,	2000).	
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Figure	1.3.	Basic	structure	of	an	IgG	molecule.	The	disulphide	bridges	are	indicated	by	red	lines.	The	
antigen	 binds	 in	 the	 complementary	 determining	 regions	 (CDRs)	 of	 the	 heavy	 and	 light	 chains.	 CL–	
Constant	light	chain;	CH–Constant	heavy	chain;	VL–Variable	light	chain;	VH–Variable	heavy	chain.	
	
	
1.5.3	Generation	of	avian	recombinant	antibodies	by	phage	display	
1.5.3.1	Recombinant	antibody	fragments		
Understanding	 of	 the	 antibody	 structure	 and	 function	 and	 developments	 in	
molecular	biology	in	the	1990s	made	it	possible	to	amplify	the	heavy	and	light	chain	
variable	domains	 (VH	and	VL)	 genes	of	 IgY	molecules	and	clone	 them	 in	eukaryotic	
expression	 vectors	 (Karu	 et	 al.,	 1995).	 This	 allowed	 the	 soluble	 expression	 of	
antibody	fragments	from	E.	coli.	The	smallest	of	such	fragments	that	retains	antigen-
binding	activity	 is	the	scFv	fragment,	a	fusion	protein	of	the	VH	and	VL	chains	of	the	
antibody,	 connected	 by	 a	 serine-glycine	 linker	 (Figure	 1.4).	 The	 scFv	 format	
possesses	a	number	of	advantages	 such	as	 simplified	antibody	 library	 construction	
and	good	scFv	yields	from	E.	coli.	Over	the	past	few	decades,	recombinant	antibody	
technology	has	allowed	the	generation	of	scFv	and	other	antibody	fragments	from	a	
number	 of	 species,	 including	 mice,	 humans,	 rabbits	 and	 chickens	 (Barbas	 et	 al.,	
2001).	 Chickens	 offer	 certain	 advantages	 for	 the	 production	 of	 immune	 libraries.	
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Avian	immunoglobulin	diversity	is	generated	by	a	single	recombination	event	and	a	
process	 known	 as	 ‘gene	 conversion’.	 Gene	 conversion	 uses	 non-functional	
pseudogenes	 located	upstream	of	the	functional	VH	or	VL	gene	to	translocate	short	
sequences	 into	 the	 variable	 regions	 and	 does	 not	 affect	 the	 N-	 or	 C-terminal	
sequences	of	the	rearranged	gene	segment,	which	means	that	only	two	primer	sets,	
one	for	VH	and	other	for	VL,	are	needed	for	gene	amplification	(Narat,	2003).	Another	
advantage	 of	 using	 chickens	 is	 the	 greater	 phylogenetic	 distance	 from	 humans,	
compared	with	other	commonly	used	lab	mammalian	animals,	resulting	in	a	stronger	
immune	response	to	epitopes	that	are	highly	conserved	in	mammals.	In	addition	to	
this,	 polyclonal	 antibodies	 (IgY)	 can	 be	 extracted	 from	 the	 eggs	 of	 the	 immunized	
chicken	 (Hof	 et	 al.,	 2008).	 Avian	 IgY	 is	 similar	 to	 the	 IgG	 in	mammals,	 although	 it	
contains	an	extra	constant	domain	and	it	is	less	flexible	than	the	IgG	molecule	due	to	
the	absence	of	the	hinge	region	(Narat,	2003).	Figure	1.4	shows	a	representation	of	
the	IgY	molecule	and	some	of	its	recombinant	antibody	formats.		
	
	
	
	
Figure	1.4.		Schematic	structure	of	the	IgY	molecule	and	scFv,	scAb	and	Fab	antibody	fragments.	The	
scFv	 consists	 of	 the	 variable	 heavy	 (VH)	 and	 variable	 light	 (VL)	 domains	 joined	 by	 a	 flexible	 protein	
linker.	The	scAb	(single	chain	antibody	fragment)	has	an	extra	fused	human	kappa	light	chain	constant	
domain	(Ck).	The	Fab	fragment	is	composed	of	one	constant	and	one	variable	domain	of	each	of	the	
heavy	and	light	chains.		
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1.5.3.2	Phage	display	
	
Phage	display	technology	was	first	described	by	Smith	in	1985	(Smith,	1985)	and,	at	
present,	is	the	main	technique	used	for	in	vitro	screening	for	identifying	ligands	that	
recognise	 antigens	 with	 high	 affinity.	 Antigen-specific	 antibody	 fragments	 can	 be	
selected	 from	 phage-displayed	 recombinant	 antibody	 libraries	 generated	 from	
immune	 or	 non-immune	 libraries.	Messenger	 RNA	 (mRNA)	 is	 isolated	 from	B-cells	
(typically	harvested	from	the	spleen	and	bone	marrow	of	an	immunised	animal)	and	
reverse	transcribed	to	complementary	DNA	(cDNA).	The	heavy	and	light	chain	genes	
are	 then	 amplified	 by	 the	 polymerase	 chain	 reaction	 (PCR)	 using	 specific	
oligonucleotide	 primers.	 The	 amplified	 heavy	 and	 light	 chains	 are	 subsequently	
annealed	 together	 (e.g.	 by	 splicing	 by	 overlap	 extension	 PCR)	 to	 construct	 a	
complete	 scFv	 fragment	 that	 is	 ligated	 into	a	phage	display	 vector	 (e.g.	 pComb3X)	
and	 then	 transformed	 into	 E.	 coli	 to	 produce	 a	 phage	 antibody	 library	 of	
approximately	108	independent	E.	coli	transformants.	The	resulting	phage	display	the	
antibody	 as	 a	 fusion	 to	 a	 phage	 coat	 protein,	 usually	 as	 pIII	 (Barbas	 et	 al.	 2001;	
Hammers	et	al.	2014).	
	
Phagemid	 vectors	 are	 filamentous	 phage-derived	 vectors	 containing	 the	 origin	 of	
replication	of	a	plasmid	and	a	phage-derived	origin	of	replication	(also	known	as	the	
major	 intergenic	region).	They	also	contain	an	affinity	tag	to	aid	 in	purification	and	
an	antibody	marker	(ampicillin-resistance	gene)	to	confer	antibiotic	resistance	to	the	
host	cell	upon	 infection	to	allow	selection	and	propagation	of	 infected	E.	coli	cells.	
Phagemids	 usually	 encode	 only	 one	 type	 of	 coat	 protein	 and	 helper	 phage	 are	
required	 to	 complete	 their	 life-cycle	 and	 produce	 new	 phage.	 Helper	 phage	 (e.g.	
VCSM13	 or	 M13K07)	 provide	 the	 phage	 proteins	 and	 enzymes	 required	 for	
replication	 and	 package	 of	 the	 phagemid	 genome.	 In	 addition,	 they	 bear	 an	
independent	 antibody	 marker	 (kanamycin-resistance	 gene)	 that	 favours	 the	
selection	 of	 cells	 co-infected	 with	 helper	 phage.	 Phage	 particles	 displaying	 coat	
protein-fused	antibodies	will	only	be	produced	when	both	the	phagemid	and	helper	
phage	 have	 infected	 the	 bacterial	 cell.	 	 The	 helper	 phage	 genome	has	 a	 defective	
origin	 of	 replication	 so	 that	 the	 resulting	 phage	 particles	 contain	 predominantly	
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phagemid	 DNA	 (Barbas	 et	 al.	 2001).	 The	 physical	 link	 between	 phenotype	 and	
genotype	 in	 phage	 display	 allows	 the	 screening	 of	 phage	 encoding	 target-specific	
antibodies	 from	 large	 phage	 pools	 and	 also	 facilitates	 the	 determination	 of	 the	
nucleotide	 sequence	 of	 the	 scFv	 product	 by	 sequencing	 the	 corresponding	 DNA	
section	from	the	phage	genome	(Crameri	et	al.	1999).	
	
1.5.3.3	Panning	of	phage	display	libraries		
Screening	of	phage	display	libraries	can	be	accomplished	by	a	technique	called	(bio-)	
panning	 (see	 Figure	 1.5).	 Surface	 display	 of	 the	 antibodies	 allows	 the	 affinity	
selection	of	phage	by	applying	the	phage	library	to	an	immobilised	antigen	(on	ELISA	
plates,	 immunoplates	 or	 on	 cells	 or	 microparticle	 surfaces)	 and	 washing	 away	
unbound	phage.	During	each	round,	bound	phage	are	eluted	by	trypsinisation	or	low	
pH	and	amplified	by	replication	in	E.	coli	for	another	round	of	selection.	Enrichment	
of	the	library	can	be	improved	by	panning	under	increasing	stringency	in	each	round,	
for	example,	by	increasing	the	number	of	washing	steps	or	reducing	the	amount	of	
coating	antigen.	Antigen-specific	binders	predominate	after	three	or	four	rounds	of	
panning	(Barbas	et	al.,	2001).	
	 	
Figure	1.5.	Panning	for	selection	of	antibody	fragments	from	phage-display	libraries.	A	phage	library	
displaying	 potential	 scFv	 of	 interest	 is	 exposed	 to	 an	 immobilised	 antigen.	 Unbound	 phages	 are	
washed	 way	 and	 specific-binders	 are	 eluted	 and	 re-amplified	 in	 E.	 coli,	 in	 the	 presence	 of	 helper	
phage.	For	panning	on	immobilised	antigens,	typically	3-6	rounds	of	panning	are	necessary.		
Incuba'on	of	the	phage	library	
with	the	immobilised	an'gen	
Wash	non-binders	and	
unspeciﬁc	binders	
Ampliﬁca'on	of	
speciﬁc-binding	
phages	in	E.coli	
cells	
Elute	speciﬁc-
binding	phage	
Co-infec'on	with	
helper	phage	
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1.5.4	Clinical	applications	of	recombinant	antibody	fragments	
	
Although	full-size	IgG	is	still	the	predominant	monoclonal	antibody	format	used	for	
clinical	 applications,	 many	 antibody	 fragments	 have	 also	 been	 successfully	
introduced	in	the	clinic,	mainly	with	therapeutic	purposes	(Table	1.5).	Fab	fragments	
have	been	the	most	developed	in	the	therapeutic	area,	receiving	FDA	approval	for	a	
variety	of	applications	over	the	last	two	decades.	The	small	size	and	the	lack	of	the	
Fc	region	in	these	antibodies	fragments	are	responsible	for	the	short	serum	half-lives	
and	lack	of	effector	functions	of	these	antibodies.	These	properties	can	be	beneficial	
when	 a	 rapid	 elimination	 of	 the	 antibodies	 from	 blood	 is	 desirable,	 such	 as	 in	
radioimmunotheraphy	 or	 imaging	 applications,	 or	 for	 local	 therapy	 (Chames	 et	 al.	
2009;	Arruebo	et	al.	2011).	
	
ScFv	 fragments	 are	 also	 becoming	 very	 relevant	 in	 the	 biopharmaceutical	 market		
and	 account	 for	 35	%	 of	 antibody	 fragments	 in	 clinical	 trials.	 Applications	 for	 scFv	
fragments	 are	 being	 explored	 in	 the	 fields	 of	 cancer	 therapy,	 neurodegenerative	
diseases,	 in	 vivo	 imaging	 and	 as	 vehicles	 for	 the	delivery	 of	 drugs	 (Monnier	et	 al.,	
2013).	 However,	 some	 challenges	 for	 the	 in	 vivo	 use	 of	 scFv	 still	 need	 to	 be	
overcome–their	 small	 size	makes	 them	 unstable	 and	 compromises	 their	 ability	 to	
concentrate	 at	 the	 target	 site.	 Some	 scFv	 antibodies	 are	 can	 overcome	 these	
limitations,	such	as	Oportuzumab	monatox	(Viventia	Bio	Inc.),	an	anti-epithelial	cell	
adhesion	 molecule	 scFv	 fused	 to	 a	 truncated	 form	 of	 Pseudomonas	 exotoxin	 A,	
which	 is	 undergoing	 phase	 II/III	 clinical	 trials	 for	 bladder	 cancer	 therapeutics.	 The	
intravesical	 administration	 of	 this	 drug	 maximizes	 local	 drug	 concentration,	 while	
limiting	its	systemic	exposure	(Kowalski	et	al.,	2012).	
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Table	1.5.	Example	of	monoclonal	antibody	fragments	with	FDA	approval	for	diagnostic	and	
therapeutic	clinic	use.		Adapted	from	Arruebo	et	al.	(2011).	
Antibody,	trade	
name	and	company	
Type	of	
antibody	 Target	 Function	 FDA	approval	year	
Abciximab	
(ReoPro)	
Centocor	B.V.	
Chimeric	Fab	 Glycoprotein	
(GP)	IIb/IIIa	
receptor	of	
human	
platelets	
Platelet	aggregation	
inhibitor	
1994,	for	prevention	
of	cardiac	ischemic	
complications	
Certolizumab	pegol	
(Cimzia®)	
UCB	
Humanised	
Fab'	
Tumor	
necrosis		
factor	α		
(TNF-α)	
Inhibition	of	
systemic	
inflammation	in	
autoimmune	and	
immune-mediated	
disorders	
2008,	for	treatment	
of	Crohn’s	disease;	
2009,	for	treatment	
of	rheumatoid	
arthritis;	2013,	for	
treatment	of	
psoriatic	arthritis	
and	ankylosing	
spondylitis	
Nofetumomab	
merpentan	
(Verlurma)	
Poniard	
Pharmaceuticals	
Inc.	
MOUSE	Fab	
IgG2b-
merpentan-
99mTc	
40	kDa	
glycoprotein		
Nofetumomab	is	
attached	to	the	
chelator	
merpentan,	which	
links	it	to	the	
radioisotope	
technetium-99m	for	
radio	imaging.	
1996,	for	diagnosis	
of	small	cell	lung	
cancer	
Lucentis	
(ranibizumab)	
Roche	
Humanised	
Fab	
Vascular	
endothelial	
growth	factor	
A	(VEGF-A)	
Inhibition	of	
angiogenesis	and	
leakiness	of	the	
vessels	
2006,	for	the	
treatment	of	Wet	
Age-Related	Macular	
Degeneration;	2010,	
for	the	treatment	of	
macular	edema;	
2015	for	treatment	
of	diabetic	
retinopathy	
ACTEMRA®	
(tocilizumab)	
Genentech	USA,	
Inc.	
Humanised	
Fab	
Interleukin-6	
(IL-6)	
Immunosupresor	 2010,	for	treatment	
of	rheumatoid	
arthritis;	2013	for	
treatment	of	
juvenile	idiopathic	
arthritis	
	
1.6	BIOSENSORS	IN	CANCER	DIAGNOSIS	
1.6.1	Overview	to	biosensors	
	
The	 term	 ‘biosensor’	 refers	 to	 an	 analytical	 device	 that	 converts	 a	 biological	
response	into	an	electrical	signal	that	can	be	amplified,	displayed	and	analysed.	The	
operation	principle	of	a	biosensor	and	its	main	components	are	shown	in	Figure	1.6.		
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Biosensors	 consist	 of	 three	 components:	 a	 bioreceptor	 or	 biorecognition	 element,	
which	recognizes	the	target	analyte;	a	signal	transducer,	that	converts	the	biological	
signal	 into	 an	electric	 signal;	 and	 a	 signal	 processor,	which	 relays	 and	displays	 the	
results	(Bohunicky	et	al.,	2011).		
	
The	specificity	of	a	biosensor	depends	on	the	binding	capabilities	of	the	bioreceptor	
molecule,	whereas	the	sensitivity	depends	on	both	the	recognition	element	and	the	
transducer	used	to	detect	the	biological	signal.	Examples	of	recognition	elements	are	
protein	receptors,	antibodies,	enzymes,	nucleic	acids,	aptamers	and	phage.	Among	
these,	 antibodies,	 DNA,	 aptamers	 and	 phage	 are	 also	 called	 affinity	 recognition	
elements	(Arugula	et	al.,	2014).	Due	to	their	high	affinity,	versatility	and	commercial	
availability,	 antibodies	 have	 been	 the	most	 widely	 used	 affinity-based	 recognition	
elements.	Antibodies	can	be	made	to	be	‘fit-for-purpose’	in	a	particular	assay.	Many	
immunoassays	 use	 labels	 covalently	 attached	 to	 antibodies,	 such	 as	 horseradish	
peroxidase	 (HRP)	 or	 alkaline	 phosphatase	 (AP),	 which	 act	 as	 signal-generating	
molecules.		
	
Analyte	binding	to	the	recognition	element	 leads	to	a	change	 in	optical	properties,	
electric	charge,	mass	or	heat	generation,	which	can	be	detected	and	converted	into	
an	 electrical	 signal	 by	 a	 variety	 of	 transducers.	 	 Transducers	 can	 be	 classified	 into	
four	 major	 categories:	 electrochemical	 (e.g.	 potentiometric,	 amperometric,	
impedimetric),	optical	(e.g.	luminescent,	fluorescent,	colorimetric),	mass-based	(e.g.	
piezoelectric,	 acoustic	 wave,	 magnetoelastic)	 and	 calorimetric	 (heat-based)	
(Bohunicky	et	al.,	2011).	
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Figure	1.6.	Schematic	representation	of	a	biosensor	operating	mechanism.	A	biosensor	consists	of	a	
biological	sensing	element	(that	recognizes	the	analyte	of	interest)	and	a	transducer,	which	translates	
the	biological	response	into	a	quantifiable	and	processable	signal.	Adapted	from	Bohunicky	et	al.	
(2011).	
	
Nanotechnology	 is	having	an	 increasing	 impact	 in	 the	 field	of	biosensors.	 In	 recent	
years,	the	use	of	nanomaterials	(in	scale	from	1	to	100	nm)	for	the	construction	of	
biosensors	has	allowed	 the	 introduction	of	new	 types	of	 transduction	mechanisms	
that	provide	an	improved	sensitivity,	selectivity	or	response	time	(Jena	et	al.,	2008;	
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Filip	 et	 al.,	 2014;	 Spain	 et	 al.,	 2015).	 Carbon	 nanotubes	 (Texeira	 et	 al.,	 2014),	
graphene	 (Tehrani,	 2014),	 quantum	 dots	 (Xia	 et	 al.,	 2015;	 Jenrette	 et	 al.,	 2015),	
nanowires	 and	 nanoparticles	 (Texeira	 et	 al.,	 2014;	 Spain	 et	 al.,	 2015)	 are	 some	
examples	 or	 nanomaterials	 that	 have	 been	 used	 in	 biosensors	 for	 diagnostics	
applications.	
	
1.6.2	Biosensors	for	cancer	detection	
	
Biosensors	are	emerging	as	practical	and	useful	bioanalytical	tools	in	the	diagnostics	
industry.	They	have	the	potential	to	provide	low-cost,	fast	and	accurate	detection	of	
target	analytes	in	biological	fluids,	such	as	blood,	serum	or	urine.	Biosensors	are	also	
good	candidates	for	point-of-care	(POC)	applications,	allowing	rapid	testing	near	the	
site	of	patient	care	(Okafor	et	al.,	2008;	Wilkes	and	Evans,	2014;		Hsieh	et	al,	2015;	).		
	
In	 terms	 of	 cancer	 diagnosis,	 biosensors	 can	 detect	 tumour	 biomarkers,	 providing	
information	 about	 the	 presence	 of	 the	 tumour	 and	 its	 nature	 (whether	 benign	 or	
aggressive).	Given	the	complexity	of	cancer,	multiplex	biosensors	that	can	detect	a	
panel	of	biomarkers	simultaneously	are	particularly	useful	 (Wei	et	al.,	2010;	Lee	et	
al.,	 2015).	 Existing	 clinical	 methods	 to	 detect	 tumor	 markers	 rely	 strongly	 on	
traditional	immunological	methods,	such	as	immunohistochemistry	(IHC)	or	enzyme-
linked	immunosorbent	assay	(ELISA),	which	can	be	highly	sensitive	and	specific,	but	
usually	 require	 specific	 and	 costly	 lab	equipment.	 Furthermore,	 in	most	 cases,	 the	
samples	collected	have	to	be	sent	to	centralized	laboratories	for	analysis	by	qualified	
medical	 staff,	which	 increases	 the	 time	 required	 to	obtain	a	 test	 result	 and	delays	
treatment	decisions.	The	introduction	of	biosensors	into	the	clinic	will	help	to	reduce	
test	costs	and	turnaround	times,	fulfilling	the	need	of	multiplexing	and	point-of-care	
early	diagnosis.			
	
Electrochemical	 biosensors	 have	 been	 demonstrated	 to	 be	 promising	 tools	 for	
pharmaceutical	and	medical	analysis,	examples	of	which	are	the	vastly	commercially	
available	glucose	biosensors	(from	Life	Scan,	Roche	Diagnostics,	Abbott	and	Bayer).	
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They	offer	certain	advantages,	 including	 low-cost	 fabrication	 (Sokolov	et	al.,	2009),	
the	 possibility	 of	 miniaturisation	 (Yang	 and	 Huang,	 2009;	 Lazerges	 et	 al.,	 2013),	
minimal	 power	 requirements,	 and	 suitability	 for	 medical	 implantable	 devices	 and	
point-of-care	applications	(Stingl	et	al.,	2013;	Ghafar-Zahel,	2014;	Sun	et	al.,	2014).	
Electrochemical	 biosensors	 are	 based	 on	 the	 detection	 of	 a	 measurable	 current	
(amperometric),	 potential	 difference	 between	 the	 working	 electrode	 and	 the	
reference	electrode	(potentiometric),	impedance	change	caused	by	a	biorecognition	
process	(impedimetric)	or	(conductometric).	Since	the	present	work	involves	the	use	
of	 recombinant	 antibodies	 as	 recognition	 elements	 in	 amperometric	 and	
impedimetric	biosensors,	these	will	be	described	in	more	detail.	
	
1.6.2.1	Amperometric	biosensors		
The	 first	 biosensors	 developed	 (Clark	 et	 al.,	 1956;	 Updike	 and	 Hicks,	 1967)	 were	
based	on	electrochemical	detection.	Amperometric	biosensors	measure	the	current	
resulting	from	the	oxidation	or	reduction	of	electroactive	materials	in	a	biochemical	
reaction,	when	a	constant	potential	 is	applied	between	two	electrodes	(Grieshaber	
et	al.,	2008).	 In	amperometry,	redox	conversion	of	the	electroactive	species	results	
in	a	succession	of	electron	transfers	that	creates	a	current	flow	(typically	from	nano	
to	micro-amperes)	proportional	to	the	analyte	concentration	that	can	be	measured.	
(Monošík	 et	 al.,	 2012).	 Since	 not	 all	 analytes	 are	 able	 to	 act	 as	 redox	 partners,	
artificial	 electrons	 acceptors	 (mediators)	 can	 be	 used	 for	 direct	 or	 indirect	
transduction	 (Chaubey	 et	 al.,	 2002;	 Grieshaber	 et	 al.,	 2008).	 In	 amperometry,	 the	
current	 is	measured	as	a	 function	of	 time,	providing	 information	about	 the	 rate	at	
which	 electrochemically	 active	 species	 (analyte	 or	mediator)	 are	 being	 oxidised	 or	
reduced	on	the	surface	of	the	electrode	(Rousell	et	al.,	2014).	
	
In	 recent	 years,	 several	 groups	 have	 investigated	 the	 use	 of	 amperometric	
biosensors	for	the	detection	of	cancer	biomarkers.	Sarkar	and	co-workers	developed	
an	immunoassay	for	PSA	detection	on	amperometric	screen-printed	electrodes	with	
a	 LOD	 of	 0.25	 ng/mL	 (Sarkar	 et	 al.,	 2002).	 An	 anti-PSA	monoclonal	 antibody	 was	
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immobilised	on	the	working	electrode	and	a	HRP-labelled	antibody	to	PSA	was	used	
as	tracer.	The	HRP	conjugated	to	the	antibody	catalysed	the	reaction	of	iodine	ions	
with	 the glucose	 oxidase	 (GOx)-generated	 hydrogen	 peroxide,	 so	 the	 resulting	
change	 in	current	was	proportional	 to	 the	concentration	of	PSA.	Similarly,	another	
group	was	able	to	detect	very	 low	concentrations	of	HER2	(26	pg/mL)	from	human	
serum	 and	 cell	 lysates	with	 an	 amperometric	magneto-immunosensor	 based	 on	 a	
sandwich	ELISA		(Eletxigerra	et	al.,	2015).	Carcinoembryonic	Antigen		(CEA)	detection	
for	 colon	 cancer	 diagnostic	 below	 clinically	 relevant	 threshold	 (5	 ng/mL)	 was	 also	
achieved	 by	 amperometric	 detection	 (Laboria	 et	 al.,	 2010).	 In	 this	 case,	 surface	
chemistry	 was	 used	 to	 facilitate	 the	 antibody	 immobilisation	 in	 a	 self-assembled	
monolayer	(SAM).	
		
1.6.2.2	Impedimetric	biosensors	
	
Impedimetric	 biosensors	 measures	 changes	 in	 the	 opposition	 to	 electron	 flow	 (in	
terms	 of	 resistance	 and	 reactance)	 of	 a	 conducting	medium,	 arising	 from	 binding	
events	 (Bahadir	 and	 Sezgintürk,	 2014)	 or	 from	bacterial	metabolic	 redox	 reactions	
(Brosel-Oliu	 et	 al.,	 2015).	 Electrochemical	 impedance	 spectroscopy	 (EIS)	measures	
the	current	 response	to	 the	application	of	an	AC	potential	voltage	as	a	 function	of	
the	 frequency,	 and	 represents	 a	 powerful	 tool	 for	 ‘label-free‘	 detection	 of	
biorecognition	 events,	 such	 as	 antibody-antigen	 interactions	 (Kongsunphol	 et	 al.,	
2014),	or	 for	 the	detection	and	quantification	of	pathogenic	bacteria	 (Wang	et	al.,	
2012;	 Barreiros	 dos	 Santos	 et	 al.,	 2013;	 McPartlin	 and	 O’Kennedy,	 2014).	 EIS	
examines	 the	 electrical	 properties	 at	 the	 biosensor	 surface	 and,	 therefore,	 is	
commonly	 used	 for	 electrode	 surface	 characterisation	 after	 modification,	 layer	
formation	 or	 immobilization	 of	 biorecognition	 elements.	 A	main	 advantage	 of	 EIS,	
compared	 to	 amperometry,	 is	 that	 it	 provides	 non-electroactive	 detection	 of	
molecules	 (ErtuğruL	 and	 Uygun,	 2013).	 However,	 this	 also	means	 that	 EIS	 is	 non-
chemically	 specific	 and	 non-specific	 binding	 on	 the	 electrode	 surface	 can	 also	
produce	 an	 impedimetric	 change.	 Therefore,	 the	 selection	 of	 highly-specific	
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recognition	elements	and	blocking	non-specific	binding	sites	are	essential	(Riquelme	
et	al.,	2016).		
	
Reported	literature	reflects	that	EIS	can	be	used	for	the	detection	of	cancer	cells	and	
biomarkers.		Seven	et	al.	(2013)	developed	a	biosensor	for	the	label-free	detection	of	
MCF-7	breast	cancer	cells	(overexpressing	HER2	on	their	surface)	using	an	anti-HER2	
antibody	 covalently	 grafted	 on	 electro-generated	 polymers	 (Seven	 et	 al.,	 2013).		
Detection	 of	 HeLa	 cervical	 cancer	 cells	 was	 also	 possible	 using	 an	 impedimetric	
biosensor	 based	 on	 PEGylated	 arginine-functionalised	 magnetic	 nanoparticles.	
Funtionalisation	of	the	magnetic	nanoparticles	accelerated	the	electron	transfer	for	
an	enhanced	detection	of	cancer	cells	(LOD	=	10	cells/mL)	(Chandra	et	al.,	2011).	In	
addition,	 several	 groups	have	 shown	 the	utility	of	 impedimetric	biosensors	 for	 the	
detection	of	serum	biomarkers		(Asav	and	Sezgintürk,	2014;	Johari-Ahar	et	al.,	2015;	
Spain	et	al.,	2015;	Jolly	et	al.,	2016).	For	example,	Jolly	and	co-workers	developed	an	
aptamer-based	 imperometric	 biosensor	 for	 PSA	 detection	 using	 thiol-terminated	
sulfo-betamine	 surface	 chemistry	 to	 prevent	 non-specific	 binding	 to	 the	 sensor	
surface	(Jolly	et	al.,	2016).		
	
1.7	MICROFLUIDICS	PLATFORMS	FOR	BIOANALYSIS	
	
Microfluidics	is	a	multidisciplinary	field	that	deals	with	the	design	and	fabrication	of	
systems	 in	 which	 micrometer-sized	 chambers	 and	 tunnels	 are	 used	 for	 the	
manipulation	and	control	of	small	fluids,	ranging	for	10–9	to	10–18	litres	(Whitesides,	
2006).				
	
Microfluidics	technology	became	popular	in	the	early	1990s,	when	the	application	of	
microchannels	 for	 sample	 separation	 for	 the	 minituarisation	 of	 chemical	 sensing	
systems	was	demonstrated	(Manz	et	al.,		1990;	Harrison	et	al.,	1992).	Nowadays,	the	
focus	 of	 microfluidics	 research	 is	 on	 their	 integration	 in	 biosensors	 to	 facilitate	
miniaturisation,	automation,	fast	turn-around	times	and	multiplexing.		
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The	 excitement	 behind	microfluidics	 systems	 for	 biosensing	mainly	 relies	 on	 their	
ability	 to	 integrate	 and	 miniaturise	 complex	 laboratory	 procedures	 onto	 a	 small	
single	chip,	cartridge	or	disc	(Chin	et	al.,	2012).		This	is	the	origin	of	‘lab-on-a-chip’	or	
‘lab-on-a-disc’	 platforms.	 In	 recent	 years,	 microfluidic	 technologies	 have	 been	
successfully	implemented	in	several	of	the	main	bioanalytical	techniques	(Table	1.6),	
including	blood	chemistries	(Nwankire	et	al.,	2014),	immunoassays	(Yu	et	al.,	2015),	
nucleic-acid	 amplification	 tests	 (Mauk	et	 al.,	 2015),	 and	 flow	 cytometry	 (Maleki	et	
al.,	 2012).	 The	 integration	 of	 multiple	 preparative	 and	 analytical	 microfluidic	
technologies	 in	 a	 single	 device	 allows	 the	 use	 of	 unprocessed	 samples	 to	 run	 an	
entire	 assay	 at	 a	 point-of-care	 (POC)	 setting.	 Preconditioning	 of	 samples,	 when	
needed,	is	possible	thanks	to	centrifugation,	which	allows	the	purification	of	plasma	
from	blood,	or	microfluidic	technologies	such	as	an	on-chip	filter	trench	where	blood	
cells	 are	 sedimented	 and	 captured	 (Yager	 et	 al.,	 2006;	 Lee	 et	 al.,	 2011).	 As	
mentioned	 previously,	microfluidic	 systems	 facilitate	 the	miniaturisation	 of	 assays,	
thus	reducing	the	surface-to-volume	ratios,	enhancing	aspects	of	assay	kinetics	and	
allowing	 significant	 reductions	 in	 sample/reagent	 volumes.	 In	 this	 context	 of	
micrometre-sized	 channels,	 sample	 flow	 is	 laminar,	 and	 fluid	 mixing	 needs	 to	 be	
achieved	by	means	other	 than	 traditional	 turbulent	diffusion.	Controlled	 fluid	 flow	
and	 mixing	 is	 essential	 for	 biosensing	 and	 in	 a	 microfluidic	 system	 this	 can	 be	
accomplished	 by	 passive	 methods	 (e.g.,	 by	 lamination,	 use	 of	 specific	 surface	
chemistries	 for	 immobilisation	 of	 reagents,	 minimisation	 of	 non-specific	 binding,	
generation	of	hydrophobic/hydrophilic	regions,	and	by	use	of	specific	geometries	or	
topographies	 of	 channels),	 by	 the	 use	 of	 micro-pumps	 or	 micro-valves,	 or	 by	
applying	an	external	energy	supply	(Lee	et	al.,	2011).	The	ability	of	sacrificial	valves	
to	 create	 vapour	 barriers	 makes	 them	 ideal	 for	 reagent	 storage.	 Traditionally,	
sacrificial	 valves	 required	 external	 actuators	 (e.g.,	 laser	 diodes)	 in	 order	 to	 be	
activated.	The	use	of	all	external	actuators	except	a	spindle	motor	can	be	excluded	
by	using	new	valve	designs,	such	as	dissolvable-film	(DF)	valves	that	dissolve	beyond	
a	critical	rotational	frequency	(Nwankire	et	al.,	2011).	Thus,	centrifugal	microfluidic	
platforms	offer	precise	 fluid	 control	and	only	 require	a	 simple	motor	 for	powering	
the	system	(Hugo	et	al.,	2014).	The	technology	needed	to	drive	the	microfluidic	discs	
is	as	simple	as	that	used	in	CD	players	or	DVD	drivers.	
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In	the	view	of	these	advantages,	the	coupling	of	microfluidics	and	biosensing	offers	
new	 opportunities	 for	 future	 sensors,	 such	 as	 portability,	 low-cost,	 reduced	 assay	
times	and	multiplexing	ability.	
	
1.7.1	Microfluidic-integrated	biosensors	for	diagnostics	
	
At	 the	 moment,	 more	 than	 ninety	 companies	 are	 working	 on	 microfluidic-based	
diagnostics	 worldwide,	 as	 registered	 in	 FluidicMEMs	 database	 (last	 updated:	
February	9,	2016).	The	ultimate	goal	 for	 lab-on-a-chip	devices	 is	 the	 integration	of	
sample	 preparation	 and	 processing	 and	 detection	 techniques	 in	 a	 self-contained,	
disposable	 system.	 One	 of	 the	 strengths	 of	 microfluidics	 is	 that	 they	 are	 able	 to	
produce	sensitive	results	by	detecting	the	signal	produced	in	a	very	small	area	using	
fluorescence	 or	 other	 more	 recently	 implemented	 but	 ultrasensitive	 detection	
methods.	 Electrochemical	 detection,	 in	 particular,	 has	 been	 widely	 explored	 for	
improving	the	sensitivity	and	also	often	the	specificity	of	traditional	tests,	generating	
quantitative	 testing	 due	 to	 the	 use	 of	 portable	 electrochemical	 analysers	 in	 POC	
platforms.	 For	 example,	 the	 i-Stat	 blood	 gas	 analyser	 (Table	 1.6)	 combines	 self-
contained	 cartridges	 with	 microfluidic	 components	 and	 electrochemical	 detection	
(including	amperometry,	 voltammetry,	 and	conductance,	depending	on	 the	 testing	
analyte).	Each	cartridge	contains	a	sample	chamber,	a	calibration	solution,	a	waste	
chamber,	 and	 a	 unique	 combination	 of	 sensors,	 depending	 on	 the	 test.	 i-Stat	
analysers	are	also	battery-powered,	making	its	use	suitable	in	remote	areas	(Sharma	
et	al.,	2016).		
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Table	1.6:	List	of	FDA-approved	microfluidic-based	tests.	Adapted	from	Sharma	et	al.	(2015).		
	
Test	name	and	
company	
Tested	
analyte	
Sample	
required	 Components	
Results	type	and	
turnaround	time	
The	Piccolo®	
(Abaxis)	
Blood	
chemistries		
10µL	of	WB/S/P	 Disposable	test	discs	
and	portable	analyzer	
Quantitative	results	
in	12	min.		
Alere	Triage®	
MeterPro	
(Biosite,	Alere)	
Blood/urine	
chemistries	
including	
“waived”	Lipid	
and	liver	
panels	
225µL	WB/P/U	 Disposable	cartridges,	
and	meter	
Qualitative	results	
in	15-20	min.	
The	epoc®	
Blood	Analysis	
System	(Epocal,	
Alere)	
Blood	
chemistries	
92μL	WB	 Test	cards	and	wireless	
card	reader	with	a	host	
mobile	computer	
Quantitative	results	
in	about	30	sec.		
Simplexa	(Focus	
Dx,		Quest)	
Flu	A/B	&	RSV		 Nasopharyngeal	
swabs	
PCR	platform	(3M™	
Integrated	Cycler)	and	
amplification	discs	with	
sample	wells	
Quantitative	results	
in	1h.	
	
BD	MAXTM,	
GBS	Assay,	IDI-
Strep	B	Assay	
(HandlyLab,	BD) 
Group	B	
Streptococcus	
(GBS)	 
Vaginal/rectal	
swab	samples		
Cepheid	Smart	Cycler®	
RT-PCR	system,	
disposable	cartridge	
and	computer	system	
Qualitative	results	
in	1h.	
i-STAT	Analyser								
(i-STAT	Corp,	
Abbot)	
Blood	
chemistries;	
coagulation;	
cardiac	
markers	
Two	drops	of	
WB	
Handheld	analyser	and	
self-contained	
cartridges	
Quantitative	results	
in	less	than	15	min.	
FilmArray	RP	
(Idaho	
Technologies)	 
Panel	of	
respiratory	
pathogens	
Nasopharyngeal	
swabs	 
FilmArray	instrument	
and	freeze-dried	
reagents	in	pouches	
Qualitative	results.	
2	min		of	hands-on	
time;	about	a	1-h	
turnaround	time	
Proxima				
(Sphere	
Medical)	
Blood		
chemistry	
Arterial	blood	 Disposable	multi-
parameter	
microanalyser,	silicon	
chips	
Quantitative	resluts	
in	approximately	3	
min.		
TearLab	
Osmolarity	
System	
(TearLab)	
Osmolarity	of	
human	tears	
(diagnosis	of	
Dry	Eye	
Disease)	
50nL	of	tear	film	 Disposable	microchip	
works	in	conjunction	
with	a	pen	that	convey	
data	to	the	osmolarity	
reader	
Quantitative	results	
in	seconds	
WB	–	whole	blood;	S	–	Serum;	P	–	Plasma;	U	–	Urine.	
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Much	of	the	research	published	on	microfluidics	 focuses	on	 individual	components	
of	microfluidic	platforms,	such	as	those	needed	for	sample	pre-treatment	(Haeberle	
et	al.,	2006;	Kim	et	al.,	2009;	Wu	et	al.,	2011)	or	reagent	mixing	(Leong	et	al.,	2007;	
Weng	et	al.,	 2009;	Weng	et	al.,	 2011)	and	 those	describing	 integrated	microfluidic	
systems	remain	in	a	proof-of-concept	state	(Hugo	et	al.,	2014;	Tai	et	al.,	2014).	Some	
companies	have,	nevertheless,	managed	to	satisfy	all	 the	criteria	needed	to	 launch	
their	microfluidic-based	platforms	on	the	market.	Table	1.6,	adapted	from	Sharma	et	
al.	(2016)	shows	a	compilation	of	FDA-approved	microfluidics-based	technologies	for	
‘on-site’	tests.	
	
1.7.2	Microfluidics	for	multiplexing	
	
Multiplexed	 assays	 are	 crucial	 in	 the	 field	 of	 diagnostics.	 The	 benefits	 of	 using	
multiplexed	 assays	 include	 improved	 differential	 diagnostic	 of	malignant	 diseases,	
thanks	to	the	use	of	biomarker	panels	(Amonkar	et	al.,	2009;	Biella	et	al.,	2013),	and	
cost-effectiveness,	saving	time	and	reducing	sample	volume	requirements.		
		
Microfluidics	provides	suitable	platforms	for	multiplexing,	facilitating	the	automation	
of	fluid	handling	and	allowing	flow	control	for	the	incorporation	of	sequential	steps.	
For	example,	 the	Optimiser™	technology	platform	(Siloam	biosciences)	provides	an	
alternative	to	conventional	96-well	ELISA	plates.	This	technology	combines	a	typical	
96-well	microtitre	 layout	with	a	microfluidic	 channels	 connected	 to	each	well.	 The	
wells	 of	 the	 Optimiser™	 are	 used	 only	 for	 sample	 loading,	 as	 the	 binding	 events	
occur	 in	 the	 microflufluidic	 channels.	 This	 increases	 the	 surface-area-to-volume	
ratio,	 increasing	 the	 area	 to	 capture	 antibodies	while	 reducing	diffusion	distances,	
improving	 assay	 kinetics.	 Traditional	 washing	 steps	 are	 also	 eliminated–each	
microchannel	 has	 a	 volume	 of	 only	 4.5	 μL,	 so	 the	 addition	 of	 the	 next	 reagent	 in	
assay	step	flushes	unbound	reagents	from	the	microchannels.	Only	a	final	wash	with	
wash	buffer	is	required	before	the	addition	of	substrate	(Kay	et	al.,	2011).	Compared	
to	 conventional	 ELISA	 plates,	 this	 platform	 reduces	 assay	 time	 (13	 minutes	 for	 a	
sandwich	 assay),	 reduces	 sample	 volumes	 (<2	 μL	 per	 data	 point)	 and	 improves	
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sensitivity	 up	 to	 1,000-fold	 (as	 claimed	 by	 manufacturers).	 Luminescence	 or	
fluorescence	detection	can	be	achieved	with	a	conventional	microplate	reader.		
	
Other	diagnostic	companies	have	developed	microfluidic-based	systems	to	perform	
multiplexed	 immunoassay	 blood	 tests	 directly	 at	 the	 point-of-care.	 Some	 of	 the	
disposable	cartridges	for	the	already	mentioned	i-Stat	analyser	(Table	1.6)	allow	for	
multiplex	detection	of	cardiac	troponin	I	(cTnI),	B-type	natriuretic	peptide	(BNP)	and	
creatine	 kinase	 MB	 isoenzyme	 (CK-MB)	 for	 the	 diagnosis	 and	 treatment	 of	
myocardial	 infarction	 (i-STAT	 System	 |	 Abbott	 Point	 of	 Care	 website).	 OPKO	
Diagnostics’	platform	(Opko	website)	also	uses	cartridges	where	different	panels	of	
biomarkers	 can	 be	measured	 from	 blood,	 such	 as	 cardiac	 cTnI,	 BNP	 and	 D-dimer	
(cardio	panel)	or	total	PSA,	free	PSA,	testosterone	and	novel	markers	(PCa	panel).		
	
1.8	AIMS		
While	PSA	has	been	a	well-established	biomarker	 in	clinical	practice,	 its	 limitations	
for	 prostate	 cancer	 diagnosis	 are	well	 known.	 A	 variety	 of	 alternative	 biomarkers,	
including	 different	 PSA	 isoforms,	 has	 been	 proposed	 by	 different	 research	 groups,	
but	 their	 use	 for	 the	 detection	 of	 prostate	 cancer	 is	 still	 unclear.	 	 The	 aim	 of	my	
project	is	to	generate	recombinant	antibodies	against	some	of	these	biomarkers	and	
incorporate	them	in	different	biosensing	platforms	to	elucidate	 if	the	simultaneous	
testing	of	 these	new	biomarkers	with	PSA	 isoforms	can	 improve	current	diagnostic	
approaches.	
	
For	this	purpose,	the	specific	objectives	of	this	work	were:	
	
• The	 generation	 of	 a	 novel	 recombinant	 antibody	 for	 the	 detection	 of	 HER2,	 a	
potential	new	biomarker	for	prostate	cancer.		
• Purification	and	characterisation	of	novel	avian	recombinant	antibody	fragments	
(scFv)	by	ELISA,	SDS-PAGE	and	Western	blotting.	
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• Incorporation	of	 anti-HER2	 scFv	 antibodies	 into	a	highly	 sensitive	 impedimetric	
immunosensor	for	HER2	detection	from	serum	samples.		
• The	 application	 of	 recombinant	 antibodies	 to	 HER2	 and	 free	 PSA	 for	 the	
development	 of	 a	 centrifugal	 microfluidic	 ‘lab-on-disc’	 to	 enable	 simultaneous	
multiplex-analyte	detection.	
• The	 integration	 of	 ‘in-house’	 generated	 anti-fPSA	 scAb	 antibodies	 on	 an	
amperometric	 magneto-immunosensor	 for	 the	 sensitive	 detection	 of	 this	 PSA	
isoform.	
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Chapter	2	
	
Materials	
and		
Methods	
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2.1	MATERIALS	AND	EQUIPMENT	 	
2.1.1	Equipment		
Equipment	name	 Supplier	
Heraeus™	Microcentrifuge	D-37520	with	
#3325	rotor	
DynaMag™-2	Magnet	
Px2	Thermal	Cycler	HBPX2220	
Thermo	Fisher	Scientific	Inc.,	
81	Wyman	Street,	
Waltham,	MA	02451,	USA.	
NanoDropTM	1000	Spectrophotometer		
	
NanoDrop	products,	
3411	Silverside	Rd.,	Bancroft	Building,			
Wilmington,	DE	19810,	USA.	
Tecan	Sunrise™	Microplate	Reader		
Tecan	Safire2™	Microplate	Reader	Infinite™	
200	
Tecan	Safire2™	Microplate	Reader	Group	Ltd.,	
Seestrasse	103,	
CH-8708	Männedorf,	Switzerland.	
Vibra	Cell™	sonicator	 Sonics	and	Materials	Inc.,	
53	Church	Hill	Road,	
Newtown,	CT	06470-1614,	USA.	
Gene	Pulser	Xcell	
PowerPac™	Basic		
Mini-PROTEAN	Tetra	Cell	
DNA	Gel	Apparatus	Bio-Rad	(Wide-Mini-	Sub®	
Cell	GT)		
Gel	Doc™	EZ	System	
Trans-Blot®	SD	Semi-Dry	Transfer	System			
Bio-Rad	Laboratories,	Inc.,	
4000	Alfred	Nobel	Drive,	
Hercules,	CA	94547,	USA.	
Centrifuge	5810	R	with	swing-bucket	rotor	
(A-4-62)	and	fixed-	angle	rotors	(F-45-30-11	
and	F-34-6-38)	
Thermomixer	C	with	Thermoblock	
Eppendorf	House,	
Gateway	1000	Whittle	Way,	
Arlington	Business	Park,	
Stevenage,	SG1	2FP,	UK.	
Spectrafuge™	Mini	Laboratory	Centrifuge	 Labnet	International,	Inc.,	
31	Mayfield	Avenue,	
Edison,	NJ,	08837,	USA.	
Roller	mixer	SRT1	 Scienlab,	Inc.,	
14025	Smith	Rd.,	
Houston,	Texas	77396,	USA.	
Homogeniser	Ultra	Turrax		
	
IKA-Werk	Ultra-Turrax,	
Janke	&	Kunkel-Str.	10.		
79219	Staufen,	Germany.	
Dark	Reader®	Transilluminator	 Clare	Chemical	Research,	Inc.,	
995	Railroad	Ave,	Unit	E,	
Dolores,	CO	81323,	USA.	
Explorer	E11140	in	Digital	Scale	 OHAUS	Corporation,	
7	Campus	Drive,	Suite	310,	
Parsippany,	NJ	07054,	USA.	
HermLe	Z2333	MK-2	refrigerated	centrifuge	 HermLe	Labortechnik	GmbH,	
Siemensstr.	25,	
D-78564	Wehingen,	Germany.	
Autoclave	(60	L)		 Priorclave	Ltd.,	
129-131	Nathan	Way,	
West	Thamesmead	Business	Park,	
London,	SE28	0AB,	UK.	
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Drying	oven	DC125	 Genlab	Limited,	
Tanhouse	Lane,	Riverview	Industrial	Estate,	
Widnes,	Cheshire,	WA8	0SR,UK.	
Sanyo	Orbital	Incubator	 Panasonic	Biomedical	Sales	Europe,	BV,	
9	The	Office	Village,	North	Road,	Loughborough,	
Leicestershire,	LE11	1QJ,	UK.	
Knife-plotter	machine	(Graphtec	CE5000)	 Graphtec	America	Inc.,	
1762	Armstrong	Avenue	Irvine,	
CA	92614-5724,	USA.	
CO2	Laser	Engraver	 Epilog	Laser,	
16371	Table	Mountain	Parkway	Golden,		
CO	80403,	USA.	
Hot	Roll	Laminator		 ChemInstrument,	
510	Commercial	Drive,	
Fairfield,	OH	45014,	USA.	
Electrochemical	workstation	CH604E	 CH	Instruments,	Inc.,	
3700	Tennison	Hill	Drive	
Austin,	TX	7838-5012,	USA	
	
2.1.2	Reagents	
	
All	 reagents	 were	 purchased	 from	 Sigma-Aldrich	 Ireland	 Ltd.,	 Vale	 Road,	 Arklow,	
Wicklow,	Ireland,	unless	otherwise	specified.	
	
Reagent	 Supplier	
GoTaq®	DNA	Polymerase	
1kb	DNA	Ladder	
	Mybio	Ltd.,		
	Kilkenny	Research	&	Innovation	Centre,	
	Saint	Kieran's	College,	College	Road,		
	Kilkenny,	Ireland.	
Deoxynucleotide	(dNTP)	Solution	Mix	 	New	England	BioLabs,	
	240	County	Road,	
	Ipswich,	MA	01938-2723,	USA.	
Primers	 	Integrated	DNA	Technologies,	BVBA,	
	Interleuvenlaan	12A,		
	B-3001	Leuven,	Belgium.	
SfiI	
T4	DNA	ligase	
Antarctic	phosphatase		
	Brennan	&	Company,																															
	61	Birch	Avenue,	Stillorgan	Industrial	Park,																
	Stillorgan	,	Ireland.	
RNA	later	
RNase	zap	
Platinum®	Taq	DNA	Polymerase	
SOC	media	
Helper	phage	
3M	Sodium	Acetate	
SYBR®	Safe	DNA	gel	stain	
	Bio-Sciences	Ltd.,	
	3	Charlemont	Terrace,	Crofton	Road,	
	Dun	Laoghaire,	Ireland.	
	
Kanamycin	
Tretracycline	
Carbenicillin	
Glycerol	
	Fisher	Scientific	Ireland	Ltd.,																	
	Suite	3	Plaza,	212	Blanchardstown,	
	Corporate	Park	2,	Ballycoolin,		
	Dublin	15,	Ireland.	
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Agarose	
Agar	
Dynabeads®	M-280	Tosylactivated	
Pierce™	1-Step	Transfer	Buffer	
	
Tryptone	
Yeast	extract	
	Cruinn	Diagnostics	Ltd.,																												
	Unit	5/6B	Hume	Centre,		
	Parkwest	Industrial	Estate,																			
	Dublin	12,	Ireland.	
	
2.1.3	Bacterial	strains		
Strain	 Supplier	
XL1-Blue	E.coli	
	
	Agilent	Technologies	Ireland,																					
	Euro	House,	Euro	Business	Park,	
	Little	Island,	Cork,	Ireland.	
TOP10F’	chemically	competent	E.coli	 	Bio-Sciences	Ltd.,	
	3	Charlemont	Terrace,	Crofton	Road,	
	Dun	Laoghaire,	Ireland.	
	
2.1.4	Antibodies		
Antibody	 Source	 Supplier	
HRP-labelled	anti-M13		
	
Mouse	
	
	
GE	Healthcare	Life	Sciences,		
Amersham	Place,	Little	Chalfont,	
Buckinghamshire,	HP7	9NA,	UK.	
Anti-HA	high-affinity	 Rat	 	Roche	Diagnostics	Ltd.,	
	Charles	Avenue,	Burgess	Hill,	
	West	Sussex,	RH159RY,	United	Kingdom	
Anti-chicken	IgY-fab-HRP	
	
Donkey	 	Gallus	Immunotech	Inc.,																											
	RR#3,	6570	1st	Line	West	Garafraxa,	
	Fergus,	ON	N1M	2W4,	Canada.	
HRP-labelled	anti-Prostate	Specific	
Antigen	antibody	[5A6]	(ab24466)	
	
Anti-Prostate	Specific	Antigen	
antibody	(ab46976)	
Mouse	
	
	
Rabbit	
	Abcam,	330	Cambridge	Science	Park,	
	Cambridge,	CB4	0F,	UK.		
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2.1.5	Antigens	
	
2.1.6	Commercial	kits		
Kit	 Supplier	
RNeasy	Mini	Kit	 	Qiagen	Ltd.,		
	Skelton	House,	Lloyd	Street	North,	
	Manchester	M15	6SH,	United	Kingdom.	
SuperScript®	II	First-Strand	Synthesis	System	for	RT-
PCR	
	Bio-Sciences	Ltd.,	
	3	Charlemont	Terrace,	Crofton	Road,			
	Dun	Laoghaire,	Ireland.	
NucleoSpin®	Gel	and	PCR	Clean-Up	
NucleoSpin®	Plasmid	
NucleoBond®	Xtra	Midi	
	Macherey-Nagel	GmbH	&	Co.		
	KG	Neumann-	Neander-Straße	6-8	
	52355	Düren	
EggPress	IgY	purification	kit	 	Gallus	Immunotech	Inc.,	
	RR#3,	6570	1st	Line	West	Garafraxa,	
	Fergus,	ON	N1M	2W4,	Canada.	
	
2.1.7	Culture	Media	formulations	
	
Media	 Components	
Luria-	Bertani	Broth	(LB)	 Tryptone	
Yeast	Extract	
NaCl	
Agar	(if	needed)	
10	g/L	
5	g/L	
10	g/L	
15	g/L	
Super	Broth	(SB)	 MOPS	
Tryptone	
Yeast	Extract	
Final	pH:	
10	g/L	
30	g/L	
20	g/L	
7.0	
100X	505	 Glycerol	
Glucose	
diH20	
50	mL	
5	g	
Up	to	100	mL	
1M	MgSO4	 MgSO4	
diH20	
12.37	g	
100	mL	
Antigen	 Source	 Supplier	
Recombinant	human	ERBB2	 Human	cells	 	CD	Biosciences,	Inc.,	
	45-16	Ramsey	Road,																															
	Shirley,	NY	11967,	USA.	
Free	PSA	 Human	
semen	
	Lee	Biosolutions,	Inc.,	
	10850	Metro	Ct.,	Maryland	Heights,		
	MO			63043,	USA.	
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2.1.8	Buffer	formulations	
2.1.8.1	General	buffers		
Buffer	 Components	
1X	Phosphate-buffered	saline	(PBS,	10	mM)		 NaCl	
Na2HPO4	
KH2PO4	
diH20	
Final	pH:	7.3	
8	g	
1.15	g	
0.24	g	
Up	to	1	L	
	
1X	PBS-Tween	20	(PBS-T)	 1X	PBS	
Tween	20	
Final	pH:	7.3	
1L	
0.05	%	(v/v)	
	
50	mM	Carbonate	buffer	 Na2C03	
NaHCO3	
diH20	
Final	pH:	9.6	
0.795	
1.465	
Up	to	500	mL	
20	mM	Tris	buffer	 Tris	Base	
NaCl	
diH20	
Final	pH:	8.5	
2.42	g	
8.77	g	
Up	to	800	mL	
	
2.1.8.2	Buffers	for	sodium	dodecyl	sulfate-polyacrylamide	gel	electrophoresis			
Buffer	 Components	for	1	gel	(6	mL)	
12.5	%	Separating	Gel	
	
1	M	TrisHCl,	pH	8.8		
30	%	(v/v)	Acrylagel	
2	%	(v/v)	Bis-Acrylagel	
Di	H2O	
10	%	(w/v)	SDS	
10	%	(w/v)	APS		
Tetramethylethylenediamine	(TEMED)	
1.5	mL	
2.5	mL	
1	mL	
934	μL	
30	μL	
30	μL	
6	μL	
4.5	%	Stacking	Gel		 1	M	TrisHCl,	pH	8.8		
30	%	(v/v)	Acrylagel	
2	%	(v/v)	Bis-Acrylagel	
Di	H2O	
10	%	(w/v)	SDS	
10	%	(w/v)	APS		
Tetramethylethylenediamine	(TEMED)	
300	μL	
375	μL	
150	μL	
1.74	mL	
24	μL	
24	μL	
2.5	μL	
4X	Loading	buffer	 0.5	M	Tris,	pH	6.8		
Glycerol																				
β-mercaptoethanol				
20	%	(w/v)	SDS																		
Bromophenol	Blue				
Di	H2O	
2.5	mL	
2	mL	
0.5	mL	
2.5	mL	
220	ppm	
2.5	mL	
10X	Electrophoresis	buffer	 10	mM	Trizma	Base	 	 	
Glycine	 	 	 	
0.1	%	(w/v)	SDS	 	 	 	
Di	H2O		
30	g	
144	g	
10	g	
Up	to	1	L	
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2.1.8.3	 Buffers	 for	 Immobilized	 metal	 ion	 affinity	 chromatography	 (IMAC)	
purification		
Buffer	 Components	
10X	Phosphate-buffered	saline	(PBS)	 NaCl	
Na2HPO4	
KH2PO4	
diH20	
Final	pH:	7.3.	Autoclave.	
80	g	
11.5	g	
2.4	g	
Up	to	1	L	
	
1X	PBS	 10X	PBS	
diH20	
Final	pH:	7.3.	Autoclave.	
100	mL	
900	mL	
Sonication	buffer	 0.5	M	NaCl	
20	mM	Imidazole	
1X	PBS	
14.71	g	
0.681	g	
500	mL	
Running	Buffer	 0.1	%	(v/v)	Tween-20	in	sonication	buffer	
Elution	buffer	1	 100	mM	NaAc,	pH	4.4	
Neutralisation	buffer	 100	mM	NaOH	 50	μL	
10X	PBS	 50	μL	
Elution	buffer	2	 250	mM	imidazole	in	1X	PBS,	pH	7.5		
	
2.1.8.4	Buffers	for	magnetic	beads	bioconjugation	
	
Buffer	 Components	
0.1 M	Borate	Buffer	
	
Boric	acid	
diH20	
Final	pH:	8.5	
0.6183	g	
Up	to	100	mL	
	
3	M	Ammonium	Sulfate	in	Borate	Buffer		 (NH₄)₂SO₄	
0.1	M	Borate	Buffer	
12.37	g	
Up	to	25	mL	
10	mM	Phosphate	Buffer		 NaHPO4	
NaH2PO4	x	H20	
diH20	
Final	pH:	7.4	
115mg	
26.18	mg	
Up	to	100	mL	
	
Phosphate	buffer,	0.1	%	(w/v)	BSA		 BSA	
NaCl	
10	mM	Phosphate	Buffer	
25	mg	
220	mg	
25	mL	
Phosphate	buffer,	0.5	%	(w/v)	BSA		 BSA	
NaCl	
10	mM	Phosphate	Buffer	
125	mg	
220	mg	
25	mL		
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2.1.8.5	Other	solution	formulations		
Buffer	 Components	
10	X	Blue	DNA	Loading	Dye	 Glycerol	
EDTA,	disodium	salt	
Bromophenol	blue	
diH20	
5	mL	
37.2	mg	
4	mg	
Up	to	10	mL	
	
		
2.2	METHODS	
2.2.1	General	molecular	biological	techniques	
2.2.1.1	Agarose	gel	electrophoresis	
	
Agarose	 gels	 were	 used	 for	 the	 separation	 and	 analysis	 of	 DNA.	 Agarose	 was	
dissolved	at	 the	 required	 concentration	 (0.6–2	%	 [w/v])	 in	 Tris-acetate-EDTA	 (TAE)	
buffer	by	boiling	the	mixture	for	1–3	minutes.	Once	cooled,	10	μL	of	SYBR®	Safe	DNA	
Gel	Stain	per	100	mL	of	agarose	gel	were	added	and	mixed	by	gently	stirring.	The	gel	
was	 immediately	 poured	 into	 a	 prepared	 gel	 mould.	 Blue	 DNA	 loading	 dye	 was	
added	 (when	 needed)	 to	 the	 samples	 at	 a	 1X	 concentration	 prior	 to	 loading	 for	
tracking	migration	 during	 electrophoresis.	 Along	with	 the	 samples,	 1	 kb	 Plus	 DNA	
molecular	weight	 ladder	 (Promega)	was	 loaded	 in	 each	 gel	 for	 size	 quantification.	
The	 gel	was	 electrophoresed	 at	 90V	 for	 approximately	 1	 hour	 until	 distinct	 bands	
were	observed.	Gels	were	visualised	using	a	blue	light	Dark	Reader	transilluminator	
and	imaged	with	a	Gel	Doc™	EZ	Imager.		
	
2.2.1.2	Extraction	of	DNA	from	agarose	gels	using	NucleoSpin®	Gel	and	PCR	Clean-
Up	(MN)	
	
The	appropriate	DNA	bands	were	cut	out	from	the	agarose	gel	using	a	sterile	scalpel	
under	 the	 blue	 light	 of	 a	 Dark	 Reader	 transilluminator.	 Extraction	 of	 DNA	 from	
agarose	gels	was	performed	using	NucleoSpin®	Gel	and	PCR	Clean-Up	kit,	as	per	the	
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manufacturer’s	guidelines.	The	product	was	then	quantified	using	the	Nanodrop	ND-
1000	Spectrophotometer	and	stored	at	-20°C.	
	
2.2.1.3	Ethanol	precipitation	of	DNA	
	
Ethanol-	precipitation	of	DNA	was	used	to	change	the	solvent	in	which	the	DNA	was	
suspended	 and/or	 to	 concentrate	 DNA	 samples.	 DNA	was	 ethanol-precipitated	 by	
adding	 0.1	 volumes	 of	 3	M	 sodium	 acetate	 (pH	 5.2),	mixing,	 adding	 2	 volumes	 of	
absolute	ethanol,	mixing,	and	incubating	O/N	at	-20°C.	Following	precipitation,	DNA	
was	pelleted	by	centrifugation	at	15,994	x	g	for	30	minutes	at	4°C	in	a	HermLe	Z2333	
MK-2	 centrifuge.	 The	 supernatant	 was	 carefully	 discarded	 and	 the	 sample	 was	
centrifuged	as	before	for	a	further	minute	to	remove	residual	liquid	from	the	pellet.	
The	 pellet	 was	 then	 rinsed	 with	 1	 mL	 of	 70	%	 (v/v)	 ethanol	 and	 centrifuged	 at	
16,000	x	g	for	2	minutes.	The	supernatant	was	carefully	removed	and	the	pellet	air-
dried	and	resuspended	in	ultrapure	molecular	grade	water.		
	
2.2.1.4	Sodium	dodecyl	sulphate	polyacrylamide	gel	electrophoresis	(SDS-PAGE)		
SDS-PAGE	 was	 used	 for	 the	 separation	 of	 proteins	 by	 electrophoresis	 for	 the	
assessment	of	protein	relative	molecular	masses,	purity	and	quality.	SDS	 is	used	to	
denature	 the	 proteins	 and	 confers	 them	 with	 a	 negative	 charge.	 SDS-treated	
proteins	have	a	similar	charge-to-mass	ratio,	resulting	in	a	separation	of	proteins	by	
relative	size	during	electrophoresis.	
	
The	1-D	vertical	gel	casting	apparatus	(Mini-PROTEAN	Tetra	Cell)	was	set	up	as	per	
the	 manufacturer’s	 instructions.	 Separating	 and	 stacking	 gels	 were	 prepared	 as	
outlined	in	Section	2.1.8.2,	adding	the	APS	and	TEMED	just	before	pouring	the	gels	in	
the	glass	plates	 (held	together	 in	 the	casting	stand	by	clamps),	as	 their	addition	to	
the	 gels	 initiates	 polymerisation.	 	 Firstly,	 the	 separating	 gel	 was	 poured	 until	 it	
reached	 approximately	 2–3	 cm	 from	 the	 top	 of	 the	 smaller	 glass	 plate.	 Once	 the	
separating	gel	had	polymerised,	the	stacking	gel	was	poured	on	top	of	the	separating	
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gel	and	a	plastic	 comb	was	gently	placed	 into	 the	gap	between	 the	 two	glasses	 to	
create	the	wells	for	sample	loading.	When	the	stacking	gel	was	fully	polymerised,	the	
gel	 cassettes	 were	 assembled	 into	 the	 running	 module	 and	 placed	 in	 the	
electrophoresis	 chamber,	 which	 was	 then	 filled	 with	 1X	 electrophoresis	 buffer.	
Samples	were	prepared	at	the	required	dilution	by	adding	loading	buffer	to	a	final	1X	
concentration	 and	 heating	 for	 5	 minutes	 at	 95°C.	 The	 loading	 buffer	 contains	 β-
mercaptoethanol,	 a	 thiol-reducing	 agent	 that	 disrupts	 disulphide	 bonds	 to	 allow	
complete	 protein	 unfolding.	 The	 comb	 was	 gently	 removed	 from	 the	 gel	 and	
approximately	 7	μL	 of	 pre-stained	molecular	 weight	marker	 (in	 the	 first	 well)	 and	
12	μL	of	sample	were	added	to	the	wells.	The	gel	was	run	at	120	V	until	the	tracker	
dye	(bromophenol	blue)	reached	the	bottom	of	the	gel.	The	gels	were	then	removed	
from	 the	 gel	 cassettes	 and	 stained	with	 InstantBlueTM	 for	 10–15	minutes	 to	 allow	
visualisation.	 The	 gels	 were	 washed	 twice	 with	 diH20	 and	 a	 gel	 photo	 was	 taken	
using	the	Gel	Doc™	EZ	System.		
	
2.2.1.5	Western	Blotting			
After	 running	 a	 SDS-PAGE	 gel,	 the	 gel	was	 equilibrated	 in	 Pierce™	 1-Step	 transfer	
buffer	 for	 10	 minutes.	 Two	 pieces	 of	 blotting	 filter	 paper	 (7	 x	 8.4	 cm)	 and	 the	
nitrocellulose	membrane	were	also	 soaked	 in	 transfer	buffer	 for	 approximately	15	
minutes.	 The	 proteins	 were	 transferred	 to	 the	 nitrocellulose	 membrane	 using	 a	
Trans-Blot®	SD	semi-dry	electrophoretic	 transfer	cell	 (Bio-Rad).	The	membrane	was	
then	placed	 in	a	 large	weight	boat	and	blocked	with	5	%	(w/v)	milk	Marvel	 in	PBS,	
with	gently	agitation,	O/N	at	4°C.	After	blocking,	the	membrane	was	washed	three	
times	 with	 10	 mL	 of	 PBS-T,	 with	 gently	 agitation,	 for	 5	 minutes	 each	 time.	 The	
membrane	was	then	incubated	with	10	mL	of	the	appropriate	HRP-labelled	antibody	
(at	 the	 required	 dilution,	 prepared	 in	 1	%	 [w/v]	 milk	 Marvel	 in	 PBS)	 while	 gently	
shaking	in	the	dark	at	RT.	After	a	2-hour	incubation,	the	membrane	was	washed	as	
before	 and	 developed	 by	 the	 addition	 of	 5	 mL	 of	 TMB	 peroxidase	 substrate	 for	
membranes.	When	 the	 protein	 bands	 became	 visible,	 the	membrane	was	washed	
with	diH20	and	a	photo	was	taken	using	the	Gel	Doc™	EZ	System.	
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2.2.2	Animal	immunisation	for	recombinant	antibody	production	
2.2.2.1	Chicken	immunization	with	the	ERBB2	extracellular	domain	
	
A	White	Leghorn	female	chicken	was	initially	immunised	sub-cutaneously	with	1	mL	
of	a	mixture	of	equal	parts	of	HER2	ECD	(ERBB2-922H,	30	μg)	in	PBS	(10	mM,	pH	7.3)	
and	 Freund’s	 complete	 adjuvant.	 The	 first	 boost	 (day	 21)	 was	 performed	 by	
administrating	15	μg	of	HER2	mixed	in	a	1:1	ratio	with	Freund’s	incomplete	adjuvant	
in	a	final	volume	of	1	mL.		Further	boosts	were	administrated	(on	days	42,	64	and	99)	
with	 smaller	 immunogen	 quantities	 (12.5	μg,	 10	μg	 and	 10	μg,	 respectively)	 in	 the	
same	manner	as	 the	 first	boost.	 	Finally,	 the	chicken	was	sacrificed	by	 intravenous	
injection	 using	 sodium	 pentobarbitone	 (day	 106).	 Spleen	 and	 bone	 marrow	 were	
collected	and	immediately	immersed	in	RNAlater®	to	stabilise	and	protect	the	RNA.	
	
2.2.2.2	Serum	antibody	titre	determination	by	indirect	ELISA		
Serum	antibody	titres	were	determined	to	measure	the	chicken	immune	response	to	
HER2.	 The	 chicken	 was	 bled	 one	 week	 after	 each	 boost	 and	 the	 collected	 whole	
blood	was	left	for	2	hours	in	the	tube	to	ensure	complete	clotting.	The	inner	surface	
of	the	tube	was	scraped	with	an	applicator	stick	to	dislodge	the	clotted	blood	from	
the	 sides	 and	 transfer	 it	 to	 a	 clean	 tube.	 The	 sample	 was	 then	 centrifuged	 at	
3,050	x	g	for	30	minutes	in	an	Eppendorf	5810R	centrifuge.	The	serum	was	collected	
in	200	μL	aliquots	and	stored	at	-20°C.	An	indirect	ELISA	format	was	used	for	titering	
the	 serum	 of	 the	 immunised	 chicken.	 To	 achieve	 this,	 Nunc	 MaxiSorp™	
immunoplates	were	 coated	with	 100	μL	 of	 HER2	 at	 a	 concentration	 of	 1	μg/mL	 in	
PBS	(10	mM,	pH	7.3)	and	incubated	O/N	at	4°C.	BSA	was	also	coated	onto	the	ELISA	
plate	to	check	for	non-specific	binding	of	the	antiserum.	The	liquid	in	the	plates	was	
discarded	and	the	plates	were	blocked	with	300	μL/well	of	3	%	(w/v)	BSA	in	PBS	and	
incubated	at	37°C	for	1	hour.	The	blocking	reagent	was	washed	with	PBS.	Five-fold	
serial	dilutions	(from	1:5	to	1:390,125	dilutions)	of	the	serum	samples	 in	1	%	(w/v)	
BSA	 in	 PBS	were	 added	 to	 each	well	 (200	μL/well).	 An	 appropriate	 blank	was	 also	
added.	 The	 plate	was	 incubated	 at	 37°C	 for	 90	minutes	 and	 then	washed	 3	 times	
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with	PBS-T	and	3	times	with	PBS.	Subsequently,	100	μL	of	a	1:2,000	dilution	of	HRP-
labelled	anti-chicken	 IgY	Fab’	conjugate	 in	PBS	was	applied	 to	each	well.	The	plate	
was	 incubated	at	37°C	 for	1	hour	and	washed	six	 times	as	before.	Then,	100	μL	of	
tetramethylbenzidine	 (TMB)	 substrate	 solution	 were	 added	 to	 each	 well.	 Once	
colour	was	 observed,	 the	 reaction	was	 stopped	with	 100	μL	 of	 10	%	 (v/v)	 HCl	 per	
well.	The	absorbance	was	read	at	450	nm.	The	results	of	the	titrations	were	graphed	
to	compare	the	response	in	different	bleeds.	
	
2.2.3	Generation	of	an	immune	chicken	scFv	library	
2.2.3.1	Extraction	and	isolation	of	total	RNA	from	immunised	chicken	spleen		
Prior	to	animal	sacrifice,	all	laboratory	plastic	ware,	instruments	and	equipment	that	
was	 not	 ‘RNase	 free’	 was	 treated	 with	 Presept	 and	 RNaseZap®	 to	 remove	 all	
contaminating	RNases	enzymes	 that	 catalyse	 the	degradation	of	RNA.	All	 reagents	
were	 also	 ‘RNase-free’.	 All	 procedures	were	 carried	 out	 in	 a	 “RNase-free”	 laminar	
flow,	sterilized	with	UV	light	and	decontaminated	from	Rnases	with	RNaseZap®.	
	
The	RNAlater®-	stabilised	spleen	was	removed	from	the	reagent	and	weighted	 in	a	
‘RNase-free’	tube.	RNA	was	purified	from	half	of	the	spleen	using	a	RNeasy	Mini	Kit	
(Qiagen)	and	the	remaining	tissue	was	flash-frozen	and	stored	at	-80°C.	Spleen	tissue	
was	 cut	 into	 small	 pieces	 and	homogenised	 using	 a	 sterile	 (autoclaved,	washed	 in	
Presept	disinfectant	solution	and	rinsed	with	molecular	grade	water	and	RNaseZap®	
prior	to	use)	homogenizer.	Ethanol	was	then	added	to	the	homogenised	sample	to	
provide	 ideal	 binding	 conditions	 before	 loading	 the	 lysate	 onto	 the	 RNeasy	 silica-
membrane	spin	columns.	Silica	selectively	binds	to	RNA	under	certain	salt	and	buffer	
conditions	 (Gauch	 et	 al.,	 1998).	 Contaminants	 were	 washed	 away	 and	 RNA	 was	
eluted	 using	 30	μL	 of	 molecular	 grade	 water.	 RNA	 was	 quantified	 using	 the	
Nanodrop	ND-1000	Spectrophotometer.	
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2.2.3.2	First-strand	cDNA	synthesis	from	total	RNA		
cDNA	 was	 synthetized	 by	 reverse	 transcription	 using	 Superscript	 III	 first-strand	
synthesis	 system	 for	 RT-PCR	 (Biosciences).	 The	 resulting	 cDNA	 was	 used	 for	
constructing	the	scFv	antibody	library.	
	
Two	master	mixes	 (mixture	1	and	2)	were	made	as	described	 in	 the	 tables	below.	
RNA	was	 incubated	with	 the	 primers	 in	mixture	 1.	Oligo	 (dT)s	 that	 hybridise	 to	 3’	
poly	 (A)	 tails	 in	 the	RNA	were	used	as	 the	priming	method.	Mixture	2	 is	 the	cDNA	
synthesis	mix,	 in	which	SuperScriptTM	III	Reverse	Transcriptase	 (‘RT’)	 is	 introduced	
to	the	reaction.	
	
	
Mixture	1	 1X	 20X	
RNA		 5	μg	 100	μg	
50	μM	Oligo	(dT)		 1	μL	 20	μL	 	
10	mM	dNTP	mix	 1	μL	 20	μL	
Total	 23	μL	 460	μL	
	
	
Mixture	2	 1X	
Concentration	in	
460	μL	reaction	
10X	‘RT’	Buffer	 2	μL	 92	μL	
25	mM	MgCl2	 4	μL	 184	μL	
0.1	M	DTT	 2	μL	 92	μL	
RNaseOut	(40	U/μL)	 1	μL	 46	μL	
SuperScript	III	‘RT’	(200	U/μL)	 1	μL	 46	μL	
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First-strand	 reaction	 was	 performed	 in	 the	 thermal	 cycler	 under	 the	 following	
conditions:	
Stage	1:	 65°C									5	minutes	
Pause	
Stage	2:	
	
50°C									50	minutes	
85°C									5	minutes																
Pause						
Stage	3:	 37°C									20	minutes	
		4°C										hold	
	
Mixture	1	and	Mixture	2	were	prepared	in	a	1:1	ratio.	For	each	reaction,	5	μg	of	total	
RNA	were	used.	The	reaction	was	scaled	up	 (20X)	and	the	mixture	1	was	split	 into	
25	μL-aliquots	that	were	quick	(‘touch’)	spin-down	in	a	benchtop	microcentrifuge	to	
collect	liquid	at	the	bottom	of	the	PCR	tubes.	Step	1	of	the	reaction	was	run.	The	PCR	
tubes	were	left	to	cool	on	ice	for	1–3	minutes	and	subsequently	and	equal	volume	of	
Mixture	2	(25	μL)	was	added	to	each	PCR	tube.		Step	2	of	the	reaction	was	run.	PCR	
tubes	were	placed	on	ice	for	1–3	minutes	and	2	μL	of	RNase	H	were	added	to	each	
tube.	Step	3	of	the	reaction	was	run.	PCR	tubes	were	placed	on	ice	and	pooled	in	a	
single	 2-mL	 tube	 afterwards.	 cDNA	 was	 quantified	 using	 the	 NanoDrop	
spectrophotometer	and		subsequently	stored	at	-20°C.		
	
2.2.3.3	PCR	Primers	for	the	construction	of	a	chicken	scFv	library	
	
The	 primers	 were	 used	 for	 the	 construction	 of	 a	 chicken	 scFv	 library	 with	 a	 long	
linker,	using	pComb	vector.	These	primers	were	previously	described	by	Barbas	et	al.	
(2001)	and	were	obtained	from	Integrated	DNA	Technologies.	The	light-	and	heavy-	
chain	sense	primers	(CSCVHo-FL	and	CSCVK)	have	a	sequence	tail	that	are	recognised	
by	 the	 overlap	 extension	 primers	 for	 the	 generation	 of	 the	 full-length	 product.		
CSCG-B	and	CSCVK	have	a	sequence	tail	that	contains	an	SfiI	site	for	the	restriction-
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digestion	of	the	overlap	product.	
	
Chicken	scFv	primers	 Nucleic	acid	sequence	
VH	Primers	
CSCVHo-FL	(sense),	
Long	Linker	
5’–	GGT	CAG	TCC	TCT	AGA	TCT	TCC	GGC	GGT	GGT	
GGC	 AGC	 TCC	 GGT	 GGT	 GGC	 GGT	 TCC	 GCC	 GTG	
ACG	TTG	GAC	GAG	–	3’	
CSCG-B	(reverse)	
5’–	CTG	GCC	GGC	CTG	GCC	ACT	AGT	GGA	GGA	GAC	
GAT	GAC	TTC	GGT	CC	–	3’	
Vλ	Primers	
CSCVK	(sense)	
5’	–	GTG	GCC	CAG	GCG	GCC	CTG	ACT	CAG	CCG	TCC	
TCG	GTG	TC	–	3’	
CKJo-B	(reverse)	
5’–	 GGA	 AGA	 TCT	 AGA	 GGA	 CTG	 ACC	 TAG	 GAC	
GGT	CAG	G	–	3’	
Overlap	
Extension	
Primers	
CSC-F	(sense)	
5’–	GAG	GAG	GAG	GAG	GAG	GAG	GTG	GCC	 CAG	
GCG	GCC	CTG	ACT	CAG	–	3’	
CSC-B	(reverse)	
5’	–	GAG	GAG	GAG	GAG	GAG	GAG	GAG	CTG	GCC	
GGC	CTG	GCC	ACT	AGT	GGA	GG	–	3’	
		
2.2.3.4	Amplification	of	chicken	antibody	variable	heavy	and	light	chain	genes		
Spleen	cDNA	obtained	from	reverse	transcription	was	used	for	the	PCR-amplification	
of	the	variable	heavy	and	variable	light	genes.	
	PCR	components	were	as	follows:	
cDNA	 0.5	μg	
dNTP’s	 0.2	mM	
Forward	primer	 60	pm	
Reverse	primer	 60	pm	
MgCl2	 4	mM	
5X	buffer	 1X	
GoTaq	Polymerase	(5	U/μL)	 1	unit	
MG	H2O	 Up	to	50	μL	
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PCR		was	performed	with	the	following	cycling	conditions	:	
	
Stage	1:	 94°C						Initial	denaturation	 2	minutes	
Stage	2:	
30	cycles	of	
94°C						Denaturation	
56°C						Annealing																
72°C						Extension	
15	seconds	
30	seconds													
90	seconds	
Stage	3:	 72°C						Final	extension	
		4°C	
10	minutes	
hold	
	
	
2.2.3.5	Optimisation	of	MgCl2	and	primer	concentration	for	amplification	of	DNA		
Magnesium	is	a	required	co-factor	for	Taq	Polymerase	and	thus	optimising	the	MgCl2		
(source	 of	 magnesium	 ion)	 concentration	 is	 critical	 to	 the	 success	 of	 the	 PCR.		
Varying	MgCl2	concentrations	from	1	mM	to	4	mM	were	analysed	(using	conditions	
described	in	Section	2.2.3.4).	
Primers	 determine	what	 region	 of	 the	 DNA	 is	 amplified	 during	 the	 PCR.	 Excessive	
primers	 concentration	 can	 lead	 to	 the	 annealing	 of	 the	 primers	 to	 non-target	
regions–generating	 false	 products	 in	 a	 PCR–or	 to	 the	 formation	 of	 primer	 dimers	
that	 amplify	 independent	 to	 the	 target	 DNA.	 On	 the	 other	 hand,	 if	 the	 primer	
concentration	 is	 too	 low,	 there	 will	 be	 little	 or	 no	 amplification	 during	 the	 PCR.	
Forward	 and	 reverse	 primer	 concentrations	 were	 optimised	 using	 concentrations	
from	0.4	to	1	μM	(Section	2.2.3.4).	
	
2.2.3.6	Splice	by	overlap	extension	(SOE)	PCR	using	Platinum	Taq	polymerase	
	
In	 the	 SOE	PCR	 the	 variable	heavy	 and	 variable	 light	products	 are	pooled	 in	 equal	
ratios	to	generate	the	scFv	library.	The	SOE	PCR	primers	recognise	the	sequence	tails	
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generated	by	the	primers	used	for	the	amplification	of	the	variable	chains,	allowing	
the	extension	of	the	full-length	product.	
	
Platinum®	Taq	DNA	Polymerase	High	Fidelity	was	used	to	generate	the	SOE	product	
to	ensure	a	high	yield	and	robust	amplification.	This	“hot	start”	 thermostable	DNA	
polymerase	 (inactive	until	 the	 initial	PCR	denaturation	 step)	also	allowed	 for	 room	
temperature	reaction	assembly.	
	
SOE	PCR	reaction	components	and	conditions	using	Platinum®	Taq	DNA	Polymerase	
High	Fidelity	Polymerase	were	as	follows:		
	
10X	High	Fidelity	PCR	Buffer	 1X	
10	mM	dNTP	mixture	 0.2	mM		
50	mM	MgSO4	 2	mM	
Forward	primer	 0.4	μM	
Reverse	primer	 0.4	μM	
VH	product	 150	ng	
Vλ	product	 150	ng	
Platinum	Taq	High	Fidelity	 1	U	
MG	water	 Up	to	50	μL	
	
	
PCR		conditions	were	as	follows:	
	
Stage	1:	 94°C						Initial	denaturation	 2	minutes	
Stage	2:	
30	cycles	of	
94°C						Denaturation	
55°C						Annealing																
68°C						Extension	
15	seconds	
15	seconds													
90	seconds	
Stage	3:	 68°C						Final	extension	
		4°C	
5	minutes	
hold			
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2.2.3.7	 Plasmid	 DNA	 purification	 and	 preparation	 of	 an	 E.	 coli	 glycerol	 stock	
expressing	pComb3XSS	
	
Initially,	 a	 glycerol	 stock	 of	 XL1-Blue	 E.	 coli	 cells	 expressing	 pComb3XSS	 was	
inoculated	in	a	LB	agar	plate	supplemented	with	100	μg/mL	carbenicillin.	Following	
incubation	at	37°C	O/N,	a	single	colony	was	picked	from	the	plate	and	grown	O/N	on	
5	mL	of	SB	+	carbenicillin	(100	μg/mL)	medium	at	37°C	and	220	rpm.	Five	hundred	μL	
of	the	overnight	culture	was	sub-cultured	into	100	mL	SB	+	carbenicillin	(100	μg/mL)	
medium.	The	subculture	was	incubated	O/N	at	37°C	and	220	rpm.		
	
The	following	morning,	cells	were	pelleted	by	centrifugation	in	an	Eppendorf	5810R	
for	15	minutes	at	4°C	and	3220	x	g.	A	NucleoBond®	Xtra	Midi	kit	(MN)	was	used	for	
plasmid	 purification	 from	 the	 harvested	 bacterial	 cells,	 as	 per	 the	manufacturer’s	
instructions.	 The	 purified	 plasmid	 was	 reconstituted	 in	 300	μL	 of	 molecular	 grade	
water.	 The	 product	 was	 subsequently	 quantified	 using	 a	 Nanodrop	 ND-1000	
Spectrophotometer	and	stored	at		-20°C.	
	
2.2.3.8	Restriction-digestion	of	the	scFv	insert	and	pComb3XSS	vector	
	
The	 SOE-PCR	 products	 and	 the	 pComb3XSS	 vector	 were	 prepared	 for	 cloning	 by	
performing	 restriction	 enzyme	 digestion	 with	 SfiI	 enzyme	 (20,000	 units/mL)	 from	
New	England	Biolabs.	
	
The	 purified	 overlap	 scFv	 PCR	 product	was	 SfiI-digested	 by	 setting	 up	 two	 100-μL	
reactions	as	follows:	
	
Purified	scFv	product	 5	μg	
SfiI	(36	U	per	μg	of	DNA)	 180	U	
10X	NE	Buffer	 10	μL	
Water		 Up	to	100	μL	
	
Both	digestion	reactions	were	incubated	at	50°C	for	5	hours.	
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For	digestion	of	the	purified	pComb3XSS	vector,	two	100-μL	reactions	were	prepared	
as	follows:	
	
pComb3XSS	 10	μg	
SfiI	(36	U	per	μg	of	DNA)	 60	U	
10X	NE	Buffer	 10	μL	
Water		 Up	to	100	μL	
	
Both	 digestion	 reactions	 were	 incubated	 at	 50°C	 for	 5	 hours.	 Then,	 Antartic	
Phosphatase	 (AP)	 enzyme	 (10	 units)	 and	 Antarctic	 Phospathase	 buffer	 (10X)	were	
added	 to	 each	 100-μL	 digestion	 reaction	 and	 this	 was	 incubates	 at	 37°C	 for	 30	
minutes.	After	this	time,	AP	was	heat-inactivated	by	incubating	the	reactions	at	65°C	
for	 5	 minutes.	 AP	 catalyzes	 the	 removal	 of	 5´	phosphate	 from	 the	 plasmid	 DNA,	
preventing	self-ligation.	
	
The	digested	scFv	products	were	purified	on	a	1.5	%	(w/v)	agarose	gel	and	the	vector	
and	Stuffer	fragment	were	purified	on	a	0.8	%	(w/v)	gel	using	NucleoSpin®	Gel	and	
PCR	 Clean-Up	 (MN).	 The	 purified,	 digested	 PCR	 products,	 vector	 and	 Stuffer	
fragment	were	quantified	using	the	Nanodrop	ND-1000	Spectrophotometer.			
2.2.3.9	Ligation	of	SOE-product	into	pComb	vector		
	
The	 ligation	 of	 the	 purified	 SfiI-digested	 scFv	 insert	 to	 the	 pComb	 vector	 was	
performed	by	setting	up	the	following	reaction:	
	
SfiI-digested,	AP-treated	pComb	
(1.4ug)	
1.4	μg	
SfiI-digested	SOE	PCR	product		 0.7	μg	
T4	DNA	Ligase	buffer	 6	μL	
T4	DNA	Ligase		 10	μL	
Water		 Up	to	60	μL		
	
Two	 ligation	 reactions	 were	 carried	 out	 and	 incubated	 O/N	 at	 RT.	 	 The	 resulting	
solution	was	ethanol-	precipitated	as	described	in	Section	2.2.1.3.	
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2.2.4	Antibody	phage	display	and	library	panning	
2.2.4.1	 Transformation	 of	 E.	 coli	 XL1-Blue	 electrocompetent	 cells	 with	 scFv-	
containing	plasmid	and	rescue	of	scFv-displaying	phage	
	
The	library	ligation	product	was	spun	at	15,994	x	g	for	30	minutes	at	4°C	in	a	HermLe	
Z2333	 M-K2	 microcentrifuge.	 The	 supernatant	 was	 discarded	 and	 the	 pellet	 was	
washed	twice	with	70	%	(v/v)	ethanol.	The	pellet	was	centrifuged	again	for	2	minutes	
and	air-dried	for	15	minutes	to	remove	any	remaining	ethanol.	The	pellet	was	then	
resuspended	in	15	μL	of	pre-warmed	MG	water	by	brief	heating	at	37°C	and	gentle	
vortexing.	
	
The	ligated	library	and	the	2.5	mm	electroporation	cuvettes	were	placed	on	ice	for	
10	 minutes.	 At	 the	 same	 time	 the	 electrocompetent	 E.	 coli	 XL1-Blue	 cells	 were	
thawed	in	ice.	Half	of	the	ligation	(7.5	μL)	was	added	to	each	of	two	tubes	containing	
150	μL	 of	 cells	 that	 were	 incubated	 in	 ice	 for	 1	 minute.	 The	 sample	 was	 then	
electroporated	 at	 2.5	 kV,	 25	μF	 and	 200	 Ω.	 The	 cuvette	 was	 immediately	 flushed	
with	1	mL	and	then	twice	with	0.5	mL	of	pre-warmed	(37°C)	SOC	medium	and	the	
resulting	 suspension	 was	 transfer	 to	 a	 50-mL	 polypropylene	 tube.	 Cells	 were	
incubated	for	one	hour	at	37°C	and	250	rpm.	After	this	time,	10	mL	of	prewarmed	
(37°C)	 SB	medium	with	3	μL	 carbenicillin	 (100	mg/mL)	 and	30	μL	of	 tetracycline	 (5	
mg/mL)	 were	 added.	 To	 titre	 transformed	 bacteria,	 100	μL	 and	 10	μL	 of	 a	 1:100	
dilution	 of	 the	 15-mL	 culture	 were	 plated	 on	 LB	 agar	 plates	 supplemented	 with	
100	μg/mL	carbenicillin.	The	plates	were	incubated	O/N	at	37°C	and	the	number	of	
transformants	was	calculated	as	follows:	
	
N° of colonies ×  culture volume µLplating volume µL  ×  total ligation volume µLligation vol transformed µL =  Total transformants 
	
The	 previous	 culture	 was	 shaken	 at	 250	 rpm	 for	 an	 additional	 hour	 at	 37°C.	
Subsequently,	4.5	μL	of	 carbenicillin	 (100	mg/mL)	was	added	 to	 the	culture,	which	
was	 then	 incubated	 as	 before.	 M13K07	 helper	 phage	 (2	 mL)	 was	 added	 to	 the	
culture,	 which	 was	 transferred	 to	 a	 500-mL	 flask	 prior	 to	 addition	 of	 183	 mL	 of	
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prewarmed	 SB	 medium,	 92.5	μL	 of	 carbenicillin	 (100	 mg/mL)	 and	 370	μL	 of	
tetracycline	 (5	 mg/mL).	 This	 was	 grown	 at	 300	 rpm	 for	 an	 hour	 at	 37°C.	 Finally,	
140	μL	of	kanamycin	(50	mg/mL)	was	added	and	the	culture	was	 incubated	O/N	at	
300	 rpm	 and	 37°C.	 Final	 antibiotic	 concentrations	 in	 the	 O/N	 culture	 were	
approximately	50	μg/mL	of	carbenicillin,	10	μg/mL	of	tetracycline	and	35	μg/mL	of	
kanamycin.	
	
The	O/N	culture	was	spun	down	at	1,520	x	g	for	30	minutes	at	4°C	and	the	resulting	
supernatant	was	 transfer	 to	 four	 clean	 sterile	Oakridge	 tubes.	 The	phage	particles	
were	precipitated	by	addition	of	PEG	8000	(to	4	%	[w/v])	and	sodium	chloride	(to	3	%	
[w/v]).	The	PEG-NaCl	solution	was	dissolved	by	shaking	at	300	rpm	for	5	minutes	at	
37°C.	The	Oakridge	tubes	were	incubated	on	ice	for	30	minutes	and	then	centrifuged	
at	10,404	x	g	for	20	minutes	at	4°C.	The	phage	pellet	was	resuspended	in	2	mL	of	1	%	
(w/v)	 BSA	 in	 PBS	 buffer	 (10	 mM,	 pH	 7.3)	 and	 then	 transferred	 to	 2	 mL	 sterile	
centrifuge	 tubes,	 that	 were	 spun	 at	 15,994	x	g	 at	 4°C.	 The	 phage-containing	
supernatant	was	used	for	panning.	
	
2.2.4.2	Enrichment	of	phage	library	via	panning	against	immobilised	HER2	
	
Four	 rounds	 of	 panning	 were	 performed	 with	 increasingly	 stringent	 conditions	 to	
enrich	 for	 high-affinity	 HER2-specific	 clones.	 The	 panning	 conditions	 employed	
during	the	screening	process	were	as	follows:	
	
	 Pan	1	 Pan	2	 Pan	3	 Pan	4	
Coating	concentration	 50	μg/mL	 25	μg/mL	 10	μg/mL	 5	μg/mL	
Number	of	washes	 3X	PBS	3X	PBS-T	
5X	PBS	
5X	PBS-T	
10X	PBS	
10X	PBS-T	
15X	PBS	
15X	PBS-T	
Culture	Volume/	
#	wells	
200	mL	/	
8	wells	
100	mL/	
4	wells	
100	mL/	
4	wells	
100	mL/	
4	wells	
Helper	phage	 2	mL	 1	mL	 1	mL	 1	mL	
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A	 Maxisorp	 ELISA	 plate	 was	 coated	 O/N	 at	 4°C	 with	 100	μL	 of	 50	μL/mL	 HER2	
dilution.	The	coating	solution	was	discarded	and	the	wells	were	blocked	with	100	μL	
of	5	%	 (w/v)	milk	Marvel	 in	PBS	 for	90	minutes	at	37°C.	The	blocking	 solution	was	
discarded	and	100	μL	of	the	freshly	prepared	phage	library	were	added	to	the	wells	
that	were	sealed	and	 incubated	for	2	hours	at	RT.	The	solution	was	removed	from	
the	ELISA	plate	and	non-binding	phage	were	discarded	by	washing	3	times	with	PBS	
and	3	times	with	PBS-T.	Freshly	prepared	ice-cold	10	mg/mL	trypsin	in	PBS	(100	μL)	
was	added	to	each	well	and	the	plate	was	sealed	and	 incubated	 for	30	minutes	at	
37°C	 to	 elute	 bound	 phage	 particles.	 	 The	 trypsin-treated	 samples	 (phage	 output)	
were	pipetted	up	and	down	and	the	eluates	were	transferred	to	a	2-mL	E.coli	XL1-
Blue	 culture	 (OD600	 ≈	 1)	 and	 incubated	 static	 for	 30	 minutes	 at	 37°C.	 For	 output	
titering,	 serial	 dilutions	 (10-1–10-4)	 in	 XL1-Blue	 cells	 were	 prepared	 and	 incubated	
static	 for	 30	 minutes	 at	 37°C.	 After	 the	 incubation,	 100	μL	 of	 each	 dilution	 were	
plated	out	on	LB	agar	containing	100	μg/mL	carbenicillin.	The	remaining	culture	was	
added	 to	 50-mL	 tube	 with	 6	 mL	 of	 pre-warmed	 SB	 medium	 with	 1.6	μL	 of	
carbenicillin	 (100	mg/mL)	 and	12	μL	of	 tetracycline	 (5	mg/mL).	After	 incubation	 at	
230	rpm	for	1h	at	37°C,	2.4	μL	of	carbenicillin	were	added	to	the	culture	and	this	was	
incubated	 for	 a	 further	 hour	 at	 the	 same	 conditions.	 Then,	 the	 culture	 was	 co-
infected	with	M13KO7	helper	phage	and	transferred	to	250	mL-	bluffed	bottom	flask	
with	91	mL	of	prewarmed	SB	medium,	46	μL	of	carbenicillin	(100	mg/mL)	and	184	μL	
of	tetracycline	(5	mg/mL).	The	culture	was	incubated	at	300	rpm	for	an	hour	at	37°C	
and	140	μL	of	kanamycin	(50	mg/mL)	were	added	before	an	O/N	incubation	at	300	
rpm	and	37°C.	
	
2.2.4.3	Polyclonal	phage	ELISA	
	
To	 evaluate	 the	 success	 of	 the	 panning	 experiment,	 phage	 pools	 resulting	 from	
different	rounds	of	panning	were	tested	by	ELISA.	A	Nunc	Maxisorb	plate	was	coated	
with	100	μL	per	well	of	10	μg/mL	HER2	(and	control	BSA)	in	PBS	(10	mM,	pH	7.3)	O/N	
at	4°C.	The	excess	antigen	was	discarded	and	the	plate	was	blocked	with	250	μL	of	
5	%	(w/v)	milk	Marvel	 in	PBS	for	90	minutes	at	37°C.	Precipitated	phage	from	each	
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round	of	panning	(100	μL	of	a	1:3	dilution	in	1	%	[w/v]	milk	Marvel	in	PBS	that	was	
incubated	for	1	hour	at	RT)	was	added	to	the	wells	 in	triplicate.	M13	helper	phage	
was	 also	 added	 in	 triplicate	 as	 a	 negative	 control.	 The	 plate	 was	 incubated	 for	 2	
hours	at	37°C	and	then	washed	three	times	with	PBS-T	and	3	times	with	PBS.	Bound	
antibodies	were	detected	 following	 the	 addition	of	 200	μL	 of	 a	 1:5,000	dilution	of	
HRP-labelled	 anti-M13	 antibody	 in	 1	%	 (w/v)	 milk	 Marvel	 in	 PBS.	 The	 plate	 was	
incubated	 for	 1	 hour	 at	 37°C	 and	 washed	 as	 before.	 TMB	 substrate	 was	 added	
(100	μL	per	well)	and	incubated	for	10	minutes	at	RT.	The	reaction	was	stopped	by	
the	addition	of	10	%	(v/v)	HCl	and	the	absorbance	was	read	at	450	nm	using	Tecan	
Sunrise™	Microplate	Reader.	
	
2.2.5	Analysis	of	scFv-expressing	single	clones	
2.2.5.1	Soluble	expression	of	antibody	fragments		
	
Soluble	scFv	fragments	were	produced	by	infecting	5	μL	of	phagemid	from	rounds	3	
and	 4	 of	 panning	 into	 two	 5mL-	 overnight	 cultures	 of	 Top10F’	 E.	 coli	 in	 SB	 with	
10	μg/mL	tetracycline	at	a	mid-logarithmic	growth	phase.	After	static	incubation	for	
1	hour	at	37°C,	each	culture	was	added	to	a	20-mL	tube	containing	6	mL	of	SB	with	
50	μg/mL	 carbenicillin	 and	 10	μg/mL	 tetracycline	 and	 further	 incubated	 while	
shaking	at	220	rpm	for	1	hour	at	37°C.	Culture	dilutions	from	10-1	to	10-7	were	plated	
on	 agar	 plates	 with	 100	μg/mL	 carbenicillin	 and	 incubated	 O/N	 at	 37°C.	 Single	
colonies	 (96	 from	 each	 round	 of	 panning)	 were	 inoculated	 into	 individual	 wells	
containing	200	μL	of	SB	with	50	μg/mL	carbenicillin	and	10	μg/mL	tetracycline	(stock	
plates).	After	an	O/N	incubation	at	37°C,	15	μL	of	each	well	of	the	stock	plates	were	
subcultured	into	150	μL	SB	in	the	presence	of	carbenicillin	(50	μg/mL)	and	shaken	at	
220	rpm	and	37°C	until	OD=0.6-0.8.	Meanwhile,	master	plates	of	the	original	clones	
were	prepared	by	adding	20	%	(v/v)	glycerol	to	the	stock	plates	and	storing	at	-80°C.	
Once	the	desired	optical	density	was	achieved,	1	mM	IPTG	was	added	and	to	each	
well	 and	 the	 cultures	 were	 induced	 O/N	 at	 220	 rpm	 30°C.	 Cells	 were	 pelleted	 by	
centrifugation	of	the	plates	for	10	minutes	at	2,750	x	g	and	4°C	using	a	A-4-62	rotor	
with	MTP	buckets	in	an	Eppendorf	5810	centrifuge.	Each	pellet	was	resuspended	in	
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300	μL	of	PBS	and	subjected	to	3	cycles	of	freeze-thawing	(the	plates	were	frozen	at							
-80°C	 and	 then	 thawed	 at	 37°C)	 for	 the	 extraction	 of	 periplasmic	 scFv.	 The	 plates	
were	then	centrifuged	for	20	minutes	as	before	and	the	resulting	lysates	were	used	
to	perform	an	ELISA-based	analysis	of	single	clones.		
	
2.2.5.2	Soluble	Monoclonal	scFv	ELISA		
To	assess	 the	 specificity	of	 the	 selected	clones,	 scFv	 from	cell	 lysates	 (prepared	as	
described	 in	 Section	 2.2.5.1)	 were	 tested	 for	 HER2-binding	 by	 ELISA.	 Two	 96-well	
ELISA	plates	were	coated	O/N	with	5	μg/mL	HER2	in	PBS	(10	mM,	pH	7.3),	and	then	
blocked	with	 250	μL	 of	 5	%	 (w/v)	milk	Marvel	 in	 PBS	 for	 90	minutes	 at	 37°C.	 The	
plates	were	washed	three	times	with	PBS-T	and	three	times	with	PBS.	ScFv-	enriched	
lysates	were	added	 in	a	1:2	dilution	 in	1	%	 (w/v)	milk	Marvel	 in	PBS-T	 to	 the	wells	
and	 incubated	 for	 1	 hour	 at	 37°C.	 The	 plates	were	washed	 as	 before	 and	 a	 HRP-
conjugated	 rat	 anti-HA	 monoclonal	 antibody	 (1:1,000	 dilution	 in	 1	%	 [w/v]	 milk	
Marvel	 in	 PBS)	 was	 used	 to	 detect	 scFv	 that	 were	 specific	 to	 HER2.	 After	 1	 hour	
incubation	 at	 37°C,	 the	 plates	 were	 washed	 as	 before	 and	 100	μL	 of	 TMB	 were	
added	to	each	well	and	 incubated	at	RT	for	5	minutes,	 followed	by	the	addition	of	
50	μL	 of	 10	%	 (v/v)	HCl	 to	 stop	 the	 reaction.	 The	 absorbance	was	 read	 at	 450	nm	
using	a	Sunrise™	Tecan	Microplate	Reader.		
	
2.2.5.3	Competitive	scFv	ELISA	for	the	detection	of	free	HER2	
	
Eight	 positive	 clones	 from	 the	 monoclonal	 scFv	 ELISA	 were	 taken	 forward	 for	
competitive	 analysis	 in	 order	 to	 determine	 if	 they	 were	 specific	 for	 free	 HER2.		
Competition	occurs	between	free	HER2	in	solution	and	adsorbed	HER2	in	the	ELISA	
plate	for	binding	to	the	anti-HER2-specific	scFv.			
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Single	clones	were	grown	inoculating	10	μL	of	the	glycerol	stocks	(from	the	Master	
plate)	 into	 5	 mL	 of	 SB	 with	 50	μg/mL	 carbenicillin	 and	 10	μg/mL	 tetracycline	 and	
incubating	O/N	at	220	rpm	and	37°C.	The	O/N	cultures	(50	μL)	were	subcultured	into	
10	 mL	 of	 SB	 with	 100	μg/mL	 carbenicillin,	 1X	 505	 and	 1mM	 MgS04	 	 and	 then	
incubated	at	220	rpm	and	37°C	until	OD600≈0.6.	The	remaining	O/N	culture	was	used	
to	 make	 20	%	 (v/v)	 glycerol	 stocks,	 that	 were	 stored	 at	 -80°C.	 Once	 the	 culture	
reached	 the	exponential	phase,	 antibody	expression	was	 induced	by	adding	1	mM	
IPTG	and	incubating	the	culture	O/N	at	220	rpm	and	30°C.	
	
Cell	 lysates	 were	 prepared	 as	 previously	 described	 in	 Section	 2.2.5.1,	 with	 the	
exception	that	50-mL	centrifuge	tubes	were	used	instead	of	ELISA	plates.	The	wells	
of	an	ELISA	plate	were	coated	with	100	μL	of	2	μg/mL	HER2	in	PBS	(10	mM,	pH	7.3)	
O/N	at	4°C.	The	plate	was	the	blocked	with	250	μL	of	5	%	(w/v)	milk	Marvel	 in	PBS	
for	90	minutes	at	37°C.	The	lysates	(50	μL)	were	added	in	a	1:50	dilution	(for	a	final	
1:100	dilution)	to	a	half	of	the	plate	with	50	μL	of	PBS	(direct	ELISA)	and	to	the	other	
half	 of	 the	 plate	 with	 50	μL	 of	 a	 4	μg/mL	 HER2	 solution	 (competitive	 ELISA),	
incubating	the	dilutions	for	5	minutes	on	the	bench	before	adding	them	to	the	wells.	
The	plate	was	washed	three	times	with	PBS-T	and	three	times	with	PBS,	followed	by	
the	 addition	 of	 100	μL	 of	 a	 1:1,000	 dilution	 of	 HRP-labelled	 monoclonal	 anti-HA	
antibody	in	1	%	(w/v)	milk	Marvel	 in	PBS.	After	1	hour	incubation	at	37°C	the	plate	
was	washed	as	before	and	100	μL	of	TMB	substrate	were	added	to	each	well	and	the	
plate	was	covered	and	incubated	for	5	minutes	at	RT.	The	reaction	was	stopped	with	
10	%	 (v/v)	 HCl	 and	 the	 absorbance	 read	 at	 450	 nm	 using	 a	 Sunrise™	 Tecan	
Microplate	Reader.		
	
2.2.5.4	Sequence	analysis	of	the	anti-HER2-specific	clones	
	
Plasmid	 preparations	 of	 the	 selected	 plasmids	 from	 round	 4	 of	 panning	 were	
prepared	and	sent	for	Sanger	sequencing.		Anti-HER2-specific	clones	glycerol	stocks	
were	used	to	streak	LB	agar	plates	with	100	μg/mL	carbenicillin.	Single	colonies	were	
grown	in	5mL	SB	with	10	μg/mL	of	tetracycline	O/N	at	37°C.	Plasmids	were	purified	
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from	the	O/N	cultures	using	the	MN	NucleoSpin	Plasmid	purification	kit,	as	per	the	
manufacturer’s	 instructions.	 Double-stranded	 DNA	 Sanger	 sequencing	 was	
performed	by	Source	Bioscience,	Tramore,	Ireland,	using	the	following	primers:	
	
Ø Ompseq	(forward	primer):		AAG	ACA	GCT	ATC	GCG	ATT	GCA	G		
	
Ø gBack	(reverse	primer):			GCC	CCC	TTA	TTA	GCG	TTT	GCC	ATC	
	
The	heavy	and	light	chain	CDRs	of	the	antibody	were	identified	(Kabat	definition)	by	
examining	 the	 sequences.	 The	 ExPASy	 translation	 tool	
(http://web.expasy.org/translate/)	 was	 used	 to	 determinate	 the	 amino	 acid	
sequences	 and	 ClustalW2	 program	 (http://www.ebi.ac.uk/Tools/msa/clustalw2/)	
allowed	the	alignment	of	the	sequences.	
	
2.2.6	Expression,	purification	and	characterisation	of	anti-HER2	scFv	A4	
2.2.6.1	Optimisation	of	expression	conditions	for	A4	scFv	
	
Expression	conditions	 for	A4	clone	were	optimised.	A4	glycerol	 stock	was	used	 for	
scFv	expression	as	described	in	Section	2.2.5.3,	with	the	exception	that	two	different	
post-induction	 temperatures–37°C	 and	 30°C–and	 three	 different	 IPTG	
concentrations–0.1	 mM,	 0.5	 mM	 and	 1	 mM–were	 tested.	 These	 variables	 are	
decisive	for	the	induction	of	scFv	expression.		
	
ScFv-enriched	lysates	(100	μL)	were	added	in	a	1:5	dilution	in	1	%	(w/v)	milk	Marvel	
in	PBS-T	 to	 an	ELISA	plate	 coated	with	2	μg/mL	HER2.	After	 an	hour	 incubation	at	
37°C,	the	plate	was	washed	three	times	with	PBS-T	and	three	times	with	PBS.	ScFv	
were	 detected	 by	 adding	 100	μL	 of	 a	 1:1,000	 dilution	 of	 HRP-	 conjugated	 anti-HA	
mAb		in	1	%	(w/v)	milk	Marvel	in	PBS-T.	The	plate	was	subsequently	incubated	for	an	
hour	 at	 37°C	 and	 washed	 as	 before.	 HRP	 product	 formation	 was	 detected	 as	
explained	in	Section	2.2.5.3.	
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2.2.6.2	Immobilised	metal	affinity	chromatography	(IMAC)	purification	
	
Prior	to	scFv	purification	by	IMAC,	the	expression	procedure	was	scaled-up.	A4	scFv	
glycerol	stock	was	streaked	on	a	LB	agar	plate	containing	100	μg/mL	carbenicillin.	A	
single	colony	was	 inoculated	 into	 in	5	mL	of	SB	media	with	100	μg/mL	carbenicillin	
and	 incubated	 O/N	 at	 220	 rpm	 and	 37°C.	 Four	 mL	 of	 the	 O/N	 culture	 were	 sub-
cultured	 in	 996	mL	 of	 SB	media	 containing	 100	μg/mL	 carbenicillin,	 1X	 505	media	
supplemnt	and	1mM	MgS04.	The	culture	was	incubated	at	220	rpm	and	37°C	until	an	
approximate	OD600=	 0.6	was	 reached.	 Expression	was	 then	 induced	by	 addition	 of					
1	mM	IPTG	and	the	culture	was	incubated	O/N	at	220	rpm	and	30°C.		
	
The	 following	morning,	 the	 culture	was	 transfer	 to	 four	 250-mL	 sorvall	 tubes	 and	
centrifuged	at	3,220	x	g	 for	30	minutes.	The	pellets	were	 resuspended	 in	10	mL	of	
sonicator	 buffer	 from	 tube	 to	 tube	 and	 transferred	 to	 a	 clean	 50-mL	 tube.		
Resuspended	pellets	were	subjected	 to	 three	cycles	of	 freeze-thawing	 to	burst	 the		
E.	 coli	 cells	 and	 release	 periplasmic	 proteins.	 To	 ensure	 complete	 cell	 lysis,	 the	
sample	was	sonicated	on	ice	4	seconds	on,	2	seconds	off,	at	40		%	amplitude,	for	2	
minutes.	 The	 sonicated	 sample	 was	 then	 dispensed	 in	 2-mL	 Eppendorf	 tubes	 and	
centrifuged	 at	 15,994	x	g	 for	 30	 minutes	 at	 4°C	 in	 a	 HermLe	 Z2333	 M-K2	
microcentrifuge.	Meanwhile,	2	mL	of	Ni+-NTA	resin	(Qiagen)	were	equilibrated	with	
40	mL	of	running	buffer.	After	centrifugation,	the	lysates	were	collected,	pooled	and	
filtered	though	a	0.2-μm	filter	to	remove	any	residual	cell	debris.	The	filtered	lysates	
were	 added	 to	 a	 50-mL	 tube	 containing	 the	 equilibrated	 resin	 and	 incubated	 in	 a	
roller	for	1	hour	at	4°C.	The	lysate/resin	mixture	was	transferred	to	a	20-mL	column.	
The	flow-though	was	collected	and	stored	at	4°C.	The	column	was	washed	twice	with	
30	mL	of	running	buffer	to	remove	any	 loosely	bound	non-specific	proteins.	Bound	
scFv	 was	 eluted	 with	 8	 mL	 of	 100	 mM	 NaOH,	 pH	 4.4	 and	 collected	 in	 a	 tube	
containing	4	mL	of	neutralisation	buffer	 (2	mL	of	100	mM	NaOH	and	2	mL	of	10X	
PBS).	A	second	elution	step	using	a	high	concentration	of	imidazole	(1X	PBS,	250	mM	
Imidazole,	 pH	 7.5)	 was	 performed	 to	 elute	 remaining	 bound	 proteins.	 The	 eluted	
scFv	was	then	buffer	exchanged	against	sterile	PBS	(10	mM,	pH	7.3)		using	a	10	kDa	
	 61	
‘cut-off’	 VivaspinTM	 column	 (AGB,	 VS0611).	 After	 buffer	 exchange,	 scFv	
concentration	was	quantified	using	the	Nanodrop	ND-1000	Spectrophotometer.		
	
2.2.6.3	 Optimisation	 of	 assay	 parameters	 for	 HER2	 detection	 in	 a	 competitive	
format	
	
The	assay	conditions	for	the	development	of	a	competitive	ELISA	for	the	detection	of	
HER2	using	the	IMAC-purified	scFv	were	optimised	by	checkerboard	ELISA	(Murphy	
and	O’Kennedy,	forthcoming).		
	
The	 optimal	 coating	 buffer	 was	 selected	 by	 testing	 three	 different	 buffers	 at	
different	pHs:	10	mM	PBS,	pH	7.3;	20	mM	Tris	buffer,	pH	8.5;	and	50	mM	carbonate	
buffer,	pH	9.6.	The	ELISA	plate	was	coated	with	1	μg/mL	of	HER2	prepared	in	each	of	
the	buffers	O/N	at	4°C.	The	immunoplate	was	blocked	with	300	μL	of	5		%	(w/v)	milk	
Marvel	 in	PBS	for	90	minutes	at	37°C	and	then	washed	three	times	with	PBS-T	and	
three	times	with	PBS.	Anti-HER2	A4	scFv	dilutions	(1:100–10,000,000)	were	added	to	
the	wells	and	incubated	for	1	hour	at	37°C.	The	plate	was	washed	as	before	and	100	
µL	of	a	1:1,000	dilution	of	HRP-labelled	anti-HA	antibody	were	added.	After	an	hour	
incubation	 at	 37°C,	 the	 plate	 was	 washed	 as	 before	 and	 HRP	 was	 detected	 as	
previously	described	in	Section	2.2.5.3.		
	
Once	 the	 optimal	 coating	 buffer	 was	 chosen,	 checkboard	 ELISA	 was	 used	 for	 the	
determination	of	optimal	HER2	coating	concentration	and	optimal	 scFv	A4	dilution	
for	 use	 in	 a	 competitive	 assay.	 A	 Nunc	Maxisorb™	plate	 was	 coated	 with	 varying	
HER2	concentrations	 (1	μg/mL,	2	μg/mL	and	4	μg/mL)	 in	carbonate	buffer	 (50	mM,	
pH	9.6).	The	direct	ELISA	was	perfomed	as	explained	in	Section	2.2.5.3.	
	
2.2.6.4	Competitive	ELISA	for	the	detection	of	HER2	using	A4	scFv	
	
A	Nunc	MaxiSorp™	clear	plate	was	coated	with	100	µL	of	1	µg/mL	HER2	 in	50	mM	
PBS,	pH	9.6	O/N	at	4°C.	The	plate	was	blocked	with	300	µL	of	5	%	(w/v)	milk	Marvel	
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in	1X	PBS	for	90	minutes	at	37°C.	Meanwhile,	50	µL	of	different	HER2	concentrations	
were	incubated	with	the	same	volume	of	a	1:5,000	dilution	of	the	chicken	anti-HER2	
A4	scFv	(for	final	HER2	concentrations	from	5-10,035	ng/mL	and	a	final	1:10,000	scFv	
dilution)	for	10	minutes	at	37°C.	The	plate	was	washed	three	times	with	PBS-T	and	
three	 times	with	PBS	and	 the	mixture	was	added	 to	 the	wells	and	 incubated	 for	1	
hour	at	37°C.	 The	plate	was	washed	as	before	and	100	µL	of	 a	1:1,000	dilution	of	
HRP-labelled	 anti-HA	 antibody	 was	 added.	 After	 an	 hour	 incubation	 at	 37°C,	 the	
plate	was	washed	as	before	and	HRP	was	detected	as	previously	described	in	Section	
2.2.5.3.	
	
2.2.6.5	Fluorescence-based	competitive	ELISA	for	the	detection	of	HER2			
The	competitive	assay	was	performed	as	previously	described	in	Section	2.2.6.4	with	
the	 following	exceptions.	The	 immunoplate	used	 to	perform	the	assay	was	a	black	
Nunc	MaxiSorp	plate,	 designed	 to	 quench	 autofluorescence.	HRP	was	detected	by	
the	 addition	 of	 Ampliflu	 Red	 peroxidase	 substrate.	 The	 Ampliflu	 Red	 working	
solution	 (50	 µM	Amplifu	 Red,	 200	 µM	H202	 in	 10	mM	 PBS)	was	 prepared	 using	 a						
10	mM	Ampliflu™	Red	stock	in	DMSO	and	a	20	mM	H202	stock	in	diH2O,	and	added	
(100	µL)	to	the	wells	following	the	washing	step	after	incubation	with	the	secondary	
antibody.	On	contact	with	the	HRP-labelled	anti-HA	antibody,	Ampliflu	Red	converts	
into	highly	fluorescent	resorufin.	After	a	30-minute	incubation,	imaging	was	done	on	
a	 Tecan	 Safire2™	 Microplate	 Reader	 Infinite™	 200	 at	 544/590	 nm	
excitation/emission	wavelengths.	
	
2.2.7	Isolation	and	characterisation	of	polyclonal	antibodies	to	HER2	
2.2.7.1	IgY	purification	from	eggs	of	an	immunised	chicken	
	
Polyclonal	antibodies	(IgY)	were	purified	from	three	eggs	of	the	immunized	chicken.	
The	egg	yolks	were	separated	from	the	albumen	using	an	egg	separator	and	IgY	was	
purified	 using	 the	 IgY	 EggsPress	 Purification	 Kit,	 as	 per	 the	 manufacturer’s	
instructions.		The	IgY	pellet	was	resuspended	in	the	original	yolk	volume	with	PBS	(10	
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mM,	 pH	 7.3)	 and	 the	 concentration	 was	 quantified	 using	 the	 Nanodrop	 ND-1000	
Spectrophotometer.	The	yield	of	 the	preparation	was	calculated	by	multiplying	the	
concentration	by	the	final	volume	of	 IgY.	The	IgY	solution	was	then	filter-sterilized,	
aliquoted	in	1-mL	volumes	and	stored	at	-20°C.			
	
2.2.7.2	Competitive	ELISA	for	anti-HER2	polyclonal	antibody	characterisation	
	
A	Nunc	MaxiSorp™	plate	was	coated	with	100	µL	of	2	µg/mL	HER2	in	PBS	(10	mM,	
pH	7.3)	O/N	at	4°C.	The	plate	was	blocked	with	300	µL	of	5	%	(w/v)	milk	Marvel	in	1X	
PBS	 for	90	minutes	at	37°C.	Meanwhile,	different	HER2	concentrations	 from	30	 to	
1,200	ng/mL	(50	µL)	were	incubated	with	the	same	volume	of	a	1:1,000	dilution	of	
the	 chicken	 anti-HER2	 pAb	 for	 10	minutes	 at	 37°C	 (for	 final	 Her	 2	 concentrations	
from	 15	 to	 600	 ng/mL	 and	 a	 final	 antibody	 dilution	 of	 1:2,000).	 The	 plate	 was	
washed	three	times	with	PBS-T	and	three	times	with	PBS	and	the	mixture	was	added	
to	the	wells	and	incubated	for	1	hour	at	37°C.	The	plate	was	washed	as	before	and	
100	µL	of	a	1:2,000	dilution	of	HRP-labelled	anti-chicken	IgY	Fab	was	added.	After	an	
hour	 incubation	at	37°C,	the	plate	was	washed	as	before	and	HRP	was	detected	as	
previously	described	in	Section	2.2.5.3.	
	
2.2.8	Development	of	a	novel	centrifugal	microfluidic	platform	for	multiplex	
biomarker	detection	
2.2.8.1	Centrifugal	disc	fabrication							
	
The	 centrifugal	 disc	 consisted	 of	 laminated	 layers	 made	 of	 poly(methyl	
methacrylate)	 (PMMA)	and	double-sized,	pressure-sensitive	adhesive	 (PSA).	PMMA	
layers	(1.5	mm	thick)	were	cut	using	a	CO2	laser	cutting	system	(Epilog	Zing,	USA)	to	
create	 through-holes,	 reservoirs	 and	air	 venting	holes.	 	Microchannels	were	 cut	 in	
PSA	 (0.086	 mm	 thick)	 using	 a	 paper	 cutter	 (CraftRobo	 Pro,	 Graphtec,	 USA).	
Dissolvable	 film	 (DF)	 valves	 were	 manufactured	 by	 cutting	 through	 holes	 in	 PSA,	
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sticking	 the	 dissolvable	 film	 (previous	 removal	 of	 the	 PSA	 top	 layer	 to	 expose	 the	
adhesive)	and	performing	a	final	cut	to	contour	the	DF	tabs.		
All	 layers	were	carefully	aligned	and	roll-	pressed	(Hot	Roll	Laminator,	Chemsultant	
Int.,	US)	following	the	diagram	in	Figure	2.1.	 	DF	tabs	we	placed	in	the	voids	 in	DF-
support	layer	and	sealed	with	DF-cover	layer.		
	
	
	
Figure	2.1.	Exploded	assembly	drawing	of	the	multi-layered,	centrifugal	microfluidic	disc.	The	disc	is	
made	up	of	four	layers	of	Poly(methyl	methacrylate)	(PMMA)–Base,	Midlayer,	Reservoirs,	Vents–and	
other	 four	 layers	 of	 Pressure-sensitive	 adhesive	 (P-SA)–Microchannels,	 DF	 cover,	 DF	 support,	 and	
Lower	channels–.	The	plastic	 layers	 (PMMA)	contain	the	chambers,	whereas	the	adhesive	 layers	 (P-
SA)	contain	the	fluidic	channels.	Figure	provided	by	Dr.	Rohit	Mishra.	
	
2.2.8.2	Centrifugal	disc	testing				
	
Centrifugal	microfluidic	discs	were	tested	in	an	‘in-house’	built	test	stand	(Figure	2.2)	
that	allowed	the	spinning	of	the	disc	and	the	observation	of	reagent	release	within	
the	fluidic	network.		
	
The	 rotational	 frequency	of	 the	 rotor	 can	be	 set	by	 the	user	using	 software	 in	 the	
control	 PC	 (Winmotion,	 Faulhaber,	 Germany).	 Images	 of	 the	 spinning	 disc	 can	 be	
obtained	thanks	to	a	stroboscopic	light	and	a	camera	attached	to	a	12X	zoom	lens.		
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Figure	2.2.	Centrifugal	testing	set	up	for	spinning	of	the	disc	and	observation	of	the	fluids	behaviour.	
The	components	inside	the	red	dashed-box	are	inside	a	protective	box.	
		
2.2.8.3	Conventional	benchtop	sandwich	ELISA	for	the	detection	of	fPSA		
The	ELISA	plate	(half-area	4.5	mm	well	bottom	diameter,	Corning)	was	coated	with	
60	μL	of	anti-PSA	polyclonal	antibody	(Abcam)	at	1.6	μg/mL	in	PBS	(10	mM,	pH	7.4)	
and	 stored	 overnight	 at	 4°C.	 The	 immunoplate	 was	 blocked	 with	 5	%	 (w/v)	 milk	
Marvel	 in	PBS	for	1	hour	at	37°C	and	40	μL	of	six	different	free	PSA	concentrations	
(0.1,	1,	4,	10,	100	and	1000	ng/mL)	were	applied	to	the	wells	and	incubated	for	10	
minutes,	 while	 shaking,	 at	 RT.	 The	 plate	 was	 washed	 once	 with	 1	%	 (w/v)	 milk	
Marvel	 in	PBS	and	40	μL	of	anti-PSA	scFv	B8	were	added.	The	plate	was	 incubated	
and	washed,	 as	 above,	 after	 the	 addition	 of	 each	 antibody	 in	 the	 following	 steps.	
Bound	 scFv	 antibodies	 were	 detected	 using	 an	 HRP-labelled	 anti-HA	 antibody	
following	 the	 addition	 of	 tetramethylbenzidine	 (TMB)	 substrate.	 The	 reaction	was	
stopped	 after	 10	minutes	 of	 incubation	 by	 the	 addition	 of	 10	%	 (v/v)	HCl	 and	 the	
Camera	
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12	x	Zoom	
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Motor	
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absorbance	was	measured	at	450	nm.	The	absorbance	values	(A)	were	normalized	by	
dividing	by	the	blank	value	(A0)	and	plotted	as	a	percentage	of	relative	absorbance	
(%	A/A0).	
	
2.2.8.4	 Conventional	 competitive	 ELISA	 for	 the	 detection	 of	 HER2	 extracellular	
domain	(ECD)			
HER2	was	added	at	a	concentration	of	1	μg/mL	in	carbonate	buffer	(50	mM,	pH	9.6)	
onto	 the	wells	 of	 an	 ELISA	 plate	 (60	μL	 per	 well)	 and	 incubated	 overnight	 at	 4°C.	
After	 blocking	 with	 5	%	 (w/v)	 milk	 Marvel	 for	 1h	 at	 37°C,	 a	 1:1	 mixture	 of	 HER2	
concentrations	(from	10	to	1000	ng/mL)	with	anti-HER2	ECD	scFv	A4	was	added	to	
the	wells.	The	plate	was	incubated	for	10	minutes,	while	shaking,	at	RT,	and	washed	
once	with	1	%	(w/v)	milk	Marvel	in	PBS.	An	HRP-labelled	anti-HA	antibody	was	used	
to	 detect	 bound	 scFv.	 This	 was	 incubated	 and	 washed	 as	 above,	 followed	 by	 the	
addition	 of	 TMB	 substrate.	 After	 10	minutes,	 the	 reaction	was	 stopped	with	 10	%	
(v/v)	HCl	and	the	absorbance	was	measured	and	plotted	as	previously	described	 in	
Section	2.2.9.5.		
2.2.8.5	Lab-on-a-Disc	ELISA	protocols		
Prior	 to	 assembly	 of	 the	 top	 two	 layers	 of	 the	 disc,	 overnight	 capture	 antibody	
coating	 followed	by	blocking	of	 the	polystyrene	surface	of	 the	 incubation	chamber	
were	carried	out	in	the	same	manner	as	in	the	conventional	ELISA	(Sections	2.2.8.3	
and	 2.2.8.4).	 After	 blocking,	 the	 top	 two	 layers	 were	 assembled	 and	 the	 assay	
reagents	 (40	μL)	 were	 added	 to	 their	 corresponding	 chamber	 and	 centrifugally	
propelled	to	the	 incubation	chamber.	The	release	sequence	was	as	 follows.	For	the	
sandwich	 ELISA:	 fPSA	 antibody	 standards,	 buffer	wash,	 scFv	 B8,	 buffer	wash,	 HRP-
labelled	anti-HA	antibody,	buffer	wash,	TMB	and	10	%	(v/v)	HCl.	For	the	competitive	
ELISA:	HER2	standards-scFv	A4	mixture,	buffer	wash,	HRP-labelled	anti-HA	antibody,	
buffer	wash,	TMB	and	10	%	(v/v)	HCl,	All	washing	steps	were	carried	out	with	40	μL	
	 67	
of	 1	%	 (w/v)	milk	Marvel	 in	PBS	with	 an	 incubation	 times	of	 30	 seconds.	All	 other	
incubation	times	were	of	10	minutes,	unless	stated	otherwise.	
2.2.9	Evaluation	of	anti-PSA	recombinant	antibodies	by	optical	and	electrochemical	
magneto-immunoassay	
2.2.9.1	Tosyl-modified	magnetic	particles	bioconjugation	
	
Surface-activated	 paramagnetic	 particles	 (Dynabeads®	 M-280	 Tosylactivated,	
Invitrogen)	allow	covalent	binding	to	primary	amino	groups	in	antibodies.		
	
Dynabeads	were	resuspended	in	the	vial	by	gently	vortexing	and	approximately	1	mg	
of	beads	was	washed	twice	in	1	mL	of	borate	buffer	by	gently	mixing	in	a	2	mL-tube	
and	 discarding	 the	 supernatant.	 To	 do	 this,	 the	 tube	 was	 placed	 in	 a	 magnet	
separator	 (DynaMagTM-2	magnet)	 for	2	minutes	and	 the	 supernatant	was	 carefully	
pipetted	without	 disrupting	 the	 beads	 that	were	 bound	 to	 the	magnet.	 Then,	 the	
tube	was	 removed	 from	 the	magnet	 and	 the	beads	were	 resuspended	 in	 20	μL	of	
antibody	(20	μg	anti-fPSA	scAb	in	PBS),	followed	by	adding	130	μL	borate	buffer	and	
100	μL	 of	 borate/NH4SO4	 buffer	 to	 a	 final	 volume	 of	 250	μL.	 The	 addition	 of	
ammonium	 sulfate	 (borate/NH4SO4	 buffer)	 to	 a	 final	 concentration	 of	 1.2	 M	
increases	 the	 amount	 of	 antibody	 coupled	 to	 the	 beads,	 improving	 the	 coupling	
efficiency.	The	solution	was	incubated	for	9	hours	in	a	Thermomixer	set	at	800	rpm	
and	37°C,	and	O/N	on	a	roller	at	RT.	After	incubation,	the	bioconjugated	beads	were	
gently	vortexed	and	placed	 in	 the	magnet	 separator	 for	2	minutes	 to	separate	 the	
beads	 from	 the	 solution.	 The	 tube	 was	 then	 removed	 from	 the	 magnet	 and	 the	
beads	 were	 blocked	 by	 adding	 1	 mL	 of	 0.5	%	 (w/v)	 BSA	 in	 phosphate	 buffer	 and	
incubating	 in	 the	 Thermomixer	 for	 2	 hours	 at	 800	 rpm	 and	 37°C.	 The	 blocking	
solution	was	discarded	and	the	beads	were	washed	twice	with	1	mL	of	0.1	%	(w/v)	
BSA	in	phosphate	buffer	as	described	before.	After	the	second	wash,	the	beads	were	
resuspended	 in	 250	μL	 of	 0.1	%	 (w/v)	 BSA	 in	 phosphate	 buffer	 to	 a	 final	
concentration	of	4	mg/mL.	Sodium	azide	 (0.01	%	 [w/v])	was	added	as	preservative	
before	storing	the	beads	at	4°C.	
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2.2.9.2	Antibody	titration	for	determination	of	bioconjugation	efficiency	
	
The	coupling	efficiency	was	evaluated	by	measuring	the	amount	of	scAb	present	 in	
the	 supernatant	 after	 bioconjugation.	 Once	 antibody	 concentration	 in	 the	
supernatant	 is	 quantified	 by	 magneto-ELISA,	 bound	 antibody	 concentration	 is	
estimated.	
	
After	 bioconjugation,	 supernatant	 was	 collected	 using	 a	 magneto	 plate	 separator	
(see	Figure	2.3).	ELISA	plates	 (Greiner	Bio-One	655061)	were	coated	with	50	µL	of	
supernatant	 dilutions	 (1:1–1:500)	 in	 triplicate,	 including	 also	 the	 dilutions	 for	 a	
titration	 curve	 for	 the	 scAb	 (in	 the	 range	of	 1–0.015	μg/mL,	prepared	 in	 the	 same	
buffer	used	for	the	bioconjugation	step	–	Borate	buffer/Borate	ammonium	sulphate	
buffer/	Phosphate	buffer	in	a	100:130:20	ratio).	This	was	incubated	O/N	at	4°C.	After	
incubation,	 the	 coating	 solution	 was	 discarded	 and	 the	 wells	 were	 washed	 with				
150	 µL	 of	 10	 mM	 phosphate	 buffer,	 while	 shaking,	 for	 5	 minutes.	 The	 washing	
solution	was	 removed	and	 the	plate	was	blocked	with	150	μL	of	3	%	 (w/v)	BSA	 in	
0.05	%	(v/v)	Tween	20	in	PBS	(PBS-T),	incubating	static	for	2	hours	at	RT.	The	ELISA	
plate	was	then	washed	twice	by	adding	150	μL	of	PBS-T	to	each	well	and	shaking	for	
5	minutes.	After	washing,	100	μL	of	HRP-labeled	secondary	antibody	dilution	in	2	%	
(w/v)	 BSA	 in	 PBS-T	were	 added	 to	 the	wells	 and	 incubated	 for	 30	minutes,	 while	
shaking,	at	RT.	The	antibody	solution	was	then	removed	and	the	plate	was	washed	
as	before.	TMB	substrate	was	diluted	tenfold	in	0.02	M	citrate	buffer	(pH	6),	100	µL	
were	added	 to	 the	plate	and	 incubated	 for	15	minutes,	while	 shaking,	 in	 the	dark.	
The	reaction	was	stopped	by	addition	of	100	µL	of	2	M	H2SO4	and	the	absorbance	
measured	at	450	nm.	 	The	coupling	efficiency,	expressed	as	the	%	antibody	uptake	
was	 calculated	 using	 the	 following	 equation:	 [(Ab	 concentration	 in	 Pre-Coupling	
Solution	 x	 D)	 –	 (Ab	 concentration	 in	 Post-Coupling	 Solution	 x	 D)]	 x	 100/(Ab	
concentration	in	Pre-Coupling	Solution	x	D),	where	D	=	dilution	factor.	
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Figure	2.3.	Schematic	display	of	the	steps	involved	in	the	bioconjugation	of	scAb	E1	to	tosyl-activated	
magnetic	particles	(Adapted	from	Liébana	et	al.,	2013).	
	
	
2.2.9.3	Colorimetric	magneto	ELISA		
	
Bioconjugated	magnetic	particles	(MPs)	were	washed	twice	with	100	μL	PBS-T	(using	
the	DynaMagTM-2	magnet)	 and	 resuspended	 in	 PBS-T	 to	 a	 final	 concentration	of	 2	
mg/mL.	Once	washed,	the	MPs	were	added	onto	each	well	containing	100	μL	PBS-T	
(final	MPs	concentration	0.1	mg/mL).	The	ELISA	plate	was	placed	in	a	magnetic	plate	
separator	to	remove	the	supernatant	and	100	μL	of	free	PSA	dilutions	(20,	10,	5,	1,	
0.1	ng/mL)	or	PBS-T	(blank)	were	added	to	the	wells.	The	plate	was	incubated	for	40	
minutes	while	shaking	at	room	temperature	and	then	washed	twice	with	100	μL	of	
PBS-T.	 Secondary	 antibody,	 ab24466	 (HRP-labelled	 anti-PSA	 antibody),	 was	 added	
(100	μL	 diluted	 1:1000	 in	 2	%	 [w/v]	 BSA	 in	 PBS-T)	 and	 incubated	 for	 30	 minutes,	
while	 shaking,	 at	RT.	 The	ELISA	plate	was	washed	 twice	as	before	and	100	μL	of	 a	
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1:10	 dilution	 of	 TMB	 in	 0.02M	 citrate	 buffer,	 pH	 6,	 was	 added	 to	 the	 wells	 and	
incubated	for	20	minutes	while	shaking	at	RT.	The	reaction	was	stopped	with	100	μL	
of	 2	M	H2SO4	and	 each	sample	was	 transferred	 to	 the	 reading	microplate	 (269620	
Thermofisher)	 to	 measure	 the	 absorbance	 at	 450	 nm	 using	 a	 Sunrise™	 Tecan	
Microplate	 Reader.	 The	 results	 were	 normalised	 by	 substracting	 the	 blank	 value	
from	the	values	of	the	standards	prior	to	plotting	the	absorbance	values.	
	
2.2.9.4	Amperometric	magneto-immunoassay		
	
All	 the	 steps	 involved	 in	 the	 amperometric	 detection	 of	 PSA	 using	 a	 magneto-
immunoassay	are	illustrated	in	Figure	2.4.		
	
Bioconjugated	MPs	 (130	μL)	were	 placed	 in	 the	DynaMag™-2	magnet	 and	washed	
twice	with	130	μL	of	PBS-T,	by	changing	buffer	and	gently	mixing.	Eppendorf	tubes	
containing	100	μL	of	PBS-T	(blank)	or	free	PSA	standards	(0,	0.1,	1,	5,	10,	20	ng/mL)	
were	prepared	in	PBS	(10	mM,	pH	7.4)	and	MPs	were	added	to	a	final	concentration	
of	0.1	mg/mL	and	incubated	for	40	minutes	at	600	rpm	and	25°C	in	a	Thermomixer.	
After	 incubation,	 the	MPs	 were	 washed	 twice	 with	 100	μL	 of	 PBS-T.	 The	 washing	
solution	 was	 discarded	 and	 100	μL	 of	 0.9	μg/mL	 HRP-labelled	 anti-PSA	 antibody	
(ab24466,	Abcam)	were	added	to	the	wells	and	incubated	for	40	minutes	at	600	rpm	
and	25°C	in	the	Thermomixer.	The	bioconjugated	beads	were	then	washed	twice	as	
before,	the	supernatant	was	removed	and	the	MPs	were	resuspended	in	95	μL	of	0.1	
M	phosphate	buffer	with	0.1	M	KCl.	Freshly	prepared	hydroquinone	(mediator)	and	
hydrogen	peroxide	 (substrate)	were	added	to	a	 final	concentration	of	2	mM	and	5	
mM,	 respectively.	 The	 solution	was	mixed	and	 transferred	 to	 the	electrode	with	a	
magnet	 underneath.	 The	 solution	 was	 incubated	 on	 the	 electrode	
(BE2150327D2/001,	 Gwent	 Group	 Ltd.)	 for	 2	 minutes	 before	 applying	 a	 -15	 V	
reduction	 potential	 during	 60	 seconds,	 taking	 measurements	 at	 30	 seconds.	
Amperometric	measurements	were	taken	for	each	PSA	dilution	and	each	electrode	
design	in	triplicate.	The	results	were	normalised	by	substracting	the	blank	value	from	
the	values	of	the	standards	prior	to	plotting	the	amperometric	signal	values.	
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Figure	 2.4.	 Schematic	 representation	 of	 the	 immunomagnetic	 separation	 and	 amperometric	
detection	of	free	PSA	(‘two-step’	protocol).	
	
	
	
2.2.10	Immunosensor	fabrication	and	characterization	for	HER2	detection	
	
	2.2.10.1	Fabrication	of	the	immunosensor	and	electrochemical	procedure	
	
The	 colloidal	 gold	was	 prepared	 in	 the	 Jaypee	 Institute	 of	 Information	 Technology	
utilising	citrate	 reduction	of	chloroauric	acid	 (HAuCl4),	based	on	a	slightly	modified	
Turkevich	method,	as	reported	by	(Turkevich	et	al.,	1951;	Kimling	et	al.,	2006).	The	
step-by-step	 fabrication	 of	 the	 nanoparticlebased	 immunosensor	 is	 illustrated	 in	
Figure	2.5.		
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Figure	2.5.	Schematic	representation	of	the	immunosensor	fabrication.	
	
	
Screen	 printed	 carbon	 electrodes	 (BE2050824D1/015,	 Gwent	 Group	 Ltd.)	 with	
carbon	as	the	working	and	counter	electrodes	and	Ag/AgCl	as	reference	electrode,	
were	used	to	fabricate	the	immunosensor.	Firstly,	the	carbon	electrode	was	cleaned	
by	 adding	 100	μL	 of	 H2SO4	 (100	 mM)	 and	 performing	 a	 single	 cycle	 of	 cyclic	
voltammetry	(CV)	over	the	potential		range	of		−1	V	to	+1	V	at		a	scan	rate	of	0.1	V/s.	
The	 electrode	 was	 then	 washed	 with	 100	μL	 of	 redistilled	 water.	 The	 cleaning	
procedure	was	repeated	with	a	saturated	solution	of	Na2CO3	followed	by	a	washing	
step	 with	 100	μL	 of	 redistilled	 water	 to	 remove	 all	 impurities.	 The	 surface	 of	 the	
working	 electrode	 was	 modified	 using	 3	μL	 of	 2	 mg/mL	 cyteamine	 hydrochloride	
(Cys)	and	the	electrode	was	kept	for	a	further	2	hours	at	room	temperature	 in	the	
dark	 for	 effective	 binding	 of	 Cys	 on	 to	 the	 electrode	 surface.	 The	 electrode	 was	
washed	 with	 100	μL	 redistilled	 water	 followed	 by	 addition	 of	 3	μL	 of	 0.8	 mg/mL	
citrate-coated	gold	nanoparticles	 	 (AuNPs).	The	high	affinity	of	 thiols	groups	of	Cys	
towards	gold	results	in	stable	covalent	Au-S	bond.	Physically	adsorbed	excess	AuNPs	
were	 washed	 away	 with	 100	μL	 PBS	 (0.1	 M,	 pH	 7.4)	 and	 then	 redistilled	 water.	
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Subsequently,	 the	AuNP-modified	electrode	 surface	was	 functionalized	with	amine	
groups	 using	 3	 µL	 cystamine	 dihydrochloride	 (2	 mg/mL)	 to	 promote	 the	 covalent	
bond	 formation	between	 the	 free	amine	groups	on	 the	 surface	of	AuNPs	with	 the	
carboxylic	 groups	 at	 the	 tail	 of	 the	 recombinant	 antibodies	 to	 ensure	 proper	
orientation	 of	 the	 antibody.	 Finally,	 3	μL	 of	 anti-HER2	 scFv	 A4	 suspended	 in	
carbonate	buffer	(1	μL		of	a	1:500	dilution	of	scFv	in	2	μL	of	carbonate	buffer,	pH	9.0)	
was	added	on	the	modified	working	electrode	and	allowed	to	incubate	overnight	at	
4°C.The	process	was	 followed	by	casting	3	μL	of	BSA	(1	mg/mL)	over	the	electrode	
and	incubated	for	45	min	at	37°C	to	block	available	active	sites	to	avoid	nonspecific	
binding.	
	
2.2.10.2	Impedance	measurement	procedure	
	
Impedance	 of	 the	 immunosensor	 was	 measured	 by	 recording	 electrochemical	
impedance	spectra	using	 the	electrochemical	workstation	CH604E	 (CH	 Instruments	
Ltd.).	Initially,	a	3	μL-droplet	of	the	desired	antigen	concentration	was	added	to	the	
immunosensor	surface	and	incubated	for	15	minutes.	Then,	the	immunosensor	was	
washed	 with	 100	μL	 of	 PBS	 (0.01	 M,	 pH	 7.4)	 to	 remove	 non-specifically	 bound	
antigen.	 Finally,	 electrochemical	 impedance	 (EIS)	measurement	was	 performed	 by	
dropping	70	μL	of	the	redox	couple	(5	mM	K4[Fe(CN)6]/K3[Fe(CN)6]	in	0.01	M	PBS	(pH	
7.4),	 thus	 covering	 the	 working,	 counter	 and	 reference	 electrodes	 of	 the	
immunosensor.		
	
Optimum	incubation	times,	pH	and	temperature	for	immunocomplex	formation	was	
evaluated	 by	 recording	 EIS	 spectra	 for	 0.1	 ng/mL	 anti-HER2	 scFv	 A4	while	 varying	
one	 of	 the	 parameters	 but	 keeping	 the	 other	 two	 parameters	 constant.	 Rct	 was	
calculated	 by	 fitting	 Randles	 equivalent	 circuit	 (Randles,	 1947)	 simulation	 results	
with	experimental	data	using	simulation	module	of	EIS	technique,	CHI604E.	
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3.1	INTRODUCTION	
	
As	previously	discussed,	there	are	two	major	problems	with	the	PSA	test	for	prostate	
cancer	(PCa)	diagnosis.	Firstly,	PSA	is	not	specific	for	prostate	cancer	and	can	also	be	
found	elevated	in	blood	during	other	prostate	pathologies.	Secondly,	this	biomarker	
lacks	the	capacity	to	predict	aggressive	disease	at	the	time	of	diagnosis.	This	 is	the	
primary	reason	why	it	is	of	utmost	importance	to	develop	new	biomarkers	that	can	
differentiate	 between	 indolent	 and	 aggressive	 PCa.	 A	 panel	 of	 non-invasive	
biomarkers	for	PCa	represents	the	best	alternative	to	PSA	testing.	HER2	is	a	potential	
candidate	biomarker	for	this	panel.	
	
3.1.1	The	HER2	oncogene		
Rodent	neu,	the	rodent	homologous	to	HER2	oncogene,	was	first	discovered	in	1981	
when	 Shih	 et	 al.	 (1981)	 described	 how	 DNA	 from	 a	 chemically-induced	 rat	
neuroglioblastoma	was	able	to	induce	malignant	transformation	of	mouse	fibroblast	
NIH3T3	cells	on	transfection	(Shih	et	al.	1981).	The	neu	gene	encodes	for	a	185	KDa	
transmembrane	 protein	 (p185)	 with	 a	 tyrosine	 kinase	 domain	 and	 also	 shows	
homology	 to	 the	 v-erbB	 (avian	 erythroblastic	 leukemia	 viral	 oncogene	 homolog	 2)	
oncogene	and	 the	epidermal	 grow	 factor	 receptor	 (EGFR)	 (Vennstrom	and	Bishop,	
1982;	Schechter	et	al.,	1985).	In	1985,	King	et	al.	demonstrated	the	amplification	of	
this	gene	in	a	human	breast	carcinoma	and	named	it	human	epidermal	growth	factor	
receptor	 2	 (HER2)	 gene.	 The	 two	 last	 members	 of	 the	 epidermal	 growth	 factor	
receptor	 family	were	 subsequently	 discovered	 (Kraus	et	 al.,	 1989;	 Plowman	et	 al.,	
1993).	 The	 complete	 family	 consists	 of	 four	members:	 EGFR	 (HER1,	 erbB1),	 HER2	
(erbB2,	HER2/neu,	p185her2/neu),	HER3	(erbB3),	and	HER4	(erbB4).		
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3.1.2	HER	family	signaling	pathways		
HER	family	members	are	type	I	transmembrane	growth	factor	receptors	that	achieve	
activation	by	forming	dimers	with	other	HER	receptors,	upon	ligand	binding	(Figure	
3.1).	 The	 exception	 is	 HER2,	 that	 always	 exists	 in	 a	 dimerization-prone	 extended	
conformation	 (Figure	3.1)	and	 it	 is	 the	preferred	heterodimerisation	partner	 for	all	
HER	receptors	(Zhang	et	al.,	2007).	Though	most	receptor	dimerisation	processes	are	
mediated	 by	 ligands,	 spontaneous	 formation	 of	 HER2	 homodimers	 has	 been	
reported	in	HER2-overexpressing	cells	(Fichter	et	al.,	2014;	Peckys	et	al.,	2015).	HER	
receptors	 possess	 a	 cytoplasmic	 tyrosine	 kinase	 domain	 and	 a	 C-terminal	 tail	with	
tyrosine	 autophosphorylation	 sites	 that	 allow	 downstream	 trans-activation.	 The	
exception	is	HER3,	which	has	a	defective	kinase	domain	and	is	only	activated	through	
heterodimerisation	(Zhang	et	al.,	2007).	
	
	
	
Figure	3.1.	Representation	of	HER	ligands	and	receptors.	After	ligand	binding	to	ErbB	receptors,	the	
extracellular	domain	changes	to	an	open	conformation	that	promotes	homo-	and	heterodimerisation.	
There	are	no	known	ligands	that	bind	to	HER2,	which	is	always	present	in	a	fixed	open	conformation.	
All	 HER	 receptors	 possess	 tyrosine	 kinase	 activity,	 except	 HER3,	 which	 contains	 a	 defective	 kinase	
domain.	Adapted	from	Zhang	et	al.	 (2007).	EGF–epidermal	growth	factor;	TGF–transforming	growth	
factor-alpha;	 AR–amphiregulin;	 HB-EGF–heparin-binding	 EGF-like	 growth	 factor;	 EPG–epigen;	 BTC–	
betacellulin;	NRG1-4–neuregulin	1–4.		
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Upon	 dimerization,	 phosphorylation	 of	 the	 intracellular	 tyrosine-kinase	 domain	 of	
the	 receptors	 occurs.	 This	 activates	 the	 receptors	 and	 initiates	 downstream	
signalling	 pathways	 (Gollamudi	 et	 al.,	 2016).	 Phosphorylated	 tyrosine	 residues	
(mainly	GRB2	and	Shc)	 activate	 SOS	protein,	which	 catalyses	 the	exchange	of	GDP	
with	GTP	to	promote	Ras-MAPK	pathway	activation	(Figure	3.2).	On	the	other	hand,	
receptor	dimerization	leads	to	the	recruitment	and	activation	of phosphoinositide-3-
kinase	 (PI3K),	which	phosphorylates	PIP2	 (phosphatidylinositol	 [3,4]-bisphosphate),	
activating	 the	 Akt	 pathway	 (Figure	 3.2).	 These	 pathways	 are	 involved	 in	 cell	
proliferation	 and	 survival.	 Thus,	 deregulation	 of	 HER2	 in	 cancer	 promotes	
tumorigenesis	 by	 the	 activation	 of	 a	 number	 of	 cellular	 responses,	 such	 as	 cell	
proliferation,	apoptosis	inhibition	and	angiogenesis	(Gollamudi	et	al.,	2016).		
	
	
	
	
Figure	 3.2	 Overview	 of	 HER	 family	 signalling	 pathways.	 Shc–SHC-transforming	 protein	 1;	 GRB2–
Growth	factor	receptor-bound	protein	2;	SOS–Son-of-sevenless	guanine	nucleotide	exchange	factor;	
GDP–Guanosine	 diphosphate;	 GTP–Guanosine	 triphosphate;	 Raf–Rapidly	 Accelerated	 Fibrosarcoma	
protein	 kinases;	 MEK–Mitogen-activated	 protein	 kinase	 kinase;	 MAPK–Mitogen-activated	 protein	
kinase;	 P13K–Phosphoinositide-3-kinase;	 PIP2–Phosphatidylinositol	 (3,4)-bisphosphate;	 PIP3–
Phosphatidylinositol	 (3,4,5)-trisphosphate;	 PTEN–Phosphatase	 and	 tensin	 homolog;	 Akt–Protein	
kinase	 B;	 VEGF–Vascular	 endothelial	 growth	 factor;	 MMPS–Matrix	 metalloproteinase	 enzymes;	
mTOR–Mechanistic	target	of	rapamycin;	NFκB–Nuclear	factor	kappa-light-chain-enhancer	of	activated	
B	 cells;	 BAD–Bcl-2-associated	 death	 promoter;	 FKHR–Forkhead	 in	 rhabdomyosarcoma	 protein;	
MDM2–Mouse	double	minute	2	homolog;	p53–Cellular	tumor	antigen	p53.	Adapted	from	Elster	et	al.	
(2015).	
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3.1.3	HER2	overexpression	in	cancer			
HER2	 is	 commonly	 expressed	 in	 foetal	 epithelial	 cells,	 where	 it	 is	 involved	 in	 cell	
proliferation	 and	 differentiation,	 while	 lower	 expression	 levels	 are	 found	 in	 adult	
epithelial	cells	(Pressl	et	al.,	1990).	However,	overexpression	of	HER2	was	observed	
in	a	variety	of	cancers,	such	as	lung,	breast	and	prostate	and	this	is	usually	correlated	
with	a	poor	prognosis	(Papila	et	al.,	2009;	Park	et	al.,	2010;	Minner	et	al.,	2010;	Emi	
et	 al.,	 2011;	 Takenaka	 et	 al.,	 2011).	 In	 PCa	 this	 	 leads	 to	 disease	 progression	 and	
hormone-reflective	 disease	 for	 various	 reasons.	 Firstly,	 HER2	 promotes	 androgen-
independent	 prostate	 cancer	 through	 the	 activation	 of	 the	 MAP	 kinase	 and	 Akt	
pathways,	 that	 result	 in	 the	 phosporylation	 and,	 therefore,	 ligand-independent	
activation	of	the	androgen	receptor	(AR)	(Sheikh	et	al.,	2003).	Secondly,	HER2	signals	
regulate	 the	 activity	 of	 the	 AR	 for	 optimal	 function	 at	 low	 concentrations	 of	
androgens	 through	 DNA	 binding	 and	 protein	 stabilisation,	 protecting	 the	 AR	 from	
proteasome-mediated	 degradation	 (Mellinghoff	 et	 al.,	 2004).	 This	 correlation	
between	HER2	and	the	progression	of	prostate	cancer	makes	this	biomarker	a	highly	
attractive	target	for	cancer	drugs.	However,	a	phase	II	trial	to	asses	the	utility	of	anti-
HER2	 antibody	 Trastuzumab	 (which	 induces	 antibody-dependent	 cell-mediated	
cytotoxicity	 in	 HER2-overexpressing	 breast	 cancer	 cells)	 in	 the	 treatment	 of	
advanced	hormone-refractory	prostate	 cancer	 (HRPC)	 showed	poor	efficacy.	These	
results	 were	 attributed	 to	 two	 possible	 causes:	 firstly,	 the	 low	 level	 of	 protein	
overexpression	 (9.5	%)	 or	 HER2	 gene	 amplification	 by	 fluorescence	 in	 situ	
hybridization	 (FISH)	 (17	%)	 in	 the	 biopsy	 samples	 used;	 and	 secondly,	 the	 use	 of	
Trastuzumab	 as	 a	 single	 treatment	 agent	 (Ziada	et	 al.,	 2004).	 Similarly,	 the	 use	 of	
Pertuzumab	(HER2	dimerization	 inhibitor)	 in	castrated	patients	with	HRPC	 	showed	
no	 clinical	 efficacy	 in	 another	 II	 phase	 study	 (Bono	 et	 al.,	 2007).	 More	 recently,	
Vaishampayan	et	al.	(2015)	showed	that	activated	T	cells	(ATC)	armed	with	anti-CD3	
x	 anti-HER2	 bispecific	 antibody	 (HER2Bi)	 have	 a	 potential	 clinical	 utility	 for	 the	
treatment	of	patients	with	castrate-resistant	prostate	cancer	 (Vaishampayan	et	al.,	
2015).	In	addition	to	this,	the	study	of	serum	HER2	levels	may	provide	novel	insights	
into	prostate	cancer	diagnosis	and	prognosis,	given	its	role	in	the	progression	of	the	
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disease	 and	 its	 correlation	with	 an	 increased	 risk	 of	 developing	metastatic	 cancer	
(Minner	et	al.,	2010;	Daoud	et	al.,	2016).	
	
3.2	AIMS	OF	THIS	CHAPTER	
	
The	extracellular	domain	 (ECD)	of	HER2	 is	 frequently	cleaved	from	the	receptor	by	
proteases	 and	 released	 into	 serum	 where	 it	 can	 be	 measured	 by	 ELISA	 (Leyland-
Jones	 and	 Smith,	 2011).	 Okegawa	 et	 al.	 (2006)	 reported	 significantly	 higher	 HER2	
levels	 in	prostate	cancer	patients,	when	compared	with	healthy	patients	(P=0.006),	
in	a	total	of	379	patients.	Also,	they	found	that	the	biochemical	recurence-free	rate	
was	 significantly	poorer	 in	metastatic	prostate	 cancer	patients	with	elevated	HER2	
levels	 (P=0.0078),	 based	on	 a	 ‘cut-off’	 value	of	 12.6	 ng/mL	 (Okegava	et	 al.,	 2006).	
Elevated	HER2	 levels	 (>	15	ng/mL)	have	also	been	associated	with	a	worse	 clinical	
outcome	 for	 HRPC	 patients	 treated	 with	 docetaxel	 (Domingo-	 Domenech	 et	 al.,	
2008).	 The	 aim	 of	 the	 research	 described	 in	 this	 chapter	 is	 the	 generation	 and	
purification	 of	 chicken	 anti-HER2	 ECD	 polyclonal	 and	 recombinant	 antibodies	 and	
their	characterisation	by	competitive	ELISA.	The	application	of	generated	anti-HER2	
scFv	 for	 the	 development	 of	 a	 highly-sensitive	 impedimetric	 biosensor	 for	 the	
detection	of	this	biomarker	in	serum	is	described.	
	
3.3	RESULTS			
3.3.1	Immunisation	of	chicken	with	HER2	ECD	and	serum	antibody	titre	
determinations	
	
A	 Leghorn	 chicken	was	 selected	 for	 immunisation	with	 30	 μg	 HER2	 ECD	 (Creative	
BioMart)	 and	 Freund’s	 complete	 adjuvant	 in	 a	 1:1	 ratio	 as	 described	 in	 Section	
2.2.2.1.	 Three	 boosts	 with	 reduced	 amounts	 of	 immunogen	 (12.5	 μg,	 10	 μg	 and	
10	μg,	 respectively)	 were	 administered	 20–35	 days	 apart.	 Serum	 antibody	 titres	
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(Section	 2.2.2.2)	 were	 performed	 after	 each	 boost	 to	 determine	 the	 immune	
response	 following	 immunisation.	 The	 chicken	 developed	 a	 strong	 antibody	
response	after	the	third	boost	(day	64)	and	the	antibody	titre	obtained,	calculated	as	
twice	 the	 background	 (control	 antigen),	 was	 1:78,000	 (Figure	 3.3).	 This	 titre	 was	
considered	high	enough	for	recombinant	antibody	library	generation.	Eggs	collected	
after	the	third	boost	were	used	for	IgY	purification	to	obtain	polyclonal	antibodies	to	
HER2.	
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Figure	 3.3.	 The	 antibody	 titre	 of	 an	 avian	 antiserum	 response	 to	 HER2	 after	 boost	 3.	 Data	 was	
normalised	by	subtracting	the	background	absorbance	value.	Serum	dilutions	(1:25–1:390,625)	were	
added	to	a	HER2-coated	ELISA	plate	and	bound	antibody	was	detected	following	the	addition	of	HRP-
labelled	 anti-chicken	 IgY	 antibody.	 Specific-binding	 to	 HER2	 is	 detected	 above	 the	 background	
(control	antigen	binding)	at	a	1:78,000	dilution.		
3.3.2	Purification	of	anti-HER2	polyclonal	IgY	from	chicken	eggs	
	
Eggs	 were	 collected	 after	 the	 3rd	 boost	 during	 the	 immunisation	 period.	 IgY	 was	
extracted	from	the	egg	yolks	using	IgY	EggsPress	Purification	Kit	(Gallus	Immunotech;	
Section	 2.2.1.1)	 and	 analysed	 by	 SDS-PAGE	 and	Western	 blotting	 (Sections	 2.2.1.4	
and	2.2.1.5),	showing	distinctive	bands	at	70	and	28	KDa	(Figure	3.4),	corresponding	
with	the	heavy	and	light	chains,	respectively.		Two	contaminating	bands,	which	have	
been	previously	 reported	 in	 IgY	preparations	 from	egg	yolks,	 can	also	be	observed	
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between	 36	 and	 55	 KDa,	 and	 may	 correspond	 to	 β-livetin	 or	 phosvitin	 proteins	
(Hatta	et	al.,	2008;	Tong	et	al.,	2014).	
	
	
	
	
		
	
	
	
	
	
		
Figure	3.4.	Western	blot	analysis	of	the	IgY	purified	from	the	eggs.	Lane	1–PageRuler	Plus	prestained	
protein	ladder	(Thermo	Scientific);	Lane	2–purified	anti-HER2	polyclonal	antibody,	with	visible	bands	
at	70	and	28	KDa,	representing	the	heavy	and	light	chains	of	the	IgY	molecule.	
			
Purified	 IgY	 was	 tested	 for	 HER2	 binding	 by	 competitive	 ELISA	 (Section	 2.2.7.2).	
Coating	 buffers,	 antigen	 and	 antibody	 concentrations	 were	 optimised	 using	
checkboard	ELISA	(data	not	shown).	IgY	was	incubated	with	HER2	dilutions	from	15	
to	600	ng/mL.	The	assay	was	performed	in	quintuplicate	and	the	standard	deviations	
were	calculated.	Figure	3.5	shows	that	binding	of	purified	IgY	to	immobilised	HER2	is	
inhibited	in	the	presence	of	HER2	free	in	solution,	with	a	limit	of	detection	(LOD)	of	
70	ng/mL.		
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Figure	3.5.		Competitive	analysis	for	the	detection	of	HER2	using	IgY	purified	from	eggs.	A	1:1	mixture	
of	HER2	concentrations	(for	final	15	to	600	ng/mL	concentrations)	with	IgY	was	added	to	the	HER2-
coated	 wells.	 The	 plate	 was	 washed	 to	 remove	 unbound	 antibody	 and	 HRP-labelled	 anti-chicken	
IgY(Fab’)2	 was	 used	 to	 detect	 bound	 antibody.	 The	 results	 were	 normalised	 by	 dividing	 the	
absorbance	values	(A)	by	the	absorbance	of	the	blank	(A0).	
			
	3.3.3	Generation	of	avian	anti-HER2	scFv	library	
3.3.3.1	 RNA	 isolation	 from	 immunised	 chicken	 spleen	 lymphocytes	 and	 cDNA	
synthesis	
	
Once	 RNA	 extraction	 from	 the	 spleen	 of	 the	 immunised	 chicken	 was	 performed	
using	a	RNeasy	Mini	Kit	(Qiagen)	as	per	manufacturer’s	instructions	(Section	2.2.3.1),	
cDNA	was	synthesised	by	reverse	transcription	using	the	SuperScript	III	First-Strand	
Synthesis	kit	(Invitrogen),	as	described	in	Section	2.2.3.2.	RNA	and	cDNA	were	run	in	
a	 1.5	%	 (w/v)	 agarose	 gel	 (2.2.1.1)	 to	 check	 integrity	 (Figure	 3.6).	 Large	 ribosomal	
RNA	species	are	visible	at	1,500	and	750	base	pairs	(bp).	
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Figure	 3.6.	 cDNA	 synthesis	 by	 reverse	 transcription	 of	 mRNA	 from	 chicken	 spleen	 using	 the	
Superscript	III	first-strand	synthesis	system	for	RT-PCR.	Lane	1	represents	a	1kB	DNA	ladder.	Samples	
of	RNA	(lane	2)	and	cDNA	(lane	3)	were	electrophoretically	separated	on	a	1.5	%	agarose	gel.	First-
strand	cDNA	was	synthesised	from	total	RNA.	
		
3.3.3.2	PCR	amplification	of	chicken	variable	heavy	(VH)	and	light	(Vλ)	chains	
	
Both	 the	 heavy	 and	 the	 light-chain	 in	 chickens	 are	 encoded	 by	 single	 VH	 and	 Vλ		
genes,	which	makes	 the	 generation	 of	 chicken	 antibody	 libraries	 a	 relative	 simple	
process,	as	only	one	set	of	primers	is	required	for	each	chain	(Andris-Widhopf	et	al.,	
2000).	 In	 the	 first	 round	of	PCR,	 the	VH		genes	were	amplified	using	the	CSCVHo-FL	
and	CSCG-B	primers,	and	the	Vλ		genes	using	the	CSCVK	and	CKJo-B	primers,	whose	
sequences	are	showed	in	Section	2.2.3.3.		
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3.3.3.2.1	Optimisation	of	MgCl2	concentration	for	PCR	amplification	
	
In	order	to	get	the	highest	yield	of	specific	PCR	product,	MgCl2	concentrations	over	
the	1	mM–4	mM	range	were	tested	 in	a	small-scale	(1X)	reaction	(Section	2.2.3.5).	
Magnesium	 is	 a	 necessary	 enzyme	 co-factor	 for	 DNA	 polymerases–excess	
magnesium	may	 reduce	 the	 specificity	 of	 the	 reaction,	 while	 a	magnesium	 deficit	
may	cause	a	reduced	yield	(Keer	et	al.,	2008).		
	
The	PCR	products	were	resolved	in	1.5	%	(w/v)	agarose	gels	(Section	2.2.1.1)	to	allow	
visualisation	using	the	Gel	Doc	EZ	system	and	Image	Lab	software.	In	the	case	of	Vλ	
amplification	 (Figure	 3.7A),	 a	 slight	 improvement	 with	 increasing	 MgCl2	
concentration	 was	 observed,	 while	 VH	 amplification	 (Figure	 3.7B)	 only	 took	 place	
when	 4mM	MgCl2	was	 used.	 In	 both	 cases,	 a	 concentration	 of	 4	 mM	 MgCl2	was	
selected	for	further	experiments.	
	
										 	
	
	 	
	
Figure	3.7.	PCR	optimisation	for	variable	light	(A)	and	variable	heavy	(B)	gene	amplifications	(visible	at	
around	350	and	400	bp,	respectively)	using	MgCl2	concentrations	from	1–4	mM.	Lane	1	represents	a	
1kB	DNA	 ladder.	 Lanes	2–5	 represents	different	MgCl2	 concentrations.	 Lane	6	 is	 the	control,	where	
the	DNA	template	is	missing	from	the	PCR	reaction.	Primer	dimers	can	be	seen	at	the	bottom	of	the	
gel.				
							bp	
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3.3.3.2.2	Optimisation	of	primer	concentration	for	VH	PCR	amplification	
	
To	 further	 optimise	 the	 VH	 amplification,	 primer	 concentrations	 from	 0.4	 to	 1	 μM	
were	 tested	 in	 a	 1X	 reaction	 (Section	 2.2.3.5).	 Figure	 3.8	 shows	 that	 a	 primer	
concentration	of	0.8	μM	was	optimal,	resulting	in	the	higher	yield	without	unspecific	
amplification	products.	
	
	
	
	
Figure	3.8.	PCR	optimisation	of	variable	heavy	gene	amplifications	using	primer	concentrations	within	
the	 range	of	 0.4–1	μM.	 Lane	1	 represents	 a	1kB	DNA	 ladder.	 Lanes	2–5	 represent	different	primer	
concentrations.	Lane	6	is	the	control,	where	DNA	template	is	missing	from	the	PCR	reaction.	Primer	
dimers	can	be	seen	at	the	bottom	of	the	gel.		
3.3.3.2.3	Amplification	of	VH	and	Vλ		with	optimised	PCR	conditions	
	
After	 successfully	 optimising	 the	 conditions	 for	 PCR	 amplification	 of	 the	 variable	
regions,	a	1X	reaction	(Section	2.2.3.4)	for	each	chain	was	carried	out	and	10	μL	of	VH	
and	Vλ	PCR	products	were	evaluated	on	a	1.5	%	(w/v)	agarose	gel,	showing	a	band	at	
≈400bp	for	the	VH	product	and	350bp	product	for	the	Vλ	product	(Figure	3.9).	Once	
the	 reproducibility	 of	 the	 amplification	 reaction	 was	 established,	 two	 large-scale	
reactions	(10X)	were	performed	and	the	PCR	products	for	each	chain	were	run	in	a	
							bp		
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1.5	%	 agarose	 gel	 (Section	 2.2.1.1.)	 and	 purified	 using	 a	NucleoSpin®	Gel	 and	 PCR	
Clean-Up	kit	(MN;	Section	2.2.1.2).		
	
	
	
	
Figure	 3.9.	Optimised	PCR	amplifications	of	 variable	heavy	and	variable	 light	genes	using	 the	cDNA	
from	a	HER2	ECD-immunised	chicken.	Lane	1	represents	a	1kB	Plus	DNA	ladder.	Lane	2	represents	the	
VH	chain	and	lane	3,	the	Vλ.	Lanes	4	and	5	are	controls	(no	DNA	template)	for	the	VH	and	Vλ			chains,	
respectively.				
3.3.3.3	 Splice	 by	 Overlap	 Extension	 (SOE)	 PCR	 to	 anneal	 variable	 heavy	 and	
variable	light	chain	genes	
	
The	gel-purified	VH	and	Vλ			chain	gene	PCR	products	were	mixed	 in	equal	 ratios	 to	
generate	the	overlap	scFv	product.	Two	10X	reactions	were	performed	as	described	
in	Section	2.2.3.6,	using	 the	CSC-F	and	CSC-B	primer	combination	 (listed	 in	Section	
2.2.3.3),	 that	 recognise	 the	 sequence	 tails	 generated	 by	 the	 primers	 in	 the	 first-
round	 PCR.	 High	 Fidelity	 Platinum	 Taq	 DNA	 Polymerase	 was	 used	 to	 assure	 high	
accuracy,	specificity	and	yield	 in	this	crucial	step	to	generate	the	scFv	product.	The	
PCR	products	were	run	on	a	1.5	%	(w/v)	agarose	gel	(Section	2.2.1.1),	where	bands	
at	750	bp	became	visible	(see	Figure	3.10).	The	products	were	purified	from	the	gel	
using	NucleoSpin®	Gel	and	PCR	Clean-Up	kit	(MN;	Section	2.2.1.2).	
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Figure	3.10.	SOE-PCR	of	VH	and	Vλ	fragments	for	the	construction	of	a	scFv	library.	Lane	1	represents	a	
1kB	 Plus	 DNA	 ladder.	 Lanes	 2–14	 represent	 the	 SOE	 products.	 Lane	 15	 is	 the	 control	 (no	 DNA	
template).		
	
	
	
3.3.3.4	 Restriction-digestion	 and	 ligation	 of	 the	 SOE	 PCR	 product	 and	 the	
pComb3XSS	vector	
	
The	pComb3XSS	phagemid	 vector	DNA	was	purified	using	 a	NucleoBond	Xtra	Midi	
plasmid	 purification	 kit	 as	 described	 in	 Section	 2.2.3.7.	 The	 pComb3XSS	 phagemid	
vector	(Figure	3.11)	is	designed	to	contain	two	SfiI	restriction	enzyme	sites	that	allow	
directional	cloning	of	antibody	fragments	for	the	construction	of	antibody	libraries.		
The	‘SS’	refers	to	the	double	stuffer–a	light	chain	cloning	region,	bound	by	SacI	and	
XbaI	 restrictions	 sites,	 and	 a	 heavy	 chain	 cloning	 region,	 bound	 by	 XhoI	 and	 SpeI	
restriction	sites.	The	1,600-bp	double	stuffer	fragment	(both	stuffer	fragments	plus	
the	PeIB	 leader	 sequence)	 can	be	 removed	by	SfiI	 digestion	 to	be	 replaced	by	 the	
DNA	to	be	cloned	(Levisson	et	al.,	2014).	
								bp	
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Figure	 3.11.	 pComb3XSS	 vector	 map.	 pComb3XSS	 is	 a	 3rd	 generation	 phagemid	 vector	 for	 phage	
display	or	for	soluble	expression	of	antibody	fragments	or	proteins.	The	ompA	leader	sequence	direct	
VH,	Vλ		and	coat	protein	 III	 to	 the	periplasm.	An	asymmetric	SfiI	 cassette	allows	one-step	directional	
cloning	of	antibody	 fragments	or	other	genes.	Alternative	 restriction-digest	are	present	 for	 cloning.	
An	 amber	 stop	 codon	 inserted	 between	 the	 3’	 SfiI	 site	 and	 the	 5’	 coat	 protein	 gene	 III	 allows	 for	
soluble	 protein	 expression	 in	 non-suppressor	 strains	 of	 E.	 coli.	 The	 hexa-histidine	 (H6)	 tag	 enables	
purification	 of	 the	 desired	 protein	 with	 immobilised	 metal	 affinity	 chromatography,	 while	 the	
hemagglutinin	(HA)	decapeptide	tag	allows	detection	using	commercially	available	anti-HA	antibodies.	
Adapted	from	Levisson	et	al.,	2014.		
	
	
SOE	 PCR	 products	 and	 the	 pComb3XSS	 vector	 were	 prepared	 for	 cloning	 by	
restriction	digesting	with	SfiI,	 as	 described	 in	 Section	 2.2.3.8.	 Small-scale	 digestion			
(1	μg	of	SOE	product	and	2	μg	of	vector)	was	carried	out	to	assess	the	suitability	of	
the	 restriction	 enzyme	 for	 complete	 removal	 of	 the	 pComb3XSS	 stuffer	 fragment	
and	 SOE	 product	 digestion.	 Figure	 3.12	 shows	 uncut	 and	 SfiI-digested	 pComb3XSS	
vector	 ran	 on	 a	 0.8	%	 (w/v)	 agarose	 gel	 (Section	 2.2.1.1).	 Complete	 digestion	 of	
double	 stuffer	 fragment	 was	 demonstrated,	 with	 the	 double-cut	 vector	 visible	 at	
3,400	bp	and	the	double	stuffer	fragment	at	1,600	bp.		
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Figure	3.12.	Digestion	of	 the	pComb3XSS	vector	and	SOE	product.	Lane	1	represents	a	1	KB	 ladder.	
Lane	2	represents	the	uncut	vector.	Lanes	3	and	4	represent	the	digestion	of	the	pComb3XSS	vector	
and	the	resulting	double-cut	vector	(≈3,400	bp)	and	stuffer	fragment	(≈1,600	bp).		
	
	
Large-scale	SfiI	digestion	of	SOE	scFv	product	and	pComb	vector	were	prepared	as	
described	 in	Section	2.2.3.9	and	digested	products	were	 resolved	 in	1	%	and	0.8	%	
(w/v)	 agarose	 gels	 (Section	 2.2.1.1),	 respectively.	 Purification	 of	 desired	 products	
from	 agarose	 gels	 was	 performed	 using	 a	 NucleoSpin®	 Gel	 and	 PCR	 Clean-Up	 kit	
(MN;	Section	2.2.1.2).	
	
The	 purified	 pComb3XSS	 vector	 was	 treated	 with	 Antarctic	 phosphatase	 enzyme	
(Section	 2.2.3.8),	which	 removes	 5’	 phosphates	 from	DNA	 (required	 by	 ligases)	 to	
prevent	self-ligation	of	the	vector.	The	scFv	fragment	was	 ligated	 into	the	digested	
pComb3XSS	 vector	 (Section	 2.2.3.9).	 The	 ligation	 product	 was	 concentrated	 by	
ethanol-precipitation	(Section	2.2.1.3)	and	transformed	 into	electrocompetent	XL1-
Blue	 cells	 by	 electroporation,	 as	 described	 in	 Section	 2.2.4.1.	 The	 transformed	
chicken	anti-HER2	scFv	library	had	a	size	of	2.5	x	106	cfu/mL.	The	desired	library	size	
would	 be	 in	 the	 order	 of	 5	 x	 107	 cfu/mL	 (Barbas	 et	 al.,	 2001),	 but	 it	 has	 been	
previously	demonstarted	that	higly	specific	antibodies	can	be	obtained	from	relative	
small	 (7.7	 x	105	and	5	 x	105		cfu/mL)	antibody	 libraries	 (Amwersdorfer	et	al.,	 2002;	
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Chassagne	 et	 al.,	 2004,	 respectively).	 Therefore,	 the	 library	 size	 obtained	 was	
considered	sufficient	for	the	selection	of	specific	antibodies	to	HER2.	The	library	was	
rescued	 with	 helper	 phage	 M13K07	 and	 enriched	 for	 HER2-specific	 clones	 via	
panning.	
	
	
3.3.4	Antibody	library	screening	
3.3.4.1	Enrichment	of	phage	library	via	panning	
	
The	scFv	library	was	panned	by	binding	of	the	scFv-displaying	phage	to	HER2-coated	
wells	on	an	ELISA	plate,	washing	off	non-specific	binders	and	elution	of	HER2-specific	
phage	by	trypsinisation	(Section	2.2.4.2).	Eluted	phage	were	re-amplified	and	three	
further	 rounds	 of	 panning	 were	 performed	 using	 decreasing	 concentrations	 of	
antigen	and	increasing	the	number	of	washings	(Table	3.1).	Increasing	the	stringency	
of	selection	at	each	round	enhances	the	selection	of	high-affinity	scFv	fragments.	
	
	
Table	3.1.	Panning	conditions	used	for	each	round	of	selection	for	the	anti-HER2	scFv	library.		
	
	
Pan	1	 Pan	2	 Pan	3	 Pan	4	
HER2	
concentration	 50	μg/mL	 25	μg/mL	 10	μg/mL	 5	μg/mL	
Number	of	
washes	
3X	PBS-T	
3X	PBS	
5X	PBS-T	
5X	PBS	
10X	PBS-T	
10X	PBS	
15X	PBS-T	
15X	PBS	
	
	
	
Preliminary	analysis	of	the	panned	scFv	library	was	performed	to	assess	the	success	
of	 the	 panning	 experiments	 by	 polyclonal	 phage	 ELISA,	 as	 described	 in	 Section	
2.2.4.3.	 Phage	pools	 from	 the	unpanned	 library	 and	 those	 resulting	 from	different	
rounds	of	panning	were	added	to	a	HER2-coated	ELISA	plate.	After	washing,	bound	
scFv-displaying	 phage	were	 detected	 using	 a	 HRP-labelled	 anti-M13	 antibody.	 The	
increasing	absorbance	from	round	2	onwards	suggested	the	presence	of	anti-HER2-
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specific	scFv-displaying	phage	within	the	library	(Figure	3.13).	Therefore,	phage	from	
rounds	3	and	4	were	taken	forward	for	further	analysis.	
	
	
Un
pa
nn
ed
Pa
n 1
Pa
n 2
Pa
n 3
Pa
n 4
Co
ntr
ol 
ph
ag
e
0.0
0.5
1.0
1.5
2.0
2.5
3.0
HER2
Control
Ab
so
rb
an
ce
 a
t 4
50
nm
	
Figure	3.13.	Polyclonal	phage	ELISA	following	four	rounds	of	panning.	The	scFv-displaying	phage	were	
tested	 for	 binding	 to	HER2	 and	 control	 antigen	 by	 ELISA.	 The	 scFv-displaying	 phage	were	 detected	
using	a	HRP-conjugated	anti-M13	antibody	and	the	absorbance	was	read	at	450	nm.	M13K07	phage		
(control)	were	also	tested	to	identify	potential	non-specific	binding.	
	
	
3.3.4.2	Soluble	expression	and	monoclonal	analysis	of	single	clones	by	ELISA	
	
Antibody	 fragments,	without	 the	 pIII	 protein,	were	 expressed	 by	 transforming	 the	
phagemid	from	rounds	3	and	4	of	panning	into	TOP10F’	cells	(Section	2.2.5.1).	When	
expressed	 in	 XL1-Blue	 E.coli	 cells,	 a	 suppressor	 transfer	 RNA	 (tRNA)	 binds	 to	 TAG	
(‘amber’)	 codons,	 producing	 a	 scFv-pIII	 fusion	 protein.	 	 However,	 TOP10F’	 E.coli	
strain,	containing	no	suppressor	tRNA	mutation,	recognises	the	stop	codon	between	
the	 pIII	 protein	 gene	 and	 that	 for	 the	 scFv	 fragment,	 allowing	 the	 production	 of	
soluble	 scFvs	 that	 are	 fused	 to	 hexa-histidine	 (H6)	 and	 hemagglutinin	 (HA)	 tags	
without	pIII	(Figure	3.11).		
	
Single	clones	(192)	from	rounds	3	and	4	of	panning	were	analysed	for	HER2-specific	
binding	 by	 monoclonal	 ELISA	 (Section	 2.2.5.2).	 Figure	 3.14	 shows	 that	 more	 than	
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84	%	of	the	clones	had	ELISA	signals	higher	than	the	‘cut-off’	(defined	as	three	times	
the	background).		
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Figure	 3.14.	 	 Soluble	 monoclonal	 ELISA	 screening	 for	 anti-HER2-specific	 scFv	 from	 96	 randomly	
selected	clones	from	round	3	(A)	and	4	(B)	of	panning.	The	clones	were	solubly	expressed	in	Top10F’	
cells.	Periplasmic	 fractions	were	applied	to	the	HER2-coated	ELISA	plate	and	specific	anti-HER2	scFv	
were	detected	using	a	HRP-labelled	anti-HA	antibody.	 The	dashed	 red	 line	 respresents	 the	 ’cut-off’	
value	(three	times	the	background	optical	density).						
A)															B)	
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3.3.4.3	Analysis	of	putative	anti-HER2	clones	by	competitive	ELISA	
	
Six	 positive	 HER2-specific	 clones	 (A4,	 D1,	 G1,	 H2,	 H3,	 H4)	 selected	 from	 the	
monoclonal	 ELISA	 from	 the	 4th	 round	 of	 panning	 were	 taken	 forward	 for	 further	
characterisation.	 Each	 clone	was	 grown	up	 in	 10-mL	 cultures	 and	 induced	by	 IPTG	
addition.	Bacteria	 cells	were	 lysated	by	 ‘freeze-thaw’	method	 (Section	2.2.5.1)	and	
scFv-containing	 lysates	 were	 analysed	 by	 ELISA.	 In	 an	 attempt	 to	 select	 scFv	 that	
recognised	 HER2	 in	 solution,	 a	 ‘single-concentration’	 competitive	 ELISA	 was	
performed	 in	parallel	 to	a	direct	ELISA.	 Figure	3.15	 shows	 that	all	 clones	exhibited	
competitive	inhibition	when	incubated	with	a	relatively	high	HER2	concentration	of	
2	μg/mL.	Therefore,	all	six	clones	were	carried	on	for	further	analysis.	
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Figure	 3.15.	 Competitive	 analysis	 of	 clone	 lysates.	 ELISA	plates	were	 coated	with	 2	μg/mL	HER2.	A	
direct	ELISA	was	performed	by	first	adding	a	1:100	dilution	of	the	scFv-containing	lysates	on	the	wells.	
The	competitive	analysis	was	carried	out	 in	paralel	by	adding	2	μg/mL	of	 free	HER2	 incubated	with	
each	of	the	cell	lysates,	on	the	ELISA	plate.	A	HRP-labelled	anti-HA	antibody	was	used	to	detect	bound	
antibodies.	
	
	
	
	 94	
3.3.4.4	Sequence	analysis	of	selected	clones	
	
Plasmid	preparations	 from	clones	A4,	D1,	G1,	H2,	H3	and	H4	were	 sent	 to	 Source	
BioScience	 for	 Sanger	 sequencing	 (Sanger	 and	 Coulson,	 1975),	 using	 the	 primers	
listed	in	Section	2.2.5.4.	DNA	sequence	analysis	was	performed	on	the	selected	avian	
clones	(Figure	3.16)	using	ExPASy	translation	tool	and	ClustalW2	sequence	alignment	
software	 (Section	 2.2.5.4).	 The	 antibodies	 CDRs	 were	 identified	 based	 on	 Kabat	
definition	(Johnson	and	Wu,	2004).	D1	and	H3	scFvs	had	identical	CDR	sequences	to	
scFv	 A4,	 showing	 that	 they	 were	 actually	 the	 same	 clone.	 A4	 and	 H4	 show	 only	
subtle	 differences	 in	 the	 light	 CDR	 regions.	 Clones	G1	 and	H2	 show	differences	 in	
both	 the	 heavy	 and	 light	 CDR	 regions.	 The	 scFv	 H2	 differs	 most	 from	 those	
sequenced	 especially	 in	 CDR-L3	 and	 CDR-H3,	 that	 are	 the	 key	 regions	 for	 antigen	
recognition.		
	
Interestingly,	 the	CDR-H3	repertory	contained	cysteine	residues	at	a	 relatively	high	
frequency.	 This	 finding	 supports	 Wu	 et	 al.	 (2012)	 study,	 which	 reports	 a	 higher	
cysteine	content	in	chicken	CDR3	repertory,	in	comparison	to	other	species	(chicken,	
9.4	%;	 human,	 1.6	%;	 and	 mouse,	 0.25	%).	 Conroy	 et	 al.	 (2014)	 suggested	 that	
cysteine	residues	 in	chicken	CDR-H3	might	play	an	 important	role	 in	 the	 functional	
and	structural	diversity	of	the	IgY	repertory,	through	the	establishment	of	disulphide	
linkages.	
	
   
   CDR-L1    CDR-L2   CDR-L3       CDR-H1     CDR-H2          CDR-H3 
          
A4 SGGNN-YYG WNDKRPS GSYGSSTN-SGI GFNFRDYAMV ISSSIDGETVYGAAV SAVTWCVGGCYG-GLIDT 
 
H4 SGSDSSWYG QNTKRPS GGYDSSAGYTGI GFNFRDYAMV ISSSIDGETVYGAAV SAVTWCVGGCYG-GLIDT 
 
G1 SGGSS-YYG SNDKRPS GSADSTAGYVGI GFTFNGYEMQ INP--GSSTYYGTAV SASGYCGWDXSSAGCIDA 
 
H2 SGGG--NYG SNNKRPP GSTDSSAG---I GFTFSSYDMN INAA-GSGTNYGAAV ESSICIDASCYRTNSIDA 
	
Figure	3.16.		Sequence	alignment	of	the	deduced	CDR	VL	and	VH	regions.	D1	and	H3	scFv	(not	shown)	
had	identical	CDR	sequences	to	scFv	A4.	Amino	acid	colour	code:	Red:	small	+	hydrophobic	(including	
aromatic,	with	the	exception	of	Y);	Blue:	acidic;	Magenta:	basic;	Green:	hydroxyl	+	sulfhydryl	+	amine	
+	G.	The	dash	symbol	indicates	a	gap	at	that	position.	
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3.3.4.5	Dose-response	competitive	studies	of	anti-HER2	clones		
	
Previously,	 the	 lysates	 of	 six	 clones	 had	 been	 analysed	 by	 direct	 and	 competitive	
ELISA	(Sections	3.3.4.3	and	3.3.4.4),	demonstrating	that	HER2	binding	was	inhibited	
by	 large	amounts	of	 free	HER2	 in	the	sample.	From	the	sequence	analysis	of	these	
positive	 clones,	 four	different	HER2-specific	 clones	were	 identified	and	 these	were	
then	 taken	 forward	 for	 a	 dose-response	 competitive	 study.	 Firstly,	 scFv-enriched	
lysates	 of	 the	 clones	 were	 prepared	 (Section	 2.2.5.3)	 and	 titred	 against	 HER2	 to	
select	 a	 suitable	 lysate	dilution	 for	 the	 competitive	analysis	 (Figure	3.17).	Western	
blotting	analysis	(Section	2.2.1.5)	of	cell	 lysates	was	also	performed	to	determine	if	
the	 higher	 titres	 could	 be	 explained	 by	 a	 better	 antibody	 expression	 rate.	 The	
Western	blotting	results	 (Figure	3.18)	suggested	that	H4	and	G1	higher	 titres	were	
the	result	of	higher	expression	levels.	For	each	clone,	the	lysate	dilution	that	results	
in	an	absorbance	value	close	to	1	 	(1:300	for	H4	and	G1,	1:200	for	H2	and	1:10	for	
A4)	was	selected	for	competitive	analysis	(Figure	3.19).		
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Figure	 3.17.	 Antibody	 titre	 of	 HER2-specific	 clones,	 screened	 against	 HER2.	 Lysate	 dilutions	 (1:5–	
1:39,000)	were	tested	for	binding	to	HER2.	Bound	antibody	was	detected	following	the	addition	of	a	
HRP-labelled	anti-HA	antibody.		
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Figure	3.18.	Western	blotting	analysis	of	cell	lysates	(1:5	dilution).	Lane	1–	PageRuler	Plus	prestained	
protein	ladder	(Thermo	Scientific);	 lane	2–clone	H4;	 lane	3–clone	G1;	 lane	4–clone	H2;	 lane	5–clone	
A4.	In	all	cases,	a	~27-KDa	band,	corresponding	to	the	scFv	size,	is	observed.	
	
	
The	 dose-response	 competitive	 ELISA	 (Figure	 3.19)	 involved	 the	 incubation	 of	 the	
scFv-containing	 lysates	 at	 the	 appropiate	 dilution	 with	 free	 HER2	 concentrations	
from	 0.2	 to	 3,125	 ng/mL	 for	 ten	 minutes.	 The	 mixture	 was	 then	 added	 to	 ELISA	
plates	 coated	with	 1	 μg/mL	HER2	 in	 PBS	 (10	mM,	 pH	 7.4),	 and	 incubated	 for	 one	
hour	at	37°C.	The	remaining	steps	of	the	competitive	ELISA	protocol	were	performed	
as	 described	 in	 Section	 2.2.6.4.	 Bound	 anti-HER2	 scFv	 was	 detected	 using	 a	 HRP-
labelled	anti-HA	antibody.	TMB	substrate	was	then	added	for	five	minutes	at	room	
temperature.	After	stopping	the	reaction	with	acid,	absorbance	was	read	at	450	nm.	
The	ELISA	analysis	shows	different	binding	patterns	to	HER2	(Figure	3.19).	 	Overall,	
clone	 A4	 showed	 the	 best	 dose-response	 relationship	 and	 a	wide	 HER2	 detection	
range	 and,	 therefore,	 the	best	 potential	 for	 immunoassay	development.	 Complete	
sequencing	analysis	for	scFv	clone	A4		is	available	in	Appendix	1.		
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Figure	 3.19.	 Competitive	 analysis	 of	HER2-specific	 clones	H4,	G1,	H2	 and	A4.	 Lysate	 dilutions	 from	
each	of	the	four	clones,	were	incubated	with	free	HER2	concentrations	from	0.2–3,125	ng/mL.	Bound	
antibody	was	detected	following	the	addition	of	a	HRP-labelled	anti-HA	antibody.		
	
	
3.3.5	Purification	and	characterisation	of	anti-HER2	scFv	A4	
3.3.5.1	 Purification	 of	 A4	 scFv	 by	 immobilised	 metal	 affinity	 chromatography	
(IMAC)		
	
A4	 clone	 expression	 conditions	 (IPTG	 concentration	 and	 antibody	 expression	
temperature)	 were	 optimised	 as	 described	 in	 Section	 2.2.6.2,	 prior	 to	 IMAC	
purification.	 It	 can	be	observed	 in	 Figure	3.20	 that	 the	 IPTG	concentration	did	not	
significantly	affect	 to	 the	antibody	expression.	 IPTG	concentration	does	not	always	
affect	 protein	 expression	 (Larentis	 et	 al.,	 2014;	 Malik	 et	 al.,	 2016).	 However,	
induction	temperature	seemed	to	have	an	effect	 in	protein	expression,	as	a	higher	
antibody	response	could	be	observed	when	expressed	at	30°C,	when	compared	with	
expression	 at	 37°C.	 Since	 1	mM	 IPTG	 showed	 a	 slightly	 better	 antibody	 response	
when	expressing	at	30°C,	these	were	the	selected	conditions	for	large-scale	antibody	
expression.		
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Figure	 3.20.	 Antibody	 titre	 for	 the	 selection	 of	 optimal	 IPTG	 concentration	 and	 expression	
temperature	 for	 scFv	 A4.	 Dilutions	 of	 lysates	 (1:5–1:39,000	 )	 from	 E.	 coli	 cultures	 which	 scFv	
expression	was	 induced	with	 different	 IPTG	 concentrations	 (0.1–1	mM)	 and	 temperatures	 (30	 and	
37°C)	were	tested	and	bound	antibody	was	detected	following	the	addition	of	a	HRP-labelled	anti-HA	
antibody.		
	
	
Large-scale	expression	and	IMAC	purification	of	scFv	A4	was	performed	as	described	
in	 Section	 2.2.6.2.	 IMAC	 is	 commonly	 used	 for	 rapid	 purification	 of	 polyhistidine	
affinity-tagged	 proteins.	 The	 hexa-histidine	 (H6)	 incorporated	 in	 the	 C-terminus	 of	
recombinant	 scFv	 by	 the	 pComb	 vector	 allows	 high-affinity	 interactions	 with	 the	
nickel-nitrilotriacetic	acid	(Ni2+-NTA)	matrix	in	the	purification	columns	(Bornhorst	et	
al.,	2000).	Following	binding	of	the	tagged	scFv,	non-specific	proteins	can	be	washed	
away	with	a	buffer	containing	modest	levels	of	imidazole	(10–50	mM).	To	elute	the	
tagged	protein	of	interest,	two	methods	were	used:	lowering	the	pH	to	4.4	(elution	
1),	which	protonates	 the	histidines	 residues,	disrupting	 their	bond	 to	 the	Ni2+-NTA	
resin;	and	competitive	elution	 (elution	2)	using	an	 imidazole-rich	buffer	 (250	mM).	
Both	 elution	 fractions	 were	 buffer-exchanged	 to	 10	 mM	 PBS	 (pH	 7.3)	 and	
concentrated	 using	 Vivaspin	 10,000	MW	 columns.	 Analysis	 of	 IMAC	 fractions	 was	
performed	by	SDS-polyacrylamide	gel	electrophoresis	and	Western	blotting.	In	both	
elution	 fractions	 a	 distinctive	 band	 can	 be	 observed	 at	 27	 KDa	 (Figure	 3.21),	
corresponding	 to	 the	purified	 scFv.	 Elution	2	was	performed	after	 the	 first	 elution	
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step,	 and	 resulted	 in	 the	 elution	 of	 many	 non-specific	 proteins.	 Therefore,	
concentrated	elute	1	was	selected	for	assay	development.	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	3.21.	SDS-PAGE	analysis	of	the	fractions	obtained	during	the	IMAC	purification	of	A4	scFv.	E1–	
concentrated	 elute	 1	 (elution	 with	 low	 pH	 buffer);	 E2–concentrated	 elute	 2	 (elution	 buffer	 with	
imidazole);	L–cell	lysate;	F-T–‘Flow-Through’.			
3.3.5.2	Development	of	a	competitive	ELISA	assay	using	scFv	A4	for	the	detection	of	
HER2		
Following	purification	of	anti-HER2	scFv	A4,	 its	use	for	the	detection	of	HER2	 in	an	
indirect	 competitive	 inhibition	 ELISA	 format	 was	 investigated	 (Figure	 3.22).	 The	
competitive	 inhibition	 ELISA	 is	 a	 competitive	 system	 in	which	 the	HER2-containing	
sample	 is	 incubated	with	 the	 capture	 antibody	 (anti-HER2	 scFv	 A4)	 for	 a	 set	 time	
preceding	their	addition	to	the	HER2-coated	wells.		
	
scFv	
	 100	
	
Figure	 3.22.	 Indirect	 competitive	 inhibition	 ELISA	 format.	 The	 ELISA	plate	was	 coated	with	HER2.	
Anti-HER2	scFv	was	 incubated	with	the	sample	(containing	free	HER2)	and	applied	to	the	wells.	The	
scFv	bound	to	free	HER2	from	the	sample	are	washed	away,	while	those	bound	to	coated	HER2	are	
detected	following	the	addition	of	HRP-labelled	anti-HA	antibody.		The	amount	of	signal	generated	is	
therefore	inversely	proportional	to	the	amount	of	HER2	present	in	the	sample.	
	
	
3.3.5.2.1	Optimisation	of	assay	conditions		
The	assay	conditions	were	optimised	to	quantify	HER2	as	a	potential	prostate	cancer	
biomarker	 candidate.	 To	 check	 the	 optimal	 pH	 for	 HER2	 coating	 into	 the	
immunoplates,	 three	 different	 coating	 buffers	 with	 different	 pH	 values	 were	
investigated	by	checkerboard	titration	(Figure	3.23),	as	described	in	Section	2.2.6.3.	
The	isoelectric	point	(IP)	of	HER2	ECD	is	6.06.	To	effectively	bind	proteins,	the	pH	of	
the	coating	buffer	must	be	greater	than	the	IP	of	the	protein	of	interest.	The	buffers	
tested	 were	 PBS,	 pH	 7.3;	 Tris	 buffer,	 pH	 8.5;	 and	 Carbonate	 buffer,	 pH	 9.6.	 The	
results	are	 illustrated	 in	Figure	3.19,	suggesting	that	the	amount	of	HER2	bound	to	
the	plate	was	optimal	using	Carbonate	buffer,	pH	9.6,	which	was	chosen	for	further	
experiments.	
	
Once	the	optimal	coating	buffer	was	selected,	a	checkerboard	ELISA	was	performed	
for	 the	determination	of	 the	optimal	HER2	coating	concentration	and	optimal	 scFv	
A4	dilution	(Figure	3.24).	A	coating	concentration	of	1	μg/mL	of	HER2	was	selected	as	
the	 optimal	 (in	 terms	 of	 absorbance	 signal	 and	 reagent-saving)	 antigen	 coating	
concentration	and	a	scFv	dilution	of	1:10,000	was	selected	for	the	competitive	assay.	
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Figure	 3.23.	 Selection	of	 optimal	 coating	buffer	 for	 use	 in	 a	 competitive	 ELISA	 for	 the	detection	of	
HER2.	 Coating	 buffers	 tested	 were:	 phosphate	 buffer,	 pH	 7.3;	 Tris-buffer,	 pH	 8.5	 and	 carbonate	
buffer,	 pH	 9.5.	 The	 anti-HER2	 scFv	 A4	 was	 serially	 diluted	 (1:100–1:10,000,000)	 and	 added	 to	 the	
HER2-coated	 wells.	 Bound	 antibody	 was	 then	 detected	 using	 HRP-labelled	 anti-HA	 secondary	
antibody.	
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Figure	3.24.	Selection	of	optimal	HER2	coating	concentration	(1–4	μg/mL)	and	scFv	dilution	for	use	in	
a	competitive	ELISA	for	 the	detection	of	HER2.	The	anti-HER2	scFv	A4	was	serially	diluted	(1:1,000–
1:10,000,000)	 and	 added	 to	 the	HER2-coated	wells.	 Bound	antibody	was	 then	detected	using	HRP-
labelled	anti-HA	secondary	antibody.	
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Using	 the	 optimised	 conditions,	 a	 competitive	 analysis	 was	 carried	 out	 (Section	
2.2.6.4)	to	assess	the	capability	of	scFv	A4	to	detect	HER2	in	solution	phase	(Figure	
3.25).	 The	 limit	 of	 detection	 (LOD),	 calculated	 as	 described	 by	 Armbruster	 et	 al.	
(2008),	 was	 45	 ng/mL.	 Typically,	 the	 calculation	 of	 the	 LOD	 requires	 at	 least	 20	
replicates.	However,	after	analysing	six	replicates	(intra/interday)	it	became	obvious	
that	 greater	 sensitivity	 was	 needed	 to	 detect	 HER2	 at	 the	 clinical	 ‘cut-off’	 for	
prostate	 cancer,	 which	 is	 around	 15	 ng/mL	 (Okegawa	 et	 al.,	 2006;	 Domingo-
Domenech	et	al.,	2008).	Therefore,	no	further	samples	were	measured.	
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Figure	3.25.	Competitive	analysis	of	anti-HER2	scFv	A4	using	optimised	conditions.	A	1:1	mixture	of	
HER2	(5–10,935	ng/mL)	with	scFv	A4	(1:10,000	dilution)	was	added	to	the	HER2-coated	wells.	Bound	
antibody	 was	 then	 detected	 using	 HRP-labelled	 anti-HA	 secondary	 antibody.	 The	 results	 were	
normalised	by	dividing	the	absorbance	values	(A)	by	the	absorbance	of	the	blank	(A0).	
	
		
3.3.5.2.2	Evaluation	of	competitive	assay	in	serum		
To	explore	the	suitability	of	generated	scFv	A4	for	the	detection	of	HER2	from	clinical	
samples,	 human	 serum	 samples	 spiked	 with	 HER2	 where	 tested	 by	 competitive	
inhibition	ELISA	(Section	2.2.6.4)	and	compared	with	those	results	obtained	 in	PBS.	
HER2	 detection	 in	 serum	 can	 be	 affected	 by	 the	 presence	 of	 rheumatoid	 factor,	
autoantibodies	or	cross-reacting	metabolites.	Assay	interference	can	also	arise	from	
pre-analytical	 steps,	 such	 as	 from	 the	 chemicals	 used	 in	 the	 sample	 collection	
devices	 (Wild,	2005).	 	 	As	observed	 in	Figure	3.26,	no	 significant	matrix	effect	was	
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observed	when	the	competitive	assay	was	performed	in	serum,	when	compared	to	
the	 assay	 performed	 in	 HER2-spiked	 PBS	 buffer.	 Once	 the	 ability	 of	 anti-HER2	 A4	
scFv	to	detect	HER2	from	serum	was	demonstrated,	the	assay	detection	method	was	
modified	to	investigate	if	sensitivity	could	be	improved.	
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Figure	3.26.	Competitive	analysis	of	anti-HER2	scFv	A4	to	detect	HER2	in	10	mM	PBS	buffer	and	in	
human	serum.	The	results	were	normalised	by	dividing	the	absorbance	values	(A)	by	the	absorbance	
of	the	blank	(A0).	
	
	
3.3.5.3	Fluorescence-based	competitive	assay		
Fluorescence	 enzyme	 assays	 are	 typically	 considered	 more	 sensitive	 than	
colorimetric	assays	(Bell	et	al.,	2013).	It	was	postulated	that	the	use	of	fluorescence	
HER2	detection	could	improve	the	sensitivity	of	the	developed	competitive	assay.	To	
maintain	the	assay	format	as	similar	to	the	colorimetric-based	assay	as	possible,	the	
only	element	changed	was	the	peroxidase	substrate,	substituting	TMB	for	Ampliflu	
Red.	Ampliflu	Red	(Sigma)	is	a	fluorescence-based	enzyme	substrate	that	allows	for	
specific	 and	 sensitive	 detection	 of	 HRP-labelled	 antibodies.	 Ampliflu	 Red	 is	
enzymatically	 converted	 into	 highly	 fluorescent	 Resorufin,	 by	 the	 action	 of	HRP	 in	
the	presence	of	H202.	Imaging	can	by	done	by	excitation	of	the	Resorufin	(λex	=	530–
560	 nm	 /	 λem	 =	 590	 nm)	 and	 fluorescence	 imaging.	 Opaque	 black	 Nunc	
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immunoplates	were	 used	 for	 this	 assay,	 as	 these	 are	 designed	 to	 reduce	 the	 light	
scattering	and	background	fluorescence.	
	
To	select	the	optimal	excitation	wavelength	for	Resorufin	in	our	assay,	an	excitation	
scan	was	performed	using	Tecan	 Infinite™	200	microplate	reader,	and	544	nm	was	
chosen	as	optimal.		Therefore,	the	competitive	assay	was	performed	as	described	in	
Section	2.2.6.5	and	fluorescence	was	measured	at	544/590	nm	excitation/emission	
wavelengths	(Figure	3.27).	The	results	show	that	the	fluorescence-based	assay	was	
unable	 to	 detect	 HER2	 concentrations	 below	 100	 ng/mL	 and	 therefore	 the	 assay	
sensitivity	was	reduced,	when	compared	with	the	colorimetric	assay.	
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Figure	 3.27.	 Fluorescence-based	 competitive	 ELISA	 for	 HER2	 detection	 (5–3,645	 ng/mL).	 After	
incubation	with	the	secondary	antibody,	Ampliflu	Red	peroxidase	substrate	was	added	to	the	wells	in	
the	 presence	 of	 H202	 and	 was	 incubated	 for	 30	 minutes	 at	 room	 temperature.	 Ampliflu	 Red	 is	
converted	 into	 Resorufin	 (highly	 fluorescent)	 by	 the	 action	 of	 HRP.	 Fluorescence	was	measured	 at	
544/590	 nm	 excitation/emission	 wavelengths.	 The	 results	 were	 normalised	 by	 dividing	 the	
fluorescence	values	(F)	by	the	fluorescence	value	of	the	blank	(F0).	
	
	
3.3.6	Impedimetric	biosensor	for	HER2	detection		
In	a	final	attempt	to	achieve	the	required	sensitivity	for	HER2	detection	from	blood	
using	 the	 generated	 scFv	 antibodies,	 a	 gold	 nanoparticle-based	 impedimetric	
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biosensor	 was	 developed	 by	 Dr.	 Shikha	 Sharma,	 in	 collaboration	 with	 the	 Jaypee	
Institute	of	Information	Technology.	
	
Electrochemical	 impedance	(Z)	can	be	measured	by	applying	an	alternating	current	
(AC)	potential	to	an	electrochemical	cell	and	subsequent	measuring	the	ability	of	the	
circuit	 to	 resist	 the	 current	 flow	 (Section	 1.6.2).	 Electrochemical	 impedance	
spectroscopy	 (EIS)	 measures	 the	 variation	 of	 the	 impedance	 of	 a	 medium	 as	 a	
function	 of	 the	 frequency	 of	 an	 applied	 AC	 current.	 One	 of	 the	 most	 common	
methods	 of	 evaluating	 EIS	 date	 is	 the	 Nyquist	 plot	 (Figure	 3.28),	 in	 with	 the	 real	
component	(Z’)	of	the	impedance,	corresponding	to	Ohmic	resistance,	is	plotted	on	
the	 X-axis;	 and	 the	 imaginary	 one	 (Z’’),	 representing	 the	 system’s	 reactance,	 is	
plotted	on	 the	Y-axis	 	 (Wang	et	al.,	2012;	Santos	et	al.,	2014).	 	 In	 the	Nyquist	plot	
(Figure	3.28),	the	semicircles	within	the	mid-high	frequencies	imply	a	charge-transfer	
limited	 process	 (due,	 for	 example,	 to	 the	 electrode	material),	while	 the	 linear	 tail	
present	at	lower	frequences	implies	a	mass-transfer	limited	process,	affected	by	the	
diffusion	within	the	electrolyte	and	active	electrode	materials	(Santos	et	al.,	2014).	
	
	
	
Figure	3.28.	Example	of	Nyquist	diagram	for	EIS	data	representation.	When	target	antigen	is	captured	
from	 the	 solution	 (antibody-	 antigen	 interaction),	 an	 additional	 layer	 is	 formed	 at	 the	 electrode	
surface,	 which	 increases	 the	 charge-transfer	 resistance	 (Rct)	 (situation	 2).	 Changes	 in	 Rct	 can,	
therefore,	report	the	presence	of	the	specific	target	in	the	solution.	Adapted	from	Santos	et	al.	(2014)	
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In	this	work,	 immunosensor	fabrication	(Section	2.2.8.1)	was	performed	on	screen-
printed	carbon	electrodes	modified	with	gold	nanoparticles	to	which	anti-HER2	scFv	
antibodies	were	conjugated	(Figure	3.29).		
	
	
	 	
Figure	3.29.	Representation	of	the	gold	nanoparticle-based	immunosensor	for	the	detection	of	HER2.	
Firstly,	 epoxy	 and	 hydroxyl	 groups	were	 added	 on	 the	 surface	 of	 the	 electrode	 by	 cleaning	 it	with	
diluted	 sulphuric	 acid.	 Secondly,	 the	 working	 electrode	 was	 functionalised	 with	 thiol	 groups	
(cysteamine	 hydrochloride)	 to	 facilitate	 the	 immobilisation	 of	 gold	 nanoparticles.	 Subsequent	
addition	 of	 cysteamine	 dihydrochloride	 onto	 the	 gold-modified	 electrode	 surface	 resulted	 in	 -NH2	
groups	on	the	surface.	Finally,	anti-HER2	scFv	A4	was	immobilised	via	amide	bonds.	
	
	
The	 fabricated	 immunosensor	 was	 then	 employed	 for	 electrochemical	
immunosensing	 and	 quantification	 of	 HER2	 antigen	 using	 electrochemical	
impedance	 spectroscopy	 (EIS)	 as	 described	 in	 Section	 2.2.8.2.	 Antibody	
immobilisation	techniques	based	on	gold	nanoparticles-modified	electrodes	(Raghav	
and	 Srivastava,	 2015	 and	 2016)	 were	 selected	 for	 immunosensor	 fabrication.	
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Immunosensor	efficiency	was	optimized	by	suitable	choice	of	temperature,	pH	and	
time	duration	that	affect	immune-complexation	between	immobilized	HER2	scFv	A4	
and	the	HER2	antigen	present	in	the	sample.	
	
3.3.6.1	Determination	of	optimum	time	duration,	temperature	and	pH	for	immune-
complexation		
Optimum	 time	 duration	 for	 immune-complexation	 was	 determined	 by	 incubating	
the	 immunosensor	 with	 0.1	 ng/mL	 HER2	 in	 0.01	 M	 PBS	 (pH	 7.4)	 at	 ambient	
temperature	conditions	 followed	by	 recording	 impedimetric	 response	spectra	at	5,	
10,	 15,	 20,	 25,	 and	30	minutes	 (Figure	 3.30A).	 Figure	 3.30B	 shows	 charge-transfer	
resistance	 (Rct)	 of	 the	 electrode/electrolyte	 interface	 as	 a	 function	 of	 time.	 Rct	
increases	with	increasing	incubation	time	up	to	15	minutes,	beyond	which	no	further	
change	is	observed,	indicative	of	saturation.		
	
Similarly,	 the	 optimal	 temperature	 for	 immune-complexation	 was	 obtained	 by	
incubating	0.1	ng/mL	HER2	in	0.01	M	PBS	(pH	7.4)	at	various	temperatures	between	
25–75°C	 for	 15	 minutes	 (Figure	 3.31A).	 Figure	 3.31B	 shows	 the	 variation	 of	
calculated	 Rct	 with	 temperartures.	 Recorded	 impedimetric	 responses	 indicates	
maximum	binding	of	the	antigen	and	antibody	at	30°C.	
	
Finally,	the	pH	dependence	of	the	interaction	was	evaluated	by	incubating	0.1	ng/mL	
HER2	antibody	 in	different	pH	conditions	 i.e.	5.5,	6.5,	7.4,	8.5,	9.5	and	10.5	 for	15	
minutes	 at	 30°C	 (Figure	 3.32A).	 Variation	 of	 Rct	with	 pH	 is	 shown	 in	 Figure	 3.32B.	
Maximum	 charge	 transfer	 resistance	 at	 pH	 7.4	 suggests	 maximum	 immune-
complexation.	A	buffer	pH	beyond	7.5	±	1.0	results	in	a	decrease	in	antibody-antigen	
complex	 formation.	Hence,	 for	all	 further	measurements	an	optimal	of	pH	7.4	was	
used.	 	
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Figure	 3.30.	 Optimisation	 of	 immune-complexation	 time.	 A)	 EIS	 of	 HER2	 immunosensor	 in	 5	 mM	
[Fe(CN)6]
3–/4–	redox	probe	at	0.1	ng/mL	HER2	as	a	function	of	HER2	incubation	time	(5–30	minutes).	
B)	Rct	as	a	function	of	HER2	incubation	time.	
	
	
A)	
B)	
B)	
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Figure	3.31.	Optimisation	of	 immune-complexation	temperature.	A)	EIS	of	HER2	immunosensor	 in	5	
mM	 [Fe(CN)6]
3–/4–	 redox	 probe	 at	 0.1	 ng/mL	 HER2	 as	 a	 function	 of	 immune-complexation	
temperature	(25–75°C).	B)	Rct	as	a	function	of	immune-complexation	temperature.		
A)	
B)	
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Figure	 3.32.	 Optimisation	 of	 immune-complexation	 pH.	 A)	 EIS	 of	 HER2	 immunosensor	 in	 5	 mM	
[Fe(CN)6]
3–/4–	 redox	 probe	 at	 0.1	 ng/mL	 HER2	 as	 a	 function	 of	 pH	 (5.5–10.5)	 for	 antibody-antigen	
interaction.	B)	Rct	as	a	function	of	pH.	
A)	
B)	
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3.3.3.6.2	HER2	measurements	using	an	impedimetric	immunosensor		
Figure	 3.33	 shows	 the	 immunosensor	 response	 with	 increasing	 concentration	 of	
antigen	 spiked	 in	 PBS	 (A)	 or	 serum	 (B).	 The	 electrochemical	 spectra	was	 recorded	
following	the	addition	of	a	a	drop	(3	μL)	of	each	HER2	concentration	(0.1–500	ng/mL)	
to	 the	 immunosensor	 surface.	 This	 was	 incubated	 for	 15	 minutes	 and	 EIS	
measurements	(Section	2.2.8.2)	were	performed	following	the	addition	of	the	redox	
probe	 (5	mM	 K4[Fe(CN)6]/K3[Fe(CN)6]).	 The	 immunosensor	 response	 in	 serum	was	
evaluated	by	addition	of	known	concentration	of	HER2	in	serum	(0.001–500	ng/mL)	
and	incubating	the	immunosensor	under	optimal	conditions.	For	EIS	measurements	
(Section	 2.2.10.2),	 the	 redox	 probe	 (5	 mM	 K4[Fe(CN)6]/K3[Fe(CN)6])	 was	 also	
prepared	 in	 serum	 instead	of	PBS.	The	 results	obtained	 from	serum	show	that	 the	
immunosensor	displays	a	dynamic	range	of	0.01	ng/mL	to	100	ng/mL	beyond	which	
saturation	 is	 observed.	 The	 immunosensor	behaviour	 at	 lower	 concentrations	 (see	
Figure	 3.34)	 shows	 the	 limit	 of	 detection	 of	 immunosensor	 as	 approximately	 0.01	
ng/mL	 which	 is	 significantly	 more	 sensitive	 than	 that	 found	 with	 ELISA	 (LOD=	 45	
ng/mL).	
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Figure	 3.33.	 EIS	 analysis	 of	 immunosensor	 in	 5	 mM	 [Fe(CN)6]
3–/4–	 redox	 probe	 with	 increasing	
concentrations	of	HER2	 (0.1–500	ng/mL)	 spiked	 in	PBS	buffer	 (A)	or	 serum	 (B).	 Insets	 show	Rct	as	a	
function	of	HER2	concentration.	
A)	
B)	
	 113	
Figure	 3.34.	 EIS	 analysis	 of	 immunosensor	 in	 5	 mM	 [Fe(CN)6]
3–/4–	 redox	 probe	 at	 low	 HER2	
concentrations	(0.001–0.1	ng/mL).		A	limit	of	detection	of	0.01	ng/mL	of	HER2	was	obtained.	
	
3.4	DISCUSSION	
	
Current	HER2	diagnosis	 focuses	on	the	 identification	of	breast	cancer	patients	 that	
would	 benefit	 from	 HER2-targeted	 treatments	 (Table	 3.2).	 Existing	 HER2	 testing	
technologies	 rely	 mainly	 on	 immunohistochemical	 (IHC)	 techniques,	 for	 the	
determination	of	HER2	protein	expression	in	cell	membranes,	or	fluorescence	in	situ	
hybridization	 (FISH),	 for	 the	assessesment	of	HER2	gene	amplification	 (Perez	et	al.,	
2014).	 Emerging	 technologies,	 such	 as	 chromogenic	 in	 situ	 hybridization	 (CISH)	 or	
dual	in	situ	hybridization	(DISH),	rely	on	chromogenic	detection	to	count	how	many	
copies	of	the	HER2	gene,	located	on	chromosome	17,	are	present	in	a	tissue	sample.	
All	 of	 these	 methods	 for	 HER2	 status	 evaluation	 are	 limited	 by	 the	 genetic	
heterogeneity	 in	 the	 tissue	 samples	 used	 (Barlett	 et	 al.,	 2011;	 Ohlschlegel	 et	 al.,	
2011)	and	the	 ‘real-time’	 follow-up	difficulties	associated	with	 the	requirement	 for	
biopsy	samples.	The	determination	of	serum	HER2	extracellular	domain	(ECD)	status		
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Table	 3.2.	 List	of	FDA	cleared	or	approved	companion	diagnostic	 (in	vitro	 and	 imaging	 tools).	HER2	
tests	Adapted	from	Myers	(2015).		
	
Drug	trade	
name	
Device	name	and	
manufacturer	
		
PMA	
	
Detection	
probe	 Technology	
Herceptin	
(trastuzumab)	
PathVysion	HER2	DNA	
probe	kit	(Abbot	
Molecular	Inc.)	
1998	 DNA	probe	 Qualitative	FISH	
PATHWAY	anti-HER2	
neu		(Ventana	Medical	
Systems	Inc.)	
2000	 Rabbit	mAb	
(Clone	4B5)	
Semiquantitative	
FISH	
HER2	CISH	pharmDx	kit	
(Dako	Denmark	A/S)	
2011	 DNA	probes	
with	
chromogenic	
dyes	attached	
Automated,	
quantitative	
dual-color	CISH	
INFORM	HER2	Dual	ISH	
DNA	Probe	Cocktail	
(Ventana	Medical	
Systems	Inc.)	
2011	 DNA	probe	 Automated,	
quantitative	
dual-color	DISH	
Bond	Oracle	HER2	IHC	
System	(Leica	
Biosystems)	
2012	 Mouse	mAb	
(Clone	CB11)	
Automated,	
semiquantitative	
IHC	
Herceptin	
(trastuzumab);	
Perjeta	
(trastuzumab);	
KADCYLA	
(trastuzumab)	
HercepTest	(Dako	
Denmark	A/C)	(Dako	
Denmark	A/S)	
1998	 Rabbit	pAb	 Semiquantitative	
IHC	
Herceptin	
(tratuzumab);	
Perjeta	
(trastuzumab);	
KADCYLA	
(trastuzumab)	
HER2	IQFISH	pharmDx	
Kit	(Dako	Denmark	A/S)	
2005	 DNA	probe	 Quantitative	
FISH	
(*)	 Manual	HER-2/neu	
Microtiter	ELISA	
(Oncogene	Science	
Inc.)	
2000	 Mouse	mAbs	
(clones	NB-3	
and	TA-1)	
Sandwich	assay	
Immuno	1	assay	for	
HER-2/neu	(Bayer	
Corp.)	
2000	 Mouse	mAbs	
(clones	NB-3	
and	TA-1)	
MP	 separation	
immunoassay	
ADVIA	Centaur	HER-
2/neu	Immunoassay	
(Bayer	Corp.)	
2003	 Mouse	mAbs	
(clones	NB-3	
and	TA-1)	
MP	 separation	
immunoassay	
	
(*)	 These	 tests	 are	not	 intended	 to	 aid	 in	 treatment	decisions,	 but	 in	 the	monitoring	of	metastatic	
breast	cancer	patients.	CISH–chromogenic	in	situ	hybridization;	DISH–dual	in	situ	hybridization;	FDA–
US	 Food	 and	 Drug	 Administration;	 FISH–fluorescent	 in	 situ	 hybridization;	 sHER2–serum	 human	
epidermal	 growth	 factor	 receptor	 2;	 IHC–immunohistochemistry;	 MP–magnetic	 particle;	 PMA–
premarket	approval;	mAb–monoclonal	antibody;	pAb–polyclonal	antibody.	
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has	the	potential	to	supplement	IHC	or	FISH,	reducing	the	number	of	false-negative	
results	(Saito	et	al.,	2016).	Serum	HER2	FDA-approved	tests	(Table	3.2)	are	based	on	
sandwich	 immunoassay	 techniques	 and	 are	 indicated	 for	 the	 monitoring	 of	
metastatic	breast	cancer	patients.	However,	a	number	of	studies	have	analysed	the	
clinical	significance	of	serum	HER2	levels	in	other	types	of	cancer,	including	prostate	
(Osman	et	 al.,	 2005;	 Siampanopoulou	et	 al.,	 2013),	 gastric	 (Saito	et	 al.,	 2016)	 and	
brain	(Darlix	et	al.,	2016)	cancer.	Due	to	the	role	of	HER2	in	tumorigenesis		(Section	
3.1),	 this	 protein	 is	 an	 ideal	 candidate	 for	 the	 development	 of	 non-invasive	
biomarker	panels	for	cancer	detection.	
	
This	 chapter	 describes	 the	 generation	 of	 avian	 anti-HER2	 scFv	 antibodies	 for	 their	
subsequent	incorporation	onto	a	highly	sensitive	electrochemical	biosensor	for	HER2	
detection	from	serum.		
	
	
The	 first	 step	 in	 the	 antibody	 library	 construction	 involved	 the	 immunisation	 of	 a	
host	to	evoke	an	immune	response	to	the	HER2	extracellular	domain	(ECD).	Chickens	
are	ideal	non-mammal	hosts	when	using	a	human	protein	for	antibody	generation	as	
the	 phylogenetic	 distance	magnifies	 the	 immunogenicity	 of	 the	 human	HER2	 ECD.	
They	 also	 allow	 rapid	 and	 simplified	 antibody	 library	 generation,	 since	 chicken	
immunoglobulin	repertory	involves	a	single	functional	VH	and	VL	gene	that	undergo	
gene	conversion	(Mc	Cormack	et	al.,	1993).	Furthermore,	chicken	antibodies	exhibit	
a	broad	epitope	coverage	and	high	affinity	and	they	express	well	in	E.coli	as	scFv	(Wu	
et	 al.,	 2012).	 Commercially	 FDA-approved	monoclonal	 anti-HER2	 antibodies	 (Table	
3.2)	have	been	selected	from	murine	or	rabbit	hybridomas,	while	the	generation	of	
immune	 recombinant	 antibody	 libraries	 to	 HER2	 has	 not	 been	 widely	 explored.	
Camelid	 single-domain	 antibodies	 (sdAbs)	 have	 been	 successfully	 isolated	 from	 an	
immune	 library	 generated	 by	 immunisation	 of	 a	 llama	 with	 the	 HER2-expressing	
ovarian	 cancer	 cell	 line	 SKOv3.	 After	 library	 screening,	 C7b	 sdAbs	 was	 fused	 to	 a	
human	Fc	portion	(C7b-Fc)	and	used	on	a	flow	cytometry-based	assay.	C7b-Fc	affinity	
to	 HER2-overexpressing	 cells	 was	 7	 nM,	 11-fold	 lower	 than	 the	 affinity	 of	 the	
bivalent	 Herceptin	monoclonal	 antibody	 analysed	 in	 parallel	 (Even-Desrumeaux	 et	
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al.,	 2012).	Ayat	et	al.	 (2013)	 isolated	anti-HER2	and	anti-carcinoembryonic	 antigen	
(CEA)	 scFv	 antibodies	 from	 human	 libraries generated	 from	 the	 lymph	 nodes	 of	
breast	 cancer	patients	expressing	 these	biomarkers	 in	 their	 tumors.	After	panning,	
they	 identified	 two	scFv	clones	 that	were	able	 to	detect	 the	HER2	receptor	on	 the	
cell	 membrane	 and	 internalized	 to	 the	 cells.	 Lu	 et	 al.	 (2014)	 selected	 specific	
antibodies	 to	 HER2	 from	 a	 human	 phage	 scFv	 library	 from	 RNA	 extracted	 from	
lymphatic	 tissue	 harvested	 from	 breast	 cancer	 patients.	 The	 specificity	 of	 these	
antibodies	 for	HER2	was	confirmed	by	ELISA	and	 IHC	methods.	 	To	 the	best	of	my	
knowledge,	 the	 work	 described	 in	 this	 chapter	 shows,	 for	 the	 first	 time,	 the	
generation	of	an	avian	antibody	library	from	an	immunised	chicken	for	the	selection	
of	 specific	 scFv	antibodies	 to	human	HER2	extracellular	domain.	A	 leghorn	chicken	
was	effectively	 immunised	with	the	human	protein,	as	demonstrated	by	the	serum	
antibody	titres	over	1:10,000,	 indicating	that	the	chicken	was	producing	antibodies	
against	HER2.	cDNA	was	synthesised	from	the	RNA	isolated	from	the	spleen	of	the	
immunised	 chicken	 (which	 contains	 antibody-producing	 B-cells),	 and	 the	 antibody	
variable	heavy	and	light	chains	were	amplified	and	annealed	by	PCR	methods	for	the	
construction	 of	 a	 scFv	 library	 (Barbas	 et	 al.,	 2011).	 The	 scFv	 PCR	 products	 were	
ligated	 into	 the	pComb3XSS	 vector	 for	pIII	 fusion	protein	display.	 This	 allowed	 the	
selection	of	anti-HER2	antibody	fragments	by	phage	display	(Smith,	1985;	Barbas	et	
al.,	2001).	The	scFv	genes	were	cloned	in	the	pComb	vector	and	transformed	in	E.coli	
XL-1	Blue	electrocompetent	cells,	obtaining	a	relatively	small	 library	size	of	of	2.5	x	
106	cfu/mL.	A	 larger	 library	 size	 increases	 the	probability	of	 finding	antibodies	 that	
could	 potentially	 bind	 to	 HER2,	 but	 modest-sized	 immune	 libraries	 can	 produce	
excellent	 antibodies	 (Amwersdorfer	 et	 al.,	 2002;	 and	 Chassagne	 et	 al.,	 2004).	
Enrichment	 of	 the	 phage	 antibody	 library	 via	 panning	 against	 immobilised	 HER2	
resulted	in	highly	specific	anti-HER2	scFv	antibodies	after	rounds	3	and	4	of	panning,	
as	 revealed	 by	 polyclonal	 phage	 ELISA.	 The	 presence	 of	 HER2-specific	 clones	 after	
the	 3rd	 and	 4th	 round	of	 panning	was	 confirmed	by	monoclonal	 soluble-scFv	 ELISA	
analysis	 of	 192	 clones,	 from	 which	 84	%	 exhibit	 a	 positive	 response.	 Competitive	
analysis	 of	 a	 selection	 of	 six	 positives	 clones	 from	 round	 4	 was	 carried	 out	 to	
determine	if	they	were	specific	for	HER2	in	solution.	To	assess	the	genetic	variability	
within	 the	 selected	 clones,	 DNA	 sequence	 analysis	 was	 performed,	 revealing	 that	
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three	of	the	six	clones	were	identical.	From	a	dose-response	analysis,	anti-HER2	A4	
scFv	 was	 selected	 for	 IMAC	 purification	 (Bornhorst	 et	 al.,	 2000)	 and	 assay	
development.	After	extensive	optimisation,	a	competitive	assay	for	the	detection	of	
HER2,	which	showed	a	LOD	of	45	ng/mL,	was	developed.	However,	to	detect	HER2	
from	 patients’	 serum,	 a	 greater	 sensitivity	 was	 required,	 as	 the	 ‘cut-off’	 value	 for	
HER2	 in	prostate	cancer	 is	around	15	ng/mL	 (Domingo-Domenech	et	al.,	2008).	To	
overcome	 this	 problem,	 fluorescence-based	 detection,	 which	 is	 considered	 more	
sensitive	 than	 colorimetric	 methods	 (Bell	 et	 al.,	 2013),	 was	 investigated.	 When	
comparing	 the	 calibration	 curve	 of	 fluorescence-based	 assay	 to	 the	 original	
colorimetric-based	assay,	a	loss	in	sensitivity	was	observed.	This	can	be	attributed	to	
the	complexity	of	the	HRP-	catalyzed	oxidation	of	the	Ampliflu	Red	substrate	(Sigma)	
by	 hydrogen	 peroxide.	 From	 a	 literature	 review,	 only	 a	 few	 studies	 describing	
Ampliflu	 Red-based	 detection	 of	 HRP-labelled	 antibodies	 by	 immunoassay	 were	
found	(Abdelghany	et	al.,	2012;	Breault-Turcot	et	al.,	2015),	while	this	substrate	has	
been	mainly	used	as	a	probe	for	H2O2	detection	(Votyakova	et	al.,	2004;	Jomaa	et	al.,	
2014;	Wulff	et	al.,	2014).	However,	Breault-Turcot	et	al.	(2015)	successfully	detected	
PSA	 as	 concentrations	 as	 low	 as	 10	 pM	 (<1	 ng/mL)	 using	 Ampliflu	 Red	 for	 HRP-
labelled	 antibodies	 detection.	 First,	 an	 anti-PSA	 antibody	 was	 immobilised	 onto	 a	
multi-channel	microfluidic	 system	 to	 capture	 PSA	 complex	with	 HRP-labelled	 anti-
PSA	antibody	and	then	this	was	incubated	with	Ampliflu	Red	solution	in	the	presence	
of	 H2O2,	 leading	 to	 a	 fluorescence	 signal.	 Surface	 plasmon	 resonance	 (SPR)	 and	
fluorescence	 ELISA	detection	were	 combined	on	 a	 single	microfluidic	 chip	 for	 dual	
detection	of	the	recognition	event	and	enzymatic	conversion.	
	
In	 a	 final	 effort	 to	 achieve	 the	 required	 assay	 sensitivity,	 the	 development	 of	 an	
impedimetric	 immunosensor	was	 also	 investigated.	 Electrochemical	 immunoassays	
have	been	gained	importance	over	the	last	years,	emerging	as	a	potential	alternative	
to	 optical	 approaches	 (Lee	 et	 al.,	 2008).	 Compared	 with	 spectrophotometric	 or	
fluorescence-based	 methods,	 electrochemical	 methods	 are	 not	 affected	 by	 the	
colour	 or	 turbidity	 of	 the	 sample	 (Lee	 et	 al.,	 2008)	 or	 by	 the	 volume	 used	 during	
measurements	 (Ricci	 et	 al.,	 2012).	 Importantly,	 it	 has	 been	 shown	 that	
electrochemical	 detection	 can	 achieve	 lower	 detection	 limits	 and	 therefore	 higher	
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sensitivity,	when	 compared	with	 spectrophotometry	 (Jiao	et	 al.,	 2000;	 Tang	et	al.,	
2014).	 Furthermore,	 signal	 amplification	 can	 be	 achieved	 by	 the	 incorporation	 of	
different	nanomaterials	 into	 the	electrode	 surface	 (including	gold,	 graphene,	 silver	
and	carbon	nanoparticles),	which	act	as	platforms	for	an	improved	immobilisation	of	
biomolecules	or	for	an	enhanced	electron	transfer	in	modified	electrodes	(Putzbach	
et	 al.,	 2013;	 Roberto	 et	 al.,	 2013).	 Sensitive	 HER2	 detection	 by	 electrochemical	
techniques	 has	 previously	 been	 reported	 by	 other	 groups.	 Al-Khafaji	 et	 al.	 (2012)	
described	 the	 development	 of	 a	 magnetic	 bead-based	 immunosensor	 for	 HER2	
detection	(LOD	=	0.6	ng/mL)	based	on	sandwich	assay	and	electrochemical	detection	
by	 differential	 pulse	 voltammetry	 (DPV).	 Impedimetric	 immunosensing	 of	 HER2	
based	 on	 a	 gold	 nanoparticles/	 multiwall	 carbon	 nanotube-ionic	 liquid	 electrode	
(AuNPs/MW-CILE)	has	also	been	reported.	Gold	nanoparticles	were	used	to	enhance	
antibody	immobilisation	on	the	electrode,	achieving	a	linear	range	of	10–110	ng/mL	
and	 a	 limit	 of	 detection	 of	 7.4	 ng/mL	 (Arkan	 et	 al.,	 2015).	 Qureshi	 et	 al.	 (2015)	
developed	a	capacitance	aptamer-based	biosensor	for	HER2	detection	in	serum.	The	
capacitance	 change	 of	 the	 gold	 interdigitated	 electrode	 occurred	 by	 charge	
distribution	 between	 the	 ssDNA	 aptamer	 and	 the	 HER2	 protein,	 allowing	 the	
detection	of	HER2	spiked	in	serum	samples	in	a	linear	range	of	0.2–2	ng/mL	and	with	
a	 LOD	 of	 0.2	 ng/mL.	 Thus,	 anti-HER2	 A4	 scFv	 was	 incorporated	 into	 a	 gold	
nanoparticle-based	impedimetric	biosensor.	Gold	(Au)	nanoparticles	are	widely	used	
in	 biosensing	 systems	 for	 their	 capacity	 to	 enhance	 transduction	 signals	 and	 their	
inert	 nature,	 which	 facilitates	 functionalization	 with	 biomolecules	 without	 loss	 of	
biological	activity	(Pingarrón	et	al.,	2008).	Au	nanoparticles	also	reduce	the	charge-
transfer	 resistance	 (Rct)	of	 the	system,	allowing	the	construction	of	highly-sensitive	
impedimetric	 biosensors	 at	 a	 single	 low	 frequency,	 sensitive	 to	 analyte	 binding	
(Wang	et	al.,	2006).	Capture	anti-HER2	A4	scFv	antibodies	were	functionalised	onto	
the	surface	of	gold	nanoparticles	immobilised	on	a	screen-printed	carbon	electrode.	
Following	extensive	optimisation	of	immune-complexation	conditions,	HER2	binding	
to	 the	capture	antibody	at	 concentrations	as	 low	as	0.1	ng/mL	was	demonstrated.	
Finally,	the	immunosensor	performance	in	serum	was	evaluated	by	spiking	different	
HER2	concentrations	in	serum	samples,	obtaining	a	dynamic	range	of	0.01	ng/mL	to	
100	 ng/mL,	 suitable	 for	 HER2	 detection	 on	 patients’	 serum.	 The	 LOD	 for	 the	
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immunosensor	was	of	0.01	ng/mL,	representing	a	significant	sensitivity	 increase,	as	
compared	with	the	colorimetric	competitive	ELISA	(LOD	=	45	ng/mL).	These	results	
suggested	that	A4	scFv	antibody	sensitivity	was	not	the	limiting	factor	for	achieving	
the	required	assay	sensitivity	and	that	electrochemical	detection	is	a	highly	sensitive	
method.	 Hence,	 the	 electrochemical	 biosensor	 showed	 enhanced	 sensitivity	 for	
HER2	detection	from	serum	in	the	clinically	relevant	range,	outperforming	previously	
described	 biosensors	 for	 the	 detection	 of	 this	 biomarker	 (Al-Khafaji	 et	 al.,	 2012;	
Arkan	et	al.,	2015;	Qureshi	et	al.	2015).		
	
Overall,	this	chapter	describes	how	avian	scFv	antibodies	were	generated	and	used	
for	HER2	immunosensing.	When	compared	with	FDA-cleared	Bayer	Immuno	1	assay	
for	HER-2/neu	 (Payne	et	 al.,	 2000),	our	platform	 shows	 similar	 linear	 range	 (0.01–
100	 vs.	 0.1–250	 ng/mL	 in	 Bayer’s	 assay),	 improved	 LOD	 (0.01	 vs.	 0.1	 ng/mL)	 and	
reduced	 assay	 time	 (15	minutes	 for	 our	 assay	 vs.	 48	minutes	 for	 Bayer	 Immuno	1	
assay).	 The	 developed	 immunosensor	 needs,	 however,	 further	 characterisation	 to	
asses	the	intra-	and	inter-	assay	reproducibility.	This	platform	could	then	potentially	
be	used	for	HER2	measurements	to	monitor	disease	progression	in	metastatic	breast	
cancer	patients	or	for	the	evaluation	of	serum	HER2	status	in	other	types	of	cancer,	
such	as	prostate	or	lung	carcinoma.		
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4.1	INTRODUCTION		
Over	 the	 last	 two	 decades,	 microfluidic	 technologies	 have	 experienced	 a	 huge	
growth	 in	 applications	 in	 the	 field	 of	 diagnosis.	 Microfluidics	 allows	 the	
miniaturisation	 and	 automation	 of	 diagnostic	 devices	 and	 presents	 several	
advantages	 for	 point-of-care	 applications.	 These	 include	 the	 ability	 to	 make	
extensive	 use	 of	 complex	 multiplexing	 approaches	 and	 formats;	 the	 capacity	 for	
inclusion	 of	 sequential	 sample	 pre-conditioning	 steps	 of	 different	 types;	 reagent	
storage;	 the	use	of	multiple	 steps	 involving	 reagent	 addition,	mixing	 and	washing;	
the	 potential	 for	 incorporation	 of	 centrifugal	 steps	 at	 various	 speeds;	 and	 the	
application	 of	 a	 range	 of	 detection	 strategies	 leading	 to	 greater	 sensitivity	 and	
resolution	of	results	(Sharma	et	al.,	2015).		
	
The	ambiguity	associated	with	PSA	test-based	prostate	cancer	diagnosis	is	the	main	
driving	 force	 behind	 the	 search	 of	 new	 biomarker	 panels	 to	 distinguish	 between	
cancerous	and	non-cancerous	conditions.	The	use	of	multiplexed	tests	based	on	PSA	
and	 additional	 cancer-specific	 biomarkers	 holds	 great	 promise	 for	 improved	
diagnosis	 of	 prostate	 cancer.	 Microfluidic	 platforms	 are	 the	 ideal	 tool	 for	 the	
simultaneous	 analysis	 of	 multiple	 markers	 in	 order	 to	 obtain	 precise	 and	 reliable	
diagnostic	results	without	the	need	of	centralised	labs.		
	
In	the	current	study,	a	centrifugal	‘lab-on-a-disc’	(LoaD)	device	for	the	simultaneous	
detection	of	free	PSA	and	HER2	from	whole	blood	was	developed.	The	role	of	HER2	
in	 cancer	 progression	 and	 its	 association	 with	 a	 bad	 prognosis	 was	 previously	
discussed	 in	 Chapter	 3.	 Free	 PSA	 (fPSA)	 is	 used	 in	 current	 clinical	 practice	 to	 help	
select	prostate	cancer	patients	in	the	diagnostic	‘gray	zone’	(4–10	ng/mL	total	PSA)	
that	should	undergo	biopsy.	Patients	with	free/total	PSA	ratio	greater	than	25	%	are	
considered	more	 likely	 to	 have	 a	 benign	 prostatic	 condition	 than	 to	 have	 cancer,	
eliminating	the	need	of	biopsy	(Catalonga	et	al.,	2000;	Harvard	Prostate	Knowledge	
website,	2011).	This	work	provides	evidence	of	the	value	of	microfluidic	technologies	
for	multi-marker	assay-based	detection	for	clinical	diagnostics.	
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4.1.1	Centrifugal	microfluidics			
Microfluidic	 ‘lab-on-a-disc’	 devices	 use	 centrifugal	 forces	 for	 fluid	 propulsion	 and	
mixing,	by	simply	controlling	the	rotational	speed.	Centrifugal	microfluidics	exploits	
mainly	two	different	types	of	forces:	inertia	and	capillary	action.	Inertia	forces	acting	
on	 fluids	 in	 rotating	 systems	 can	 be	 divided	 in	 three	 categories–centrifugal	 force,	
Euler	force	and	Coriolis	force	(Figure	4.1)	(Tang	et	al.,	2016).	
	
	 	
Figure	4.1.	 Inertial	forces	acting	 in	centrifugal	microfluidics.	Centrifugal	force	acts	radially	outwards,	
the	 Coriolis	 force	 acts	 perpendicular	 to	 the	 angular	 rotational	 frequency	 (ω)	 and	 the	 Euler	 force	 is	
related	 to	 the	 angular	 acceleration.	 Coriolis	 and	 centrifugal	 forces	 increase	 with	 rotational	 speed.	
(Adapted	from	Strohmeier	et	al.,	2015).	
	
Centrifugal	force	(Fc)	acts	radially	outward	on	the	disc,	and	can	be	defined	as:	
	Fc = mω2r  	
where	m	 is	 the	mass,	 r	 is	 the	position	 in	 the	disc	 	 and	ω	 is	 the	angular	 rotational	
frequency.	According	 to	 this	equation,	 the	centrifugal	 force	 for	all	 fluid	 samples	of	
the	same	mass	at	a	given	radius	 is	constant.	This	allows	parallel	testing	of	multiple	
‘flow-cells’	within	the	microfluidic	disc.		
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The	 two	 other	 inertial	 forces	 affecting	 centrifugal	 microfluidic	 systems	 are	 the	
Coriolis	force	(Fco)	and	the	Euler	force	(Fe).	The	Coriolis	force	increases	with	velocity	
(v)	and	is	given	by:	 Fco= –2mω × v  
The	Euler	force	(Fe)	only	exists	when	the	angular	acceleration	is	different	than	zero,	
according	to	the	equation:	Fe = –m !!! ! × r   
Capillary	 action	 is	 very	 important	 at	 small-scale,	 and	 therefore	 also	plays	 a	 role	 in	
microfluidics,	allowing	the	fluids	to	advance	in	opposition	to	gravity.		Capillary	force	
occurs	 at	 the	 interfaces	 of	 liquid,	 solid	 and	 vapour	 phases	 and	 is	 a	 well-known	
mechanism	for	microfluidic	flow	propulsion	or	control	by	using	capillary	valves	(Cho	
et	 al.,	 2004;	 Irimia,	 2014).	 Capillary	 valves	 use	 superficial	 tension	 at	 the	 interface	
between	 different	 fluids	 to	 prevent	 the	 entrance	 of	 fluids	 in	 microchannels	 filled	
with	 a	 second	 fluid	 (normally	 air)	 until	 a	 certain	 threshold	 rotational	 frequency	 is	
exceeded	and	centrifugal	forces	overcome	surface	tension	forces,	causing	the	liquid	
to	enter	the	channel	(Hugo	et	al.,	2014).	
	
4.1.2	Dissolvable-film	tabs		
Microvalves	allow	the	control	of	the	liquid	flow	in	the	microfluidic	channels,	and	are	
essential	for	designs	with	complex	functionality.	In	centrifugal	platforms,	the	valves	
can	 be	 classified	 in	 two	 main	 groups,	 depending	 on	 the	 actuation	 mechanism:	
passive	vales	 (solely	actuated	by	centrifugal	 forces),	 including	capillary	 (Zeng	et	al.,	
2000),	 hydrophobic	 (Ducreé	 et	 al.,	 2007),	 siphoning	 (Siegrist	 et	 al.,	 2010)	 and	
pneumatic	(Kinahan	et	al.,	2010)	valves;	and	active	(externally	actuated)	valves	(Park	
et	al.,	2012;	Lee	et	al.	2015).		
	
The	main	drawback	of	rotationally	actuated	valves	(such	as	capillary	burst	valves)	is	
that	 their	 burst	 frequency	 depends	 on	 the	 centrifugal	 force.	 Because	 there	 is	 a	
maximum	 spin	 rate	 that	 can	 be	 practically	 used	 and	 a	 limited	 radial	 space	 in	 the	
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microfluidic	 disc,	 only	 a	 limited	 number	 of	 sequential	 assay	 steps	 can	 be	
incorporated	 into	 the	 centrifugal	 platform	 (Kinahan	 et	 al.,	 2014).	 To	 solve	 this	
problem,	 different	 designs	 of	 centrifugal-pneumatic	 valving	 systems	 	 based	 on	
sacrificial	 dissolvale	 film	 (DF)	 valves	 have	 been	 proposed,	 which	 allow	 the	
incorporation	of	 liquid	handling	steps	that	are	 independent	of	 the	rotational	speed	
(Gorkin	 et	 al.	 2012,	 Kinahan	 et	 al.,	 2014,	 Kinahan	 et	 al.,	 2015).	 These	 are	 event-
triggered	valves,	in	which	the	movement	of	liquid	on-disc	actuates	the	valves.	In	the	
microfluidic	platform	described	in	this	chapter	(Figure	4.5),	a	DF	tab	design	based	on	
those	described	by	Kinahan	et	al.	(2013)	and	Dimov	et	al.	(2014)	was	used.	Figure	4.2	
shows	a	 representation	of	 the	DF	 valve	mechanism,	optimised	by	Dr.	Rohit	Mishra	
(from	the	School	of	Physical	Sciences	in	DCU),	which	employs	a	pneumatic	chamber	
and	 a	 DF-sealed	 chamber,	 both	 connected	 to	 a	 bypass-style	 expansion	 chamber.	
They	are	based	on	the	balance	between	the	centrifugal	induced	hydrostatic	pressure	
and	the	pressure	of	the	pocket	of	trapped	air	within	the	pneumatic	chamber	(Figure	
4.2)	(Kinahan	et	al.,	2014).	These	kinds	of	DF	tabs	provide	liquid	and	vapour	barriers	
when	 at	 rest	 and	 burst	 beyond	 a	 critical	 rotational	 frequency	 (ω),	 above	 which	 a	
small	volume	of	liquid	crosses	the	trigger	lip,	wetting	the	DF-tabs	and	thus	opening	a	
new	 channel,	 releasing	 the	 air	 pressure	 and	 allowing	 the	 liquid	 flow	 into	 the	
incubation	chamber	(Figures	4.2	and	4.5).	The	critical	release	frequency	(ωC)	for	the	
current	system	can	be	defined	as:	
	
𝜔! = 𝑉!𝑉! –  𝑉! – 1 𝑃!𝜌∆𝑟𝑟	
	
where	Po	is	the	atmospheric	pressure,	ρ	is	the	density	of	the	incoming	liquid,	Vt	is	the	
total	 volume	 of	 the	 pneumatic	 chamber	 (Figure	 4.2A),	 Vd	 is	 the	 volume	 of	 gas	
displaced	by	the	proceeding	liquid	in	the	valve	until	the	lip	(Figure	4.2B),	and	Δr	and	𝑟	are	 defined	 as	 R2	 –	 R1	 and	 (R1	 +	 R2)/2,	 respectively.	 Hence,	 the	 critical	 release	
frequency	is	directly	related	to	the	radial	position	of	the	valve	(Figure	4.4).		
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Figure	 4.2.	 Actuation	of	 centrifugo-pneumatic	dissolvale	 film	 (DF)	 valves	using	a	 combination	of	 an	
expansion	 chamber	 opening	 into	 the	 dissolvable	 film	 void	 via	 an	 overflow	 trigger	 lip	 at	 a	 radial	
distance	R2	(which	in	turn	is	connected	to	a	pneumatic	compression	chamber).	A)	Initially,	the	liquid	
(red)	in	the	reservoir	 is	held	back	due	to	the	trapped	air	 in	the	pneumatic	connections	between	the	
liquid	 and	 the	 dissolvable	 film	 tab.	 B)	 At	 the	 critical	 frequency	 (ωC),	 the	 centrifugally-induced	
hydrostatic	 pressure	 compresses	 the	 enclosed	 gas	 so	 that	 the	 liquid	 front	 reaches	 the	 trigger	 lip.	
Thereafter,	a	slight	increase	in	the	frequency	to	reach	the	so-called	release	frequency	allows	a	small	
amount	 of	 liquid	 to	 leap	 to	 the	 DF	 tab	 thus	 wetting	 the	 dissolvable	 film	 and	 hence	 allowing	 the	
release	of	the	liquid	in	the	reservoir.	Figure	provided	by	Dr.	Rohit	Mishra.	
	
	
Figures	4.3	and	4.4	 illustrate	how	the	release	 frequency	 (ωC)	of	chambers	with	DF-
tabs	 increases	 as	 the	 pneumatic	 chamber	 radius	 (and	 therefore,	 volume)	 and	 its	
distance	 from	 the	 center	of	 the	 disc	 (radial	 position,	 ‘R’)	 decreases.	 Given	 a	 fixed	
radial	position,	different	ωC	of	the	DF-valves	can	be	achieved	by	changing	the	volume	
of	 the	pneumatic	 chamber,	enabling	positional	multiplexing	 (Figure	4.3).	Figure	4.4	
shows	 the	 experimentally	 characterised	 release	 frequencies	 of	 the	 valves	 with	
variable	pneumatic	chamber	radii	at	three	different	radial	positions	(R1	<	R2	<	R3)	in	
agreement	 with	 the	 theoretical	 model.	 This	 enables	 a	 complex	 on-disc	 liquid	
handling.	
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Figure	4.3.	Radially	and	circularly	patterned	release	chambers	with	DF	tabs	(positional	multiplexing).	
Given	a	 fixed	 radius	 from	the	spin	centre	 the	critical	 release	 frequency	ωC	of	valve	depends	on	 the	
difference	in	pneumatic	chamber	volume	(V1	>	V2).		Diagram	provided	by	Dr.	Rohit	Mishra.		
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Figure	4.4.	Dependence	of	release	frequency	on	the	radial	position	(R)	of	the	trigger	lip	and	the	radius	
of	the	pneumatic	compression	chamber.	Plot	shows	theoretical	and	experimental	data	(denoted	by	E)	
for	 three	 radii	 (R1	 <	 R2	 <	 R3).	 Error	 bars	 indicate	 standard	 deviation	 from	 a	 minimum	 of	 three	
measurements	on	multiple	discs.		
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4.1.3	Design	of	the	microfluidic	‘flow	cell’	
	
The	disc	‘flow	cells’	were	designed	by	Dr.	Rohit	Mishra	for	a	multiplexed	multi-step	
sample	handling	protocol	on	a	LoaD	for	the	detection	of	prostate	cancer	biomarkers	
from	 whole	 blood	 (Figure	4.5).	 All	 steps	 from	 the	 separation,	 metering	 and	
aliquoting	 of	 plasma,	 sequential	 release	 and	 incubation	 of	 various	 reagents	 and	
buffer	washes	 including	 the	 stop	 reagent	 are	 carried	 out	 on	 the	 disc	 using	 purely	
rotational	flow	control.	
	
The	 liquid	 handling	 protocol	 for	 the	 detection	 of	 anti-fPSA	 antibodies	 using	 a	
sandwich	 ELISA	 consists	 of	 a)	 plasma	 extraction	 from	 whole	 blood,	 b)	 plasma	
metering	and	aliquoting,	c)	incubation	of	plasma	in	the	incubation	chamber	in	which	
the	 capture	antibodies	are	pre-immobilised,	d)	buffer	wash#1,	e)	primary	antibody	
release	 and	 incubation,	 f)	 buffer	 wash#2,	 g)	 secondary	 antibody	 release	 and	
incubation,	 h)	 enzymatic	 substrate	 release	 and	 incubation,	 i)	 and	 acid	 release	 for	
stop	 reagent	 followed	 by	 absorbance	 reading.	 Detection	 of	 the	HER2	biomarker	 is	
based	 on	 a	 competitive	 ELISA	 comprising	 of	 a)	 primary	 antibody	 (anti-HER2	 scFv)	
incubation	 with	 the	 whole	 blood	 before	 aliquoting	 the	 serum	 to	 the	 incubation	
chambers,	b)	plasma	separation,	metering	and	aliquoting,	c)	incubation	of	plasma	in	
the	 incubation	 chamber	 where	 HER2	 ECD	 is	 pre-immobilized,	 d)	 buffer	 wash,	 e)	
secondary	 antibody	 release	 and	 incubation,	 f)	 enzymatic	 substrate	 release	 and	
incubation,	 g)	 acid	 release	 for	 termination	 of	 the	 reaction	 followed	by	 absorbance	
reading.		
	
The	 competitive	 ELISA	 protocol	 can	 be	 implemented	 on	 the	 same	 disc	 as	 the	
sandwich	 ELISA	 (which	 requires	 a	 higher	number	of	 assay	 steps)	 by	 simply	 leaving	
the	 first	 two	 reagent	 chambers	 in	 the	 release	 series	 empty	 (buffer	 wash	 #1	 and	
primary	 antibody	 as	 in	 Figure	 4.	5).	 This	 can	 be	 achieved	 because	 the	 incubation	
times	of	the	secondary	antibody	and	the	enzymatic	substrate	are	the	same	for	both	
protocols.	
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Figure	4.5.	Lab-on-a-Disc	for	multiplexed	detection	of	prostate	cancer	biomarkers	from	whole	blood.	The	plasma	is	extracted	from	the	blood	in	chamber	A	(for	competitive	ELISA,	the	blood	is	
pre-incubated	with	anti-HER2	scFv	A4JZ),	metered,	aliquoted	and	then	released	(using	special	DF	tabs	that	require	around	40	seconds	to	dissolve	as	timed	release	in	chambers	A1,	A2	and	A3)	
into	an	incubation	chamber	C	immobilized	with	capture	antibodies	(in	case	of	the	sandwich	ELISA;	for	the	competitive	ELISA,	HER2	ECD	is	immobilized	on	the	surface).	The	release	frequencies	
of	all	the	reagents	and	buffer	washes	are	chosen	to	exceed	those	required	for	plasma	extraction,	plasma	metering	and	the	exit	siphon	on	chamber	C.	The	protocol	for	an	ELISA	(depicted	here	
is	 the	sandwich	ELISA	 for	 f-PSA;	 for	a	competitive	ELISA	 for	HER2	the	 first	 two	chambers	corresponding	 to	valves	DF2	and	DF3	are	 left	empty)	 is	 then	performed	by	controlled	release	of	
individual	reagents	/	buffer	washes.	The	opening	sequence	of	the	valves	is	also	depicted	as	they	occur	on	the	disc	along	with	a	depiction	of	the	individual	steps.	The	reaction	is	stopped	by	the	
addition	 of	 acid;	 emptying	 of	 the	 siphon	 is	 avoided	 in	 order	 to	 prevent	 the	 loss	 of	 the	 final	 product	 that	 is	 ready	 for	 absorbance	measurement.	 Figure	 provided	 by	 Dr.	 Rohit	Mishra.
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4.2	AIM	OF	THIS	CHAPTER		
In	 this	chapter	 the	use	of	 ‘in-house’	generated	recombinant	antibodies	 to	prostate	
cancer	biomarkers	(including	A4	scFv	antibody	described	in	Chapter	3)	in	a	‘lab-on-a-
disc’	device	for	the	detection	of	free	PSA	and	HER2	from	blood	is	outlined.		
	
This	 project	 focuses	 on	 the	development	of	 a	 centrifugal	microfluidic-based	multi-
step	 immunoassay	 for	 the	 simultaneous	 detection	 of	 up	 to	 three	 prostate	 cancer	
biomarkers	 from	 whole	 blood.	 The	 final	 aim	 is	 the	 automation	 of	 all	 assay	 fluid	
handing	 steps,	 from	 pre-conditioning	 of	 sample	 to	 addition	 of	 the	 peroxidase	
substrate,	 in	 this	 cost-efficient	 device,	 suitable	 for	 point-of-care	 applications.	 The	
novelty	of	 this	platform	relies	on	the	ability	of	multiplexing	using	a	combination	of	
sandwich	 and	 competitive	 immunoassays	 in	 a	 single	 disc,	 using	 recombinant	
antibodies.	 Additionally,	 the	 flexibility	 of	 this	 disc	 cartridge	 design	 will	 also	 allow	
other	ELISA	assays	to	be	applied	on	the	same	disc,	once	a	suitable	panel	of	prostate	
cancer	biomarkers	was	validated.	
4.3	RESULTS		
4.3.1	Reduction	of	assay	incubation	times		
Fast	 turn-around	 times	 are	 essential	 for	 point-of-care	 applications.	 Most	
conventional	ELISA	assays	use	one-hour	incubation	times	for	each	antibody-antigen	
recognition	step,	despite	that	in	an	ideal	situation	the	binding	occurs	within	minutes.	
In	order	to	reduce	the	total	assay	time,	three	different	 incubation	times	(5,	10	and	
20	minutes)	were	 tested	 for	 the	 antigen	 binding	 to	 the	 primary	 antibody	 and	 the	
antigen	 capture	 by	 the	 secondary	 antibody	 incubation	 times	 (Section	 2.2.8.4).	 To	
simulate	the	lab-on-a-disc	conditions	(continuous	liquid	movement	in	the	incubation	
chamber),	the	ELISA	plate	was	gently	shaken	in	a	rocker	during	the	incubation	steps.	
This	 allows	 complete	mixing	 of	 the	 reactants	 and	 faster	 interaction	 kinetics.	 From	
the	 results	 (Figure	 4.6),	 it	was	 postulated	 that	 10	minutes	was	 the	minimum	 time	
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required	to	allow	a	strong	dose-response	signal	with	a	good	differentiation	between	
the	 sample	 results	 and	 the	 negative	 controls.	 The	 same	 incubation	 times	 were	
applied	to	the	competitive	ELISA	to	allow	the	parallel	running	of	both	assays	in	the	
same	disc.	
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Figure	4.6.	Optimisation	of	sandwich	ELISA	incubation	times	for	the	detection	of	fPSA.		Three	different	
incubation	 times	 (5,	 10	 and	 20	minutes)	 for	 each	 incubation	 step	 (antigen	 binding	 to	 primary	 and	
secondary	antibody)	were	tested.	The	results	were	normalised	by	dividing	the	absorbance	values	(A)	
by	the	absorbance	of	the	blank	(A0).	
	
	
4.3.2	Protein	immobilisation	on	the	incubation	chamber		
The	 microfluidic	 discs	 were	 manufactured	 using	 multi-laminae	 (Figure	 2.2)	
xurography	 (rapid	 prototyping	 techniques)	 as	 described	 by	 Bartholomeusz	 et	 al.	
(2005).	Different	materials	such	as	silicon,	glass	or	plastic	substrates	such	as	PMMA	
[Poly(methyl	methacrylate)],	polystyrene	(PS)	and	COC	(cyclic	olefin	copolymer)	have	
been	 traditionally	 used	 for	 the	 immobilization	 of	 proteins	 in	 microfluidic	 systems	
(Kim	and	Herr,	2013).	Typically,	PMMA	is	chosen	due	to	the	low	cost	of	fabrication	
(Dimov	 et	 al.,	 2014;	 Kinahan	 et	 al.,	 2014).	 Thus,	 the	 initial	 disc	 design	 (used	 for	
optimization	 of	 the	 fluid	 handling	 protocol)	 was	 composed	 of	 four	 layers	 of	 poly-
methyl	methacrylate	 (PMMA)	along	with	 four	 layers	of	pressure	sensitive	adhesive	
(Adhesives	Research,	Limerick,	Ireland),	as	seen	in	Figure	2.1.	However,	PMMA	inert	
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surface	 proved	 to	 be	 not	 suitable	 for	 protein	 immobilization	 in	 initial	microfluidic	
assay	experiments.	To	prepare	the	disc	base	surface	for	immobilisation	of	proteins,	
three	different	strategies	were	investigated	(Figure	4.7):		oxygen	plasma	treatment,	
polystyrene	 coating	 and	 surface	 raster.	Oxygen	plasma	 treatment	 aims	 to	 activate	
PMMA	 surface,	 introducing	 polar	 groups,	 improve	 PMMA	 surface	wettability	 with	
changing	surface	chemistry	and	topography	(Vesel	et	al.,	2012),	and	facilitate	protein	
immobilisation	 (via	amine	groups)	by	the	 introduction	of	aldehyde	groups	 (Zhao	et	
al.,	 2016).	 	 Polystyrene	 coating	 intended	 to	 simulate	 the	 hydrophobic	 conditions	
found	 in	 the	 ELISA	 plates,	 made	 of	 this	 material.	 Finally,	 it	 was	 postulated	 that	
etching	 a	 raster	 pattern	 on	 the	 wells	 surface	 would	 increase	 the	 protein	 binding	
area.	Immobilisation	experiments	were	performed	on	the	wells	of	microfluidic	chips	
consisting	 of	 the	 same	 layers	 as	 the	microfluidic	 disc	 (simulating	 disc	 conditions),	
with	 the	 aim	 of	 simplifying	 the	 device	 fabrication	 process	 during	 the	 optimisation	
testing.	Coating	with	polystyrene	resulted	in	a	significant	signal	increase,	as	well	as	in	
a	much	higher	signal-to-noise	 ratio	 (Figure	4.7).	This	was	an	expected	result,	given	
that	polystyrene	coating	simulated	the	conditions	found	 in	ELISA	plates	(also	made	
of	polystyrene),	in	which	the	assays	were	optimised.	To	avoid	the	source	of	protein	
immobilisation	 variability	 associated	 to	 an	 uneven	 polystyrene	 coating	 within	 disc	
manufacturing	batches,	the	bases	of	the	microfluidic	discs	used	for	the	generation	of	
the	dose-response	curves	were	made	of	polystyrene.		
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Figure	 4.7.	 Funtionalisation	 of	 disc	 PMMA	 surface.	 Three	 techniques	 were	 used:	 oxygen	 plasma	
treatment,	polystyrene-coating	and	surface	raster.	Sandwich	assay	was	performed	as	usual,	using	10	
ng/mL	of	PSA	and	blank	wells	(0	ng/mL	PSA).	The	results	were	normalised	by	dividing	the	absorbance	
values	(A)	by	the	absorbance	of	the	blank	(A0).		
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4.3.3	Liquid	handling	protocol			
Once	the	disc	is	loaded	with	all	the	reagents	and	mounted	on	the	centrifugal	testing	
set	up	 (Figure	2.2),	 the	 spindle	 is	 rotated	at	a	defined	 frequency	curve	 (Table	4.1).	
Plasma	separation	from	blood	occurs	at	occurs	at	20	Hz	over	typically	8	minutes,	as	
previously	described	 in	other	LoaD	systems	(Haeberle	et	al.,	2006;	Nwankire	et	al.,	
2014).	Thereafter	 the	 frequency	 is	 increased	to	25	Hz	 to	open	the	DF1	 (Figure	4.5)	
and		aliquot	the	plasma	into	chambers	A1,	A2	and	A3	(Figure	4.5).	The	DF	valves	used	
in	these	chambers	take	40	seconds	to	dissolve,	providing	sufficient	time	for	plasma	
metering	in	chambers	A1–A3	and	overflow	of	the	remaining	plasma	into	waste.	
	
Once	the	plasma	is	released	into	the	incubation	chamber,	’shake-mode’	mixing		(Lutz	
et	al.,	2008)	is	induced	by	rapidly	alternating	the	spin	rate	between	15	Hz	and	30	Hz.	
After	 plasma	 incubation,	 the	 incubation	 chamber	 is	 emptied	 by	 siphon	 priming		
(Siegrist	et	al.,	2010)	upon	reduction	of	the	spin	rate	and	then	 lifting	to	25	Hz.	The	
mixing	 and	 emptying	 protocols	 are	 applied	 between	 each	 step	 until	 the	 TMB	
substrate	 is	 released	 (Table	4.1)	 to	allow	 incubation	and	washing	 steps,	discarding	
the	liquid	after	each	step	into	the	waste	chamber	(Figure	4.5).	After	the	third	wash,	
bound	HRP-labelled	antibodies	are	detected	by	the	release	of	TMB	substrate	into	the	
incubation	chamber.	The	TMB	is	incubated	for	10	minutes	while	applying	the	‘shake-
mode’	mixing	and	finally	the	reaction	is	stopped	by	the	addition	of	acid.	
	 133	
Table	4.1.	Spin	frequency	protocol	for	each	laboratory	unit	operation	(LUO)	in	the	LoaD	ELISA.		
*	Steps	5–10	absent	in	competitive	ELISA.	(Taken	from	Mishra	et	al.,	2016).	
	
Step	#	 Description	 Frequency	(Hz)	 Time	(s)	
1	 Plasma	separation	 20	 480	
2	 DF1	valve	release	(plasma	
aliquoting	and	release)	
25	 40	
3	 Plasma	incubation		 15–30	(shake	mode	mixing)	 600	
4	 Incubation	chamber	empties	to	
waste		
Siphon	primes	at	5Hz,	empties	at	
25Hz	
15	
5*	 Buffer	wash	1	release	 38	 10	
6*	 Buffer1	washing	 15–30	(shake	mode	mixing)	 30	
7*	 Incubation	chamber	empties	to	
waste		
Siphon	primes	at	5,	empties	at	25	 15	
8*	 Primary	antibody	release	 43	 10	
9*	 Primary	antibody	incubation		 15–30	(shake	mode	mixing)	 600	
10*	 Incubation	chamber	empties	to	
waste		
Siphon	primes	at	5,	empties	at	25	 15	
11	 Buffer	wash	2	release	 48	 10	
12	 Buffer2	washing	 15–30	(shake	mode	mixing)	 30	
13	 Incubation	chamber	empties	to	
waste		
Siphon	primes	at	5,	empties	at	25	 15	
14	 Secondary	antibody	release	 53	 10	
15	 Secondary	antibody	incubation		 15–30	(shake	mode	mixing)	 600	
16	 Incubation	chamber	empties	to	
waste		
Siphon	primes	at	5,	empties	at	25	 15	
17	 Buffer	wash	3	release	 57	 10	
18	 Buffer3	washing	 15–30	(shake	mode	mixing)	 30	
19	 Incubation	chamber	empties	to	
waste		
Siphon	primes	at	5,	empties	at	25	 15	
20	 TMB	(enzyme	substrate)	release	 62	 10	
21	 TMB	incubation	 15–30	(shake	mode	mixing)	 600	
22	 Acid	release	(stops	enzymatic	
activity)	
68	 10	
23	 Termination	 15–30	(shake	mode	mixing)	 10	
	 Total	time	 	 3180	
TMB–Tetramethyl	benzidine;	Buffer	1/2/3–1	%	(w/v)	Marvel	semi-skimmed	milk	in	10	mM	PBS.	
	
4.3.4	Detection	of	prostate	cancer	markers:	Benchtop	vs.	Lab-on-a-disc	
	
The	 ability	 of	 the	 sandwich	 and	 competitive	 assay	 to	 detect	 the	 fPSA	 and	 HER2	
biomarkers	was	demonstrated	using	a	standard	benchtop	ELISA	(see	Section	2.2.6.4)	
for	 competitive	 ELISA;	 the	 sandwich	 ELISA	 was	 developed	 by	 Dr.	 Sarah	 Gilgunn	
(Gilgunn	2016)	with	100	µL	reagent	volumes	(in	standard	96	well	plates	with	a	6.35	
mm	 well	 bottom	 diameter),	 one-hour	 incubation	 times	 for	 the	 primary	 and	
secondary	antibodies	and	six	washes	(3	times	with	0.5	%	(v/v)	Tween	20	in	PBS	and	3	
times	with	PBS)	after	each	incubation	step.	
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For	point-of-care	deployment,	the	reduction	of	the	assay	times	and	reagent	volumes	
without	compromising	sensitivity	of	detection	is	important.	The	assay	was	therefore	
adapted	 for	 incorporation	 into	 the	 microfluidic	 disc	 with	 significant	 reduction	 of	
reagent	volumes	(to	40	µL),	incubation	times	(down	to	10	min)	and	washing	steps	(to	
only	 one	 wash	 with	 1	%	 [w/v]	 Marvel	 semi-skimmed	 milk	 in	 PBS	 after	 each	
incubation	step).		
	
The	 biomarker	 standards	 (0.1–1000	ng/mL	 of	 fPSA	 and	 10–1000	ng/mL	 of	 HER2)	
spiked	in	PBS	buffer	and	a	blank	sample	were	measured	in	triplicate	and	the	ability	
of	the	generated	scFv	antibodies	to	detect	their	target	antigens	under	such	adapted	
conditions	were	 assessed	 on	 a	 half-area	 96-well	 ELISA	 plate	 (4.5	mm	well	 bottom	
diameter,	Corning),	as	described	in	Sections	2.2.8.3.	and	2.2.8.4.	The	results	(Figure	
4.8)	 provide	 clear	 evidence	 for	 characteristic	 dose-response	 curves	 after	 the	
optimisation	process.		
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Figure	 4.8.	 fPSA	 and	HER2	 calibration	 curves	using	 conventional	 ELISA.	A)	 Calibration	 curve	 for	 the	
detection	 of	 fPSA	 using	 conventional	 sandwich	 ELISA.	 fPSA	 standards	 (0.1–1,000	 ng/mL)	 were	
captured	 on	 a	 goat	 anti-PSA	 polyclonal	 antibody-coated	 immunoplate.	 Anti-fPSA	 scFv	 B8	was	 then	
added	and	detected	following	the	addition	of	HRP-labelled	anti-HA	antibody.	B)	Calibration	curve	for	
the	detection	of	HER2	using	 conventional	 competitive	ELISA.	A	1:1	mixture	of	HER2	 standards	 (10–
1,000	ng/mL)	with	anti-HER2	 scFv	A4JZ	was	added	 to	 the	HER2-coated	wells	 and	bound	antibodies	
were	detected	using	HRP-labelled	anti-hemagglutinin	(HA)	antibody.	The	results	were	normalised	by	
dividing	 the	 absorbance	 values	 (A)	 by	 the	 absorbance	 of	 the	 blank	 (A0),	 and	 expressed	 as	 a	
percentage	 (%	A/A0),	where	0	%	and	a	100	%	are	defined	as	 the	smallest	and	biggest	value	 in	each	
data	set,	respectively.	Error	bars	indicate	standard	deviation	from	at	least	three	measurements.		
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The	results	from	the	LoaD	measurements,	performed	as	described	in	Section	2.2.8.5,	
for	 the	 two	markers	 are	 shown	 in	 Figure	 4.9.	 The	 signal-to-noise	 ratio	 (A/A0)	was	
calculated	using	absorbance	values	detected	on	the	same	disc	for	the	controls	(A0)	
and	plotted	as	a	percentage	of	relative	absorbance	(%	A/A0).		
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Figure	4.9.	fPSA	and	HER2	calibration	curves	using	LoaD	platform.	Percentage	of	relative	absorbance	
results	 for	 LoaD	 immunoassays	 to	 detect	 A)	 fPSA	 marker	 in	 buffer	 (1–1000	ng/mL)	 and	 B)	 HER2	
marker	in	buffer	(10–500	ng/mL).	The	results	were	normalised	by	dividing	the	absorbance	values	(A)	
by	the	absorbance	of	the	blank	(A0),	and	expressed	as	a	percentage	(%	A/A0),	where	0	%	and	a	100	%	
are	 defined	 as	 the	 smallest	 and	 biggest	 value	 in	 each	 data	 set,	 respectively.	 Error	 bars	 indicate	
standard	deviation	from	at	least	three	measurements.		
	
	
	
For	the	sandwich	ELISA	for	fPSA	detection,	the	dose-response	curve	is	similar	to	that	
obtained	in	the	benchtop	experiment,	but	the	sensitivity	of	the	assay	was	reduced.	
The	 competitive	 ELISA	 for	 the	 detection	 of	 HER2	 from	 buffer	 also	 exhibits	 a	
characteristic	 inverse	 dose-response	 curve,	 but	 with	 greater	 variations	 from	 the	
benchtop	version	than	the	sandwich	assay.		
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4.3.3	 Interference	 studies	 for	 the	 parallel	 running	 of	 competitive	 and	 sandwich	
ELISA	on	a	microfluidic	disc		
The	final	aim	of	this	project	 is	to	parallel	run	the	sandwich	assay	for	PSA	detection	
and	the	competitive	assay	for	HER2	detection	in	the	same	disc.	To	do	this,	the	blood	
sample	would	have	to	be	pre-incubated	with	anti-HER2	scFv	antibodies	(Figure	4.5)	
to	allow	the	 formation	of	HER2-scFv	complexes	prior	 to	aliquoting	of	 the	serum	to	
the	 incubation	 chamber	 for	 the	 competitive	 assay.	 	 Since	 the	 same	 blood	 sample	
would	be	used	for	the	detection	of	PSA,	it	is	crucial	to	prove	that	the	anti-HER2	scFv	
do	 not	 interference	 with	 the	 sandwich	 assay.	 In	 order	 to	 check	 any	 potential	
interference,	 anti-HER2	 scFv	 (1:10,000	 dilution,	 as	 per	 the	 competitive	 ELISA)	was	
spiked	 in	 the	 PSA	 standards	 (0,	 10	 and	 100	 ng/mL)	 and	 a	 sandwich	 ELISA	 for	 PSA	
detection	was	performed,	as	described	in	Section	2.2.8.4,	running	a	positive	control	
(buffer	 with	 PSA	 only)	 in	 parallel.	 No	 significant	 interference	 was	 observed	 when	
anti-HER2	 scFv	 were	 present	 in	 the	 fPSA	 standard	 solutions	 (Figure	 4.10),	 which	
suggests	that	the	addition	of	this	antibody	to	the	blood	sample	would	not	result	 in	
unwanted	cross-reactivity	or	interference	with	the	detection	of	fPSA.	
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Figure	4.10.	Investigation	of	interference	of	anti-HER2	scFv	in	the	serum	sample	with	PSA	detection.	
fPSA	standards	(0,	10	and	100	ng/mL)	were	spiked	with	anti-HER2	scFv	and	added	to	the	ELISA	plate	
coated	with	anti-PSA	polyclonal	antibody.	Control	PSA	standards	 (no	anti-HER2	scFv)	were	added	 in	
parallel.	 Bound	 fPSA	was	 detected	 following	 the	 addition	 of	 the	 primary	 and	 secondary	 antibodies	
and	 the	 response	 for	 each	 spiked	 sample	 (red)	 was	 compared	 with	 the	 response	 of	 the	 control	
samples	(grey).	
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4.4.	DISCUSSION		
Recent	advances	 in	microfluidic	 technology	and	device	 fabrication	have	 led	to	new	
diagnostic	 platforms	 with	 the	 potential	 to	 be	 implemented	 in	 low-resource	
laboratory	settings	(Hugo	et	al.,	2014;	Jing	et	al.,	2014;	Sharma	et	al.,	2015).	On-disc	
miniaturisation	 and	 integration	 of	 common	 laboratory	 unit	 operations	 (LUOs)	 in	
easy-to-use	low-cost	cartridges	allows	sample	analysis	outside	of	traditional	labs.	
	
This	work	underpins	the	ability	of	a	novel	recombinant	antibody-based	microfluidic	
‘lab-on-a-disc’	device	to	automate	a	multi-step	ELISA,	using	a	single	spindle	rotor	to	
implement	 plasma	 separation	 and	 fluid	 control.	 The	 system	 also	 permits	
multiplexing,	 suggesting	 potential	 for	 the	 simultaneous	 detection	 of	 multiple	
biomarkers	of	clinical	value	in	disease	detection.	In	this	project,	the	use	of	generated	
scFv	antibodies	for	prostate	cancer	biomarkers	detection	from	whole	blood	using	a	
‘lab-on-a-disc’	 platform	was	 investigated.	 The	 inherent	 advantages	 of	 utilising	 ‘in-
house’	 produced	 antibodies	 (low-cost,	 easy	 production	 and	 high	 specificity	 and	
sensitivity),	 in	 conjunction	 with	 those	 associated	 with	 the	 developed	 microfluidic	
platform	 (cheap	 to	 manufacture,	 easily	 modifiable	 and	 low	 sample-size	
requirements),	 give	 an	 ideal	 combination	 for	 point-of-care	 applications.	 The	
actuation	of	the	DF-valves	for	sequential	reagent	release	was	shown,	 in	agreement	
with	 theoretical	 predictions,	 revealing	 the	 feasibility	 of	 microfluidic	 actuation	 by	
simple	 changes	 on	 the	 disc	 spinning	 speed.	 A	 variety	 of	 DF	 valving	 systems	 has	
already	been	developed	by	 the	Ducrée	group	 in	 the	 School	of	 Physical	 Sciences	 in	
DCU.	 Gorkin	 et	 al.	 (2012)	 described	 a	 centrifugal-pneumatic	 valving	 technology	 in	
which	 the	 burst	 frequency	 of	 the	 DF	 tabs	 could	 be	 tuned	 over	 a	 wide	 range	 of	
rotational	 speeds,	 having	 potential	 for	 the	 integration	 of	 multi-step	 biochemical	
assay	protocols.	However,	a	major	limitation	of	this	system	was	the	dependence	of	
the	 valve	 actuation	 of	 DF	 tabs	 dissolution	 time	 and	 transfer	 time	 of	 the	 liquid,	
leaving	 insufficient	 time	 for	 the	 long	mixing	or	 incubation	 steps	 required	 for	more	
complex	immunoassays.	To	solve	this,	they	presented	a	new	system	in	which	paper	
imbibition	was	used	to	increase	the	scope	of	temporal	process	control	(Kilahan	et	al.,	
2012).	Kinahan	et	al.	 (2014)	also	described	a	centrifugal	DF-based	 ‘lab-on-a-disc’	 in	
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which	 liquid	 handling	 sequence	 for	 RNA	 extraction	 from	 mammalian	 cell	
homogenate	 was	 controlled	 through	 event-triggered	mechanisms,	 independent	 of	
the	disc	rotational	frequency.	However,	the	research	described	in	this	chapter	is	the	
first	time	in	which	the	integration	of	a	complex	sandwich	ELISA	(with	four	incubation	
steps	 and	 three	washing	 steps)	 in	 the	 DF-based	 LoaD	 platform	was	 achieved.	 The	
slight	 error	 in	 experimental	 values,	 mainly	 associated	 with	 smaller	 pneumatic	
chambers,	 can	 be	 attributed	 to	 issues	 with	 manufacturing	 tolerances.	 The	
implementation	of	sequential	LUOs,	such	as	liquid	transport	and	metering,	as	well	as	
plasma	 separation	 and	 fluid	mixing	 in	 the	disc	 cartridge	 is	 demonstrated,	 allowing	
the	integration	of	all	the	steps	required	for	immunoassays	in	a	single	disc.	Other	CD-
based	multiplexed	assays	have	been	reported	by	a	number	of	academic	groups	(Lee	
et	al.,	2009;	Chen	et	al.,	2010;	Park	et	al.,	2012;	Czugala	et	al.,	2013;	Nwankire	et	al.,	
2014;	Lee	et	al.,	2015),	but	many	of	them	differ	from	the	system	described	here	in	
that	they	are	based	on	methods	other	than	immunoassay.	For	example,	Nwankire	et	
al.	(2014)	developed	a	5-parameter	liver	assay	panel	(albumin,	alkaline	phosphatase,	
gamma	 glutamyl	 transferase,	 total	 and	 direct	 bilirubin)	 from	 a	 finger-prick	 blood	
sample	 (Nwankire	 et	 al.,	 2014).	 The	 test,	 which	 took about	 20	minutes	 to	 run,	
utilized	enzyme-based	and	dye-binding	assays,	such	as	Jendrassik	and	Grof’s	bilirubin	
test	(Jendrassik	et	al.,	1938)	or	the	Bromocresol	Green	albumin	assay	(Doumas	et	al.,	
2009),	 respectively.	 On	 the	 other	 hand,	 most	 of	 the	 systems	 integrating	
immunoassay	 protocols	 relied	 on	 external	 actuators	 other	 than	 the	 spindle	 rotor,	
such	as	 lasers,	 for	 the	actuation	of	microvalves	 (Lee	et	al.,	2009,	Park	et	al.,	2012;	
Lee	et	al.	2015).	
	
Following	the	demonstration	of	controlled	sequential	 reagent	release	 in	the	disc,	a	
sandwich	assay	for	PSA	detection	and	a	competitive	assay	for	HER2	detection	were	
optimised	for	implementation	in	the	LoaD	platform.	This	led	to	a	reduced	number	of	
washing	 steps	 (from	 9	 in	 the	 conventional	 ELISA	 to	 3	 on-disc),	 smaller	 reagent	
volumes	(from	100	μL	to	40	μL)	and	shorter	incubation	times	(from	60	minutes	each	
to	 just	 10	minutes).	 The	 on-disc	 assays	 resulted	 in	 a	 slightly	 lower	 sensitivity	 and	
higher	 inter-assay	 variability,	 when	 compared	 with	 the	 conventional	 assays	 on	
immunoplates.	 	 These	 variations	 between	 the	 conventional	 ELISA	 and	 the	 LoaD	
	 139	
assays	 can	 be	 attributed	 to	 various	 factors.	 A	major	 aspect	 is	 the	 surface-binding	
capacity	 of	 the	 polystyrene	 disc	 surface,	 compared	with	 that	 of	 commercial	 ELISA	
plates	used	for	the	benchtop	assays,	which	are	manufactured	from	special	medical-
grade	polystyrene	for	uniform	binding	and	low	background	absorption.	Also,	the	top	
vents	 that	 seal	 the	 incubation	 chamber	 are	 not	 made	 of	 polystyrene	 due	 to	
manufacturing	issues,	reducing	the	surface	area	available	for	protein	coating.	Factors	
such	 as	 reagent	 losses	 in	 the	 channels	 and	 valves	 can	 lead	 to	 variance	 in	 the	
recorded	signals.	This	 is	especially	evident	 in	 the	competitive	ELISA,	which	 is	more	
sensitive	 to	 changes	 in	 antibody	 concentration.	 This	 method	 is	 based	 on	 the	
formation	of	HER2-scFv	complexes	that	are	washed	away,	while	only	free	antibodies	
are	 able	 to	 react	 with	 the	 coated	 antigen.	 Thus,	 scFv	 losses	 in	 the	 microfluidic	
structure	may	result	in	a	reduction	of	free	scFv	antibodies	and	therefore	a	reduction	
in	the	absorbance	signal,	as	seen	in	Figure	4.9B.	
	
Recombinant	antibodies	produced	by	the	Applied	Biochemistry	Group	 in	DCU	have	
recently	 started	 to	 be	 exploited	 for	 centrifugal	 microfluidics-based	 analytical	
platforms,	 leading	to	a	commercial	collaboration	with	Biosurfit	SpinIt®	startup,	and	
to	 the	 development	 of	 promising	 toxin	 detection	 systems,	 such	 as	 the	 Atlanta	
platform	for	algal	microcystin	detection	(Maguire	et	al.,	2015;	Maguire	et	al.,	2016).	
The	 Biosurfit	 SpinIt®	 diagnostic	 solution	 is	 a	 clear	 example	 of	 how	 microfluidic	
technology	 is	 capable	 of	 delivering	 multi-parameter	 blood	 analysis	 information	 in	
minutes.	From	a	finger-prick	blood	sample,	and	with	no	need	for	sample	preparation	
or	extra	reagents,	the	SpinIt®		microfluidic	discs	can	provide	real-time	and	accurate	
results	 for in-vitro	 diagnostic	 testing.	 Currently,	 there	 are	 two	 commercially-
available	 SpinIt®	 discs:	 the	 CRP	 test,	 a	 quantitative	 immunoassay	 for	 the	
measurement	of	C-reactive	protein	(CRP);	and	the	BC	(blood	cell	counting)	test,	for	
the	 quantitative	 measurement	 of	 total	 leucocytes,	 5-part	 differential	 white	 blood	
cells	and	haematocrit.	Immunoassays	are	performed	in	the	SpinIt®	analyser	(with	an	
integrated	 spin	 rotor)	 using	 Surface	 Plasmon	 Resonance	 (SPR)	 detection,	 while	
cytology	 is	 possible	 thanks	 to	 an	 integrated	 microscopy	 module	 and	 standard	
haematological	 dyes.	 Multi-analyte	 panels,	 such	 as	 the	 SpinIt®	 lipid	 panel,	 are	
currently	under	development	 (Biosurfit	|	Solution	website).	Samsung	LABGEO	 IB10	
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(Samsung	healthcare)	 and	Gyrolab	 Explore	 (Gyros)	 are	 also	 commercial	 centrifugal	
microfluidic	 devices	 for	 immunoassay	 applications.	 The	 Samsung	 platform	 has	
overcome	the	difficulties	associated	with	multiplexing,	and	it	allows	the	testing	of	up	
to	three	analytes	in	a	single	run,	as	in	the	CD	described	in	this	chapter.	For	example,	
Samsung’s	Cardiac	3-in-1	Panel	Test	measures	the	amount	of	Troponin	 I	 (cTnI),	CK-
MB	and	Myoglobin	in	human	whole	blood	(500-μL	sample),	providing	results	in	only	
20	minutes	(Samsung	LABGEO	IB10	|	Samsung	Business	website).	Gyros	technology	
is	able	to	process	up	to	112	data	points	per	CD	run	within	one	hour.	Each	GyrolabTM	
Bioaffy	CD	contains	112	channels	with	a	15-nL	volume	affinity	column	each,	in	which	
reagents	 bind	 to	 streptavidin-coated	 particles.	 Then,	 a laser-induced	 fluorescence	
detector	records	fluorescence	on	each	column.	The	main	drawbacks	associated	with	
this	 device	 are	 the	 requirements	 for	 a	 delicate	 robotic	 liquid	 handler	 system	 for	
liquid	transfer	from	a	microtiter	plate	to	the	CD	and	the	inability	to	perform	plasma	
separation	(Gyrolab	Xplore	website).		
	
Overall,	a	proof	of	concept	diagnostic	platform	that	possesses	the	ability	to	perform	
multiplexed	 assays	 from	 whole	 blood	 in	 a	 total	 time	 of	 less	 than	 one	 hour	 was	
demonstrated.	 Compared	with	 similar	 commercially	 available	microfluidic	 systems,	
our	disc	demonstrated	 similar	 features:	 lack	of	need	 for	 sample	pretreatment	 (on-
disc	 plasma	 separation),	 multiplexing	 ability	 (up	 to	 three	 tests	 per	 disc),	 minimal	
sample	 and	 reagents	 volume	 requirements	 (185	 μL	 of	 blood	 and	 40	 μL	 of	 each	
reagent	per	test)	and	automated	fluid	handling.	Significant	optimisation	and	further	
testing	will,	however,	be	 required	prior	 to	biomarker	measurement	 from	blood.	 In	
order	to	increase	the	analytical	sensitivity	and	reproducibility,	the	disc	base	surface	
could	 be	 chemically	 modified	 to	 introduce	 functional	 groups	 for	 efficient	 protein	
immobilization	 (Bai	et	al.,	 2006;	Henares	et	al.,	 2008;	Wen	et	al.,	 2009*).	Another	
approach	would	be	the	use	of	microbeads	for	antibody	(or	antigen,	in	the	case	of	the	
competitive	ELISA)	immmobilisation	(Lee	et	al.,	2006;	Lacharme	et	al.,	2009;	Park	et	
al.,	2012;	Glynn	et	al.,	2013).	For	example,	Park	et	al.	(2012)	used	polystyrene	beads	
modified	 with	 antibodies	 for	 the	 detection	 of	 high	 sensitive	 C-reactive	 protein	
(hsCRP),	cardiac	troponin	I	(cTnI),	and	N-terminal	pro-B	type	natriuretic	peptide	(NT-
proBNP)	by	a	sandwich	ELISA-based	LoaD.	This	system	was	able	to	detect	the	panel	
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of	 three	 cardiovascular	 disease	 (CVD)	 biomarkers	 with	 a	 LOD	 <	 1	 ng/mL	 in	 20	
minutes.	A	drawback	of	this	system	is	the	requirement	of	three	types	of	HRP-labelled	
detection	antibodies	(anti-hsCRP,	anti-cTnI	and	anti-	NT-proBNP),	in	contrast	to	ours,	
which	 only	 requires	 a	 universal	 anti-HA	 for	 both	 assays,	 as	 a	 result	 of	 the	 use	 of	
recombinant	 capture	 antibodies	 containing	 a	 HA	 tag.	 Moreover,	 Cho’s	 group	
employed	 laser	 irradiated	 ferrowax	microvalves	 (LIFM)	 for	 sequential	 fluid	 control,	
requiring		an	external	laser	for	the	melting	and	opening	of	the	valves,	while	our	DF-
tabs	are	fully	rotationally-controlled.	In	addition	to	this,	our	system	is	more	flexible,	
in	 that	 it	 allows	 the	 incorporation	 of	 different	 assay	 formats	 (sandwich	 and	
competitive)	in	the	same	disc,	and	requires	smaller	sample	and	reagent	volumes.		
	
In	 summary,	 the	 benefits	 of	 the	 described	 LoaD	 device	 include	 the	 automation	 of	
sequential	steps,	 reducing	pipetting	steps,	as	well	as	the	reduction	of	conventional	
assay	times,	reagent	volumes	and	number	of	washes.	All	immunoassay	steps	for	the	
detection	 of	 fPSA	 and	 HER2	 markers	 are	 performed	 on	 the	 LoaD,	 by	 simple	
variations	 in	 the	 rotational	 speed.	 This	 kind	 of	 microfluidic	 low-cost	 device	 holds	
great	 promise	 for	 revolutionising	 the	way	 in	which	diagnostics	 tests	 are	delivered,	
allowing	fast,	multi-marker	ELISA-based	disease	detection.	
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Chapter	5	
	
Development	of	a	Single-
Chain	Antibody-Based	
Magneto-Immunosensor	for	
the	Detection	of	Free	PSA	
	
	 143	
5.1	INTRODUCTION	
	
In	recent	years,	magnetic	particles	(MPs)	have	been	being	applied	to	various	fields,	
including	 cell	 separation	 (Bai	 et	 al.,	 2014;	 Plouffe	 et	 al.,	 2014),	 immunoassays	
(Ranzoni	et	al.,	2012;	Wang	et	al.,	2014),	drug	 targeting	and	delivery	 (Mody	et	al.,	
2013,	Mou	et	al.,	2015),	and	magnetic	resonance	imaging	(Zhu	et	al.,	2014;	Estelrich	
et	al.,	2015).	Advances	on	synthesis	and	characterisation	of	magnetic	nanoparticles	
have	allowed	the	development	of	a	wide	range	of	commercial	magnetic	biomaterials	
attractive	for	clinical	applications,	such	as	those	produced	by	BioMag®,	Dynabeads®,	
Adembeads®	and	SiMAG®		
	
Among	 MPs,	 superparamagnetic	 particles,	 which	 can	 be	 magnetised	 under	 an	
external	 magnetic	 field	 and	 demagnetise	 when	 removed	 from	 the	 magnet,	 are	
especially	 attractive	 (Ramanujan,	 2009).	 They	 precipitate	 under	 a	 magnetic	 field,	
enabling	efficient	separation	from	the	sample,	yet	lose	the	attraction	for	each	other	
when	 the	 magnetic	 field	 is	 removed,	 allowing	 complete	 resuspension.	 This	 is	
especially	 useful	 when	 the	 paramagnetic	 particles	 are	 conjugated	 to	 antibodies,	
allowing	the	separation	and	concentration	of	proteins	(or	microorganisms)	from	the	
sample.	
	
5.1.1	The	history	of	Dynabeads	
	
In	 1976,	 the	 Norwegian	 professor	 John	 Ugelstad	 discovered	 a	 process	 to	
manufacture	monodisperse,	 uniformly	 sized	 spherical	 polystyrene	beads	 (currently	
known	 as	 Dynabeads).	 Previously,	 this	 had	 only	 been	 achievable	 by	 NASA	 in	 the	
weightless	 conditions	 of	 space.	 The	method	 involves	 a	 two-step	 swelling	 process:	
first,	 a	 water-insoluble,	 low-molecular	 weight	 compound	 is	 introduced	 in	
polystyrene	seed	particles	 in	water,	and	then,	a	slightly	soluble	compound	diffuses	
through	water	and	is	absorbed	into	these	particles,	which	can	absorb	more	than	100	
times	 their	own	volume	(Ugelstad	et	al.,	1979).	 	Soon	after	 this	discovery,	another	
breakthrough	 followed,	 when	 these	 beads	 were	 made	 paramagnetic	 by	 mixing	
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porous	beads	with	oxidative	groups	with	Fe2+	salt	solutions	to	form	magnetic	oxides	
for	immunomagnetic	cell	separation		(Nustad	et	al.,	1982;	Ugestad	et	al.,	1988).			
	
A	wide	range	of	magnetic	Dynabeads	of	various	sizes	and	surface	functionalities	has	
since	 been	 developed	 for	 different	 purposes,	 from	 cell,	 protein	 or	 nucleic	 acid	
isolation	to	assay	development,	and	are	commercially	available	from	the	Invitrogen	
corporation.			
	
5.1.2	Dynabeads	for	immunoassay	
	
For	 assay	 development,	 Dynabeads	 can	 be	 coupled	 with	 a	 ligand	 (such	 as	 an	
antibody	or	a	DNA/RNA	probe)	with	an	affinity	for	the	desired	target.	When	added	
to	the	sample,	the	pre-coupled	beads	bind	to	the	target	biomolecule,	which	can	then	
be	easily	separated	from	the	rest	of	the	sample	by	the	use	of	a	magnet	to	immobilise	
the	 beads	 and	 their	 trapped	 analyte,	 while	 the	 unbound	 material	 is	 removed	 by	
aspiration.	 	 The	 ligand	 can	 be	 coupled	 directly	 onto	 tosyl-activated	 Dynabeads	 or	
indirectly	onto	streptavidin-coated	Dynabeads,	though	biotinylation	(He	et	al.,	2004).	
	
Magnetic	 particles	 provide	 several	 advantages	 for	 the	 development	 of	
immunoassays.	 They	 allow	 efficient	 and	 reproducible	 ligand	 immobilisation	 and	
increase	 the	 surface	 area	 for	 the	 immunological	 reaction,	 as	 they	 are	 spherical	 in	
shape.	 They	 facilitate	 fast	 assay	 kinetics	 because	 the	 beads	 are	 in	 suspension.	 In	
addition	 efficient	 washing	 and	 minimising	 of	 matrix	 effects	 due	 to	 the	 magnetic	
separation	of	the	target	is	possible.	Their	use	also	shortens	assay	development	time,	
while	 increasing	 sensitivity	 (Centi	 et	 al.,	 2008;	 Bruls	 et	 al.,	 2009;	 Castilho	 et	 al.,	
2011).	
	
The	 incorporation	of	MPs	 in	 ELISA	was	 shown	 to	be	beneficial	 in	multiple	 studies.	
Zhang	and	co-workers evaluated	a	chemiluminescence	enzyme	immunoassay	based	
on	 magnetic	 microparticles	 (MPs-CLEIA)	 to	 detect	 serum	 α-fetoprotein	 (AFP)	 in	
parallel	 with	 traditional	 colorimetric	 ELISA.	 They	 found	 that	 the	 MPs-CLEIA	 was	
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advantageous	over	the	ELISA	in	terms	of	the	need	for	less	reagent	volumes,	reduced	
assay	time	and	wider	linear	ranges	(Zhang	et	al.,	2012).	Another	study	reported	the	
application	of	a	competitive	colorimetric	immunoassay	for	the	detection	of	aflatoxin	
B1	 (AFB).	 They	 used	 AFB-BSA-modified	 MPs	 as	 a	 detection	 probe	 and	 anti-AFB	
antibody-coated	gold	nanoparticles	as	a	signal	probe.	The	assay	was	able	to	detect	
AFB	from	maize	sample	extract	in	a	timesaving	and	cost-effective	manner,	within	the	
low	nanogram	per	liter	range	(Wang	et	al.,	2014).	Other	researchers	investigated	the	
use	 of	 MPs	 in	 biosensors.	 Bruls	 et	 al.	 (2009)	 developed	 an	 optomagnetic	
immunosensor	 that	 enables	 high-sensitive	 one-step	 multiplex	 assays	 for	 the	
detection	 of	 drugs	 of	 abuse	 (morphine,	 amphetamine,	 methamphetamine,	
tetrahydro-cannabinol,	 and	 cocaine)	 from	 saliva,	 in	 a	 disposable	 cartridge.	 The	
detection	of	sub-nanogram	per	milliliter	concentrations	of	drugs	was	achieved	 in	a	
total	assay	time	of	one	minute	(Bruls	et	al.,	2009).	In	addition,	electrochemical-based	
magneto-immunosensing	 for	 highly	 sensitive	 detection	of	microorganisms,	 such	 as	
Plasmodium	 falciparum	 (related	 to	malaria)	 or	 Salmonella	 has	 also	 been	 reported	
(Castilho	et	al.,	2011;	Liébana	et	al.,	2009).		
5.2	AIMS	OF	THIS	CHAPTER		
PSA	exists	 in	serum	in	at	 least	two	forms:	uncomplexed/free	(fPSA)	and	complexed	
to	α1-anti-chymotrypsin	(PSA-ACT)	or	α2-macroglobulin	(PSA-A2M).	As	discussed	in	
Section	 1.4,	 despite	wide	 use,	 total	 PSA	 test	 (that	measures	 the	 sum	 of	 fPSA	 and	
PSA-ACT	 [PSA-A2M	 is	not	detectable	by	 conventional	 immunoassays,	 as	 the	PSA	 is	
encapsulated	by	the	A2M])	 lacks	specificity	for	prostate	cancer	(Zhang	et	al.,	1998;	
Wang	et	al.,	1999).	Free	forms	of	PSA	are	less	abundant	in	prostate	cancer	patients,	
compared	with	 those	with	 BHP.	 In	 current	 clinical	 practice,	 the	 free	 PSA	 (fPSA)	 to	
total	PSA	ratio	(%	fPSA)	is	used	to	avoid	unnecessary	biopsies.	In	men	with	total	PSA	
levels	 between	 4	 and	 10	 ng/mL,	 a	 cut-off	 of	 <25	%	 of	 fPSA	 is	 used	 for	 biopsy	
recommendations	(Catalona	et	al.,	1998).		
	
In	this	project,	a	magneto-immunosensor	for	the	detection	of	fPSA	using	‘in-house’	
generated	 scAb	 antibodies	 was	 developed.	 Superparamagnetic	 Dynabeads	 M-280	
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Tosylactivated	 (Life	 Technologies)	 were	 conjugated	 with	 anti-fPSA	 scAbs	 for	 fPSA	
capture	before	optical	or	electrochemical	detection.	The	final	aim	was	to	develop	an	
assay	 that	 can	be	 run	 in	 the	Gwent	Group	Handi-Lab	 instrument,	 for	point-of-care	
chronoamperometric	measurements	of	fPSA	from	clinical	samples	(Figure	5.1).	
	
	
Figure	5.1.	 	Selected	strategy	for	the	detection	of	free	PSA:	A)	Handi-Lab	instrument	(Gwent	Group);	
B)	 Screen-printed	 electrode	 (Gwent	 Electronic	 Materials.	 Ltd.);	 C)	 Assay	 format	 for	 the	
electrochemical	detection	of	fPSA;	D)	Electron	transfer	at	the	electrode/solution	interface.		Adapted	
from	Liébana	et	al.	(2014*).	
	
5.3	RESULTS		
5.3.1	ScAb	E1	conjugation	to	paramagnetic	particles	
	
Dynabeads	 M-280	 Tosylactivated	 are	 paramagnetic	 polystyrene	 beads	 (4.5-μm	
diameter)	 possessing	 a	 hydrophobic	 surface	with	 p-toluene-sulfonyl	 (Tosyl)	 groups	
to	 allow	 covalent	 binding	 by	 primary	 amine	 (-NH2)	 or	 sulphydryl	 (-SH)	 groups.	
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According	to	manufacturer	instructions,	1	mg	of	beads	can	be	coupled	to	5-20	μg	of	
antibody.		
	
The	single-chain	antibody	fragments	were	covalently	coupled	to	the	tosyl-activated	
MPs	 by	 amine	 bonds	 (Section	 2.2.9.1).	 In	 order	 to	 determine	 the	 amount	 of	 scAb	
immobilised	 on	 the	 MPs,	 an	 antibody	 titre	 in	 the	 post-conjugation	 supernatant	
(Section	 2.2.9.2)	was	 carried	 out.	 The	 amount	 of	 scAb	 present	 in	 the	 supernatant	
after	 immobilisation	was	 calculated	using	a	 calibration	 curve	obtained	with	known	
concentrations	of	 the	scAb,	and	compared	with	 the	scAb	concentration	before	 the	
conjugation	step.	The	coupling	efficiency	was	found	to	be	greater	than	94	%.	
	
5.3.2	Optimisation	of	assay	conditions	by	magneto-ELISA	
	
In	 this	 procedure,	 the	 scAb-conjugated	 MPs	 were	 first	 incubated	 with	 the	 fPSA	
solution	 in	 the	 immunoplate	 wells	 for	 40	 minutes.	 After	 fPSA	 capture,	
immunomagnetic	separation	of	fPSA	was	performed,	following	detection	by	an	HRP-
labelled	 anti-PSA	 secondary	 antibody.	 TMB	 peroxidase	 substrate	 was	 then	 added	
and	resulting	absorbance	was	read	at	450	nm.	
	
The	concentration	of	anti-PSA	scAb	E1	was	optimised	using	three	different	antibody	
concentrations	 (0.25,	 0.5	 and	 1	mg/mL	 in	 10	mM	PBS,	 pH	 7.4)	 for	 bioconjugation	
with	 MPs.	 A	 magneto-ELISA	 (Section	 2.2.9.3)	 was	 performed	 using	 the	 MPs	
conjugated	 with	 different	 antibody	 concentrations	 and	 varying	 concentrations	 of	
fPSA	 (0.1–20	 ng/mL),	 along	 with	 a	 blank	 sample.	 From	 the	 dose-response	 curves	
(Figure	5.2A),	1	mg/mL	of	scAb	was	selected	as	optimal	antibody	concentration	for	
coating	of	MPs.	
	
Similarly,	 optimal	 concentration	 of	 bioconjugated	 MPs	 for	 magneto-immunoassay	
was	 evaluated	 by	 incubating	 fPSA	 standards	 with	 0.1	 mg/mL	 or	 0.2	 mg/mL	 of	
antibody-MPs	 conjugate	 per	 well	 (Figure	 5.2B).	 The	 amount	 of	magnetic	 particles	
added	 to	 the	 ELISA	 wells	 was	 shown	 to	 have	 an	 influence	 in	 the	 dose-response	
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curve,	 and	 a	 slightly	 higher	 response	 was	 obtained	 using	 0.2	 mg/mL	 of	 MPs.	
However,	 to	 reduce	 the	cost	of	 the	 test,	 saving	expensive	antibodies	and	MPs,	0.1	
mg/mL	was	selected	for	further	experimental	work.	
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Figure	5.2.	Optimisation	of	assay	conditions	by	magneto-ELISA.	A)	Optimisation	of	scAb	concentration	
(0.25,	 0.5	 and	 1	 mg/mL)	 for	 bioconjugation	 to	 magnetic	 beads.	 B)	 Optimisation	 of	 bioconjugated	
magnetic	beads	(MPs)	concentration	(0.1	or	0.2	mg/mL	per	well)	for	magneto-ELISA.	The	absorbance	
was	read	at	450	nm.	The	error	bars	represent	the	mean	+/-		the	standard	deviation	(n=3).	
	
	
The	magneto-ELISA	 standard	 curve	 for	 fPSA	was	 performed	 in	 PBS	 buffer	 (Section	
2.2.9.3)	on	three	independent	days	(n=9)	in	a	three-month	period.	Figure	5.3A	shows	
the	 sigmoidal	 dose-response	 obtained	 for	 the	 concentrations	 ranging	 from	 0.1	 to	
100	 ng/mL	 (R2=0.9936).	 The	 signal	 corresponding	 to	 the	 LOD	 was	 estimated	 by	
processing	the	negative	control	samples	and	performing	three	different	single	inter-
day	assays,	obtaining	a	mean	value	of	0.053	AU	with	a	standard	deviation	of	0.008	
AU.	The	signal	corresponding	to	the	LOD	value	was	then	extracted	with	a	one-tailed	
t-test	at	a	99	%	confidence	level,	giving	a	value	of	0.076	AU	(shown	in	Figure	5.3B	as	
the	dashed	horizontal	line).	This	method	to	calculate	the	detection	limit	is	based	on	
Glaser	et	al.	(1981)	approach	and	can	be	described	as	“the	minimum	concentration	
of	a	substance	that	can	be	identified,	measured	and	reported	with	99	%	confidence	
that	 the	 analyte	 concentration	 is	 greater	 than	 zero”.	 The	 limit	 of	 detection	 was	
found	 to	 be	 0.3	 ng/mL	with	 a	 dynamic	 range	 up	 to	 5	 ng/mL	 of	 fPSA	 (R2=0.9961).	
Coefficients	of	variability	were	found	to	range	from	3.5	to	8	%.	
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Figure	5.3.	Magneto-ELISA	immunosensing	of	fPSA.	A)	Magneto-ELISA	standard	curve	was	established	
using	 the	 optimised	 conditions	 whilst	 combining	 the	 results	 from	 three	 different	 days	 (n=9).	 B)	
Magneto-ELISA	linear	range	and	limit	of	detection	(represented	by	dashed	line).	
	
	
5.3.3	Development	of	an	amperometric	magneto-immunoassay	
	
Following	 optimisation	 of	 assay	 conditions,	 electrochemical	 magneto-
immunosensing	was	performed	in	order	to	increase	the	assay	sensitivity	and	reduce	
the	 turn-around	 time.	 The	 amperometric	 detection	 of	 fPSA	 was	 performed	 as	
illustrated	in	Figure	5.1,	but	using	an	Uniscan	Instrument	Potentiostat,	instead	of	the	
Handi-Lab	instrument.	
	
5.3.3.1	Cyclic	voltammetry		
The	 characteristaion	 of	 the	 magnetic	 screen	 carbon	 printed	 (m-SCP)	 by	 cyclic	
voltammetry	 (CV)	 (Bard	et	al.,	1980)	was	performed	by	Dr.	Susana	Liébana	 (Figure	
5.4),	 using	 a	 three-electrode	 cell	 comprosed	 of	 a	 carbon	 working	 electrode,	 and	
Ag/AgCl	 reference	 and	 counter	 electrodes	 (Figure	 5.1B).	 The	 amperometric	
detection	was	based	on	the	action	of	the	HRP	enzyme	(conjugated	to	the	secondary	
antibody),	 by	 using	 hydroquinone	 as	 a	 mediator	 and	 H202	 as	 the	 peroxidase	
substrate,	as	previously	reported	(Ahammad,	2013).	A	working	potential	of	 -0.15	V	
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vs.	Ag/AgCl	reference	electrode	was	chosen	according	to	the	cyclic	voltammogram,	
shown	in	Figure	5.4.	
	
Figure	 5.4.	 Cyclic	 voltammogram	 derived	 using	 a	 6-mm	 working	 electrode	 carbon	 screen-printed	
electrode.	A	volume	of	100	µL	of	phosphate	buffer	with	2	mM/L	hydroquinone	was	used.	The	scan	
rate	was	10	mV/s.	
	
	
5.3.3.2	Selection	of	optimal	bioconjugated	magnetic	particles	concentration	for	
immunosensor	
	
The	 concentration	 of	 MPs	 is	 a	 critical	 step	 for	 the	 development	 of	 the	
electrochemical	magneto-immunosensor.	Low	concentrations	of	MPs	may	affect	the	
sensitivity	of	the	test,	while	high	deposition	of	MPs	in	the	screen-printed	electrode	
may	compromise	electrode	transfer.		Optimal	bioconjugated	MPs	concentration	was	
determined	by	incubating	the	MPs	with	5	and	10	ng/mL	of	fPSA	(prepared	in	10	mM	
PBS,	pH	7.4),	at	two	different	concentrations	(0.2	and	0.1	mg/mL	per	electrode)	for	
the	amperometric	immunoassay	(Section	2.2.9.3).	As	shown	in	the	Figure	5.5,	a	MP	
concentration	of	0.2	mg/mL	per	electrode	resulted	in	a	higher	signal-to-background	
ratio	(μA/μA0,	where	μA	is	the	amperometric	response	for	each	fPSA	value	and	μA0	
is	the	amperometric	signal	of	the	blank),	but	0.1	mg/mL	was	also	able	to	discriminate	
between	 the	 different	 fPSA	 concentrations,	 so	 this	was	 selected	 to	 allow	 low-cost	
testing.	
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Figure	5.5.	Amperometric	response	obtained	for	0.1	and	0.2	mg/mL	of	bioconjugated	MPs	on	the	SPE	
using	 two	 different	 fPSA	 concentrations	 (5	 and	 10	 ng/mL).	 For	 amperometric	 measurements,	
hydroquinone	was	used	as	the	mediator	with	H2O2	as	the	substrate.	The	potential	applied	was	-0.15V	
over	30	seconds,	with	2	minutes	delay.	MP–magnetic	beads;	SPE–screen-printed	electrode.	
	
5.3.3.3	Amperometric	measurements	for	free	PSA	detection			
Free	PSA	measurements	(0.1-100	ng/mL)	were	made	in	10	mM	PBS	buffer	(Section	
2.2.9.4).	In	order	to	reduce	the	assay	time,	two	methodologies	were	tested:		
	
• A	‘two-step’	protocol,	consisting	of:		a)	immunomagnetic	separation	(IMS)	of	
fPSA	 from	 the	 sample	 using	 anti-fPSA	 scAb-MPs	 conjugates;	 b)	
immunorecognition	of	captured	fPSA	with	an	HRP-labelled	anti-PSA	antibody;	
and	c)	amperometric	detection	based	on	magnetic	screen-printed-electrodes	
(Figure	2.5);	and		
• A	‘one-step’	protocol,	in	which	the	fPSA	and	HRP-labelled	anti-fPSA	antibody	
were	incubated	prior	to	addition	of	the	scAb-conjugated	MPs.	The	‘one-step’	
protocol	 eliminates	 one	 incubation	 and	washing	 step,	 reducing	 the	 time	of	
assay	by	approximately	one	hour.		
	
Figure	 5.6	 shows	 that	 the	 ‘one-step’	 protocol	 resulted	 in	 an	 improved	 sensitivity,	
when	 compared	 with	 the	 ‘two-step’	 assay.	 Thus,	 the	 ‘one-step’	 protocol	 was	
selected	 for	 further	 studies.	 These	 results	 suggest	 that	 the	primary	 and	 secondary	
antibody	bind	to	different	epitopes	in	the	PSA	molecule,	as	the	binding	of	the	HRP-
labelled	 anti-PSA	 Ab	 to	 PSA	 (epitope	 5,	 as	 indicated	 by	 manufacturer)	 does	 not	
interfere	with	the	PSA	capture	by	the	scAb-conjugated	MPs.		
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Figure	5.6.	Amperometric	response	obtained	using	a	one-step	protocol	versus	the	two-step	protocol.	
A	fPSA	range	from	0.1	to	100	ng/mL	was	tested.	Hydroquinone	was	used	as	the	mediator	and	H2O2	as	
the	substrate.	Potential	applied	was	-0.15	V	for	30	seconds,	with	a	2	minute	delay.	
	
	
	
	
The	 standard	 curve	 for	 fPSA	 detection	 by	 the	 magneto-immunosensor	 (Section	
2.2.9.4)	was	performed	 in	PBS	buffer	on	three	days	(n=9)	 in	a	three-month	period.		
Figure	 5.7A	 shows	 the	 sigmoidal	 dose-response	 obtained	 for	 the	 concentrations	
ranging	from	0.1	to	100	ng/mL	(R2=0.8353).	The	signal	corresponding	to	the	LOD	was	
estimated	 by	 processing	 the	 negative	 control	 samples	 and	 performing	 three	
different	 single	 inter-day	 assays,	 using	 screen-printed	 electrodes	 from	 three	
different	batches,	obtaining	a	mean	value	of	 0.51	µA	with	a	 standard	deviation	of	
0.13	µA.	The	signal	corresponding	to	the	LOD	value	was	then	extracted	with	a	one-
tailed	t	 test	at	a	99	%	confidence	 level,	giving	a	value	of	0.88	µA,	 (shown	 in	Figure	
5.7B	as	the	dashed	horizontal	line).	The	limit	of	detection	was	found	to	be	0.5	ng/mL	
with	a	dynamic	range	up	to	10	ng/mL	of	fPSA	(R2=0.9979).	Coefficients	of	variability	
were	found	to	range	from	8	to	12%.		
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Figure	5.7.	Amperometric	magneto-immunosensor	standard	curve	(A)	with	a	 linear	range	from	0	to	
10	 ng/mL	 fPSA	 (B).	 Hydroquinone	was	 used	 as	 the	mediator	with	 H2O2	 as	 the	 substrate.	 Potential	
applied	was	-0.15	V	for	30	seconds,	with	a	2	minute	delay.	
	
	
5.3.4	Interference	studies	
	
Potential	interferants	were	evaluated	by	spiking	a	PSA	standard	(50	ng/mL)	with	5.5	
g/dL	human	serum	albumin	(HuSA),	150	ng/mL	human	kallikrein	2	(hk2)	or	50	ng/mL	
α1-antichymotrypsin	 (ACT)-complexed	PSA	 (cPSA)	and	checking	 for	 interference	on	
the	PSA-scAb	 interaction.	 The	amperometric	 response	 for	 each	 spiked	 sample	was	
determined	 (Section	 2.2.9.4)	 and	 compared	 with	 the	 response	 of	 the	 PSA-only	
standard	(control).		No	apparent	interference	was	observed	(Figure	5.8).	
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Figure	 5.8.	 Interference	 analysis.	 Amperometric	 response	 obtained	 for	 a	 PSA	 standard	 (50	 ng/mL)	
spiked	in	triplicate	with	5.5	g/dL	of	human	serum	albumin	(HuSA),	140	ng/mL	human	kallikrein	2	(hK2)	
or	 50	 ng/mL	 of	 complex	 PSA	 (cPSA).	 Hydroquinone	 was	 used	 as	 the	 mediator	 with	 H2O2	 as	 the	
substrate.	The	potential	applied	was	-0.15	V	for	30	seconds,	with	a	2	minute	delay.		
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5.4	Discussion	
	
The	 utility	 of	 using	 PSA	 isoforms	 for	 increasing	 the	 likelihood	 of	 prostate	 cancer	
detection	was	 investigated	 in	 a	 recent	population	 screening	 study,	which	analysed	
the	free	and	total	PSA	levels	in	a	total	of	1,277	men	aged	between	55	and	69	years	
with	 total	 PSA	 levels	 of	 2-10	 ng/mL	 (Kitagawa	 et	 al.,	 2014).	 In	 this	 study,	 the	
probabilities	of	prostate	cancer	at	three	years	were	64.5,	41.2,	28.5,	and	14.3	%	for	
the	 men	 with	 free/total	 PSA	 ratio	 ≤0.08,	 0.09–0.13,	 0.14–0.22,	 and	 ≥0.23,	
respectively.	 Significant	 lower	 free/total	 ratios	 were	 found	 in	 patients	 with	
unfavorable	 cancerous	 features	 in	 prostate	 biopsy.	 From	 these	 results,	 it	 was	
concluded	 that	 fPSA	 measurements	 are	 useful	 for	 prostate	 cancer	 diagnosis	 and	
prognosis.	
	
Current	and	novel	analytical	technologies	used	for	PSA	detection	have	been	recently	
reviewed	 (Healy	 et	 al.,	 2007;	 Sharma	 et	 al.,	 2016),	 showing	 the	 need	 for	
development	 of	 novel	 biosensor	 detection	 strategies.	 Most	 of	 the	 methods	
developed	 for	 PSA	 detection	 are	 immunoassay	 based	 with	 different	 detection	
approaches.	The	versatility	of	antibodies	 is	well	demonstrated	 in	a	range	of	clinical	
applications,	 ranging	 from	 those	used	as	 recognition	elements	 in	diagnostic	 assays	
and	 bio-sensing	 devices	 to	 therapeutic	 antibodies	 and	 targeted	 drug	 delivering	
systems	 (Siddiqui	 et	 al.,	 2010).	 Antibody	 engineering	 techniques	 allowed	 the	
production	of	 large	amounts	of	high-quality	antibodies	 in	a	cost-	and	time-efficient	
manner.	 In	 order	 to	 improve	 the	 performance	 of	 the	 traditional	 immunoassay	
format,	 many	 researchers	 exploited	 the	 possibility	 of	 performing	 the	
immunoreaction	 on	 the	 surface	 of	magnetic	micro	 and	 nanoparticles	 (Mani	et	 al.,	
2011;	Ranzoni	et	al.,	2012;	Sharif	et	al.,	2013).	Magnetic	particles	(MPs)	have	been	
widely	 used	 as	 a	 universal	 separation	 tool	 for	 the	 separation	 of	 biological	
compounds,	such	as	cells,	proteins	or	DNA,	from	a	sample	fluid.	The	advantages	of	
utilising	 MPs	 for	 immunoassay,	 along	 with	 a	 number	 of	 magneto-immunoassay	
examples	were	previously	discussed	in	Section	5.1.2.	The	use	of	MPs	has	proven	to	
be	particularly	beneficial	when	combined	with	electrochemical	approaches,	as	non-
specific	 protein	 adsorption	 onto	 the	 electrode	 surface	 is	 avoided,	 thus	 enhancing	
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assay	sensitivity	(Zani	et	al.,	2011;	Li	et	al.,	2012;	Liébana	et	al.,	2014;	Carinelli	et	al.,	
2015).	 In	 particular,	 benefits	 are	 obtained	 when	 screen-printing	 microfabrication	
technology	 is	 used	 (Liébana	 et	 al.,	 2016).	 This	 technology	 is	 nowadays	 well	
established	for	the	production	of	 thick-film	electrochemical	 transducers	and	allows	
the	mass	production	of	 reproducible	yet	 inexpensive	and	mechanically	 robust	strip	
solid	electrodes	(Escamilla-Gómez	et	al.,	2009).	
	
The	aim	of	 this	chapter	was	to	assess	the	potential	of	employing	an	amperometric	
magneto-immunosensor,	 based	 on	 screen-printed	 electrodes	 (SPE)	 and	 ‘in-house’	
generated	recombinant	antibodies,	 	 for	fPSA	detection.	The	work	described	here	 is	
part	 of	 a	 PROSENSE	 secondment’s	 collaborative	 project	 with	 Dr.	 Susana	 Liébana,	
from	the	Gwent	Group	Ltd.		
	
Initially,	 scAb	antibodies	were	conjugated	 to	 tosyl-activated	paramagnetic	particles	
by	 amine	 bonds.	 Antibody-conjugated	Dynabeads	were	 used	 for	 immunomagnetic	
separation	 of	 free	 PSA,	 prior	 to	 antigen	 recognition	 by	 a	 Horseradish	 peroxidase	
(HRP)-labelled	 secondary	 antibody	 in	 a	 sandwich	 ELISA	 format.	 Immunomagnetic	
separation	is	a	widely	used	technique	for	the	capture	and	separation	of	pathogenic	
organisms	from	body	fluids	(Intorasoot	et	al.,	2016;	Agga	et	al.,	2016),	food	(Lim	et	
al.,	 2016;	 Hohweyer	et	 al.,	 2016)	 or	 environmental	matrices	 (Richard	et	 al.,	 2016;	
Brugnera	et	al.,	2016),	but	also	for	the	purification	and	enrichment	of	proteins	from	
complex	serum	samples	(Yao	et	al.,	2008;	Neubert	et	al.,	2013;	Capangpangan	et	al.,	
2014).	 This	 last	 application	 is	 especially	 useful	when	 sandwich	 assays	 are	 used	 for	
the	capture	and/or	enrichment	of	proteins	in	serum	(Sarkar	et	al.,	2008;	Osmekhina	
et	 al.,	 2010;	 Tennico	 et	 al.,	 2010),	 as	 they	 allow	 highly	 specific	 separation	 and	
detection	of	the	protein	of	interest	(because	two	different	antibodies	are	used).	The	
current	 sandwich	 assay	 was	 optimised	 by	 testing	 the	 effect	 of	 different	 scAb	
concentrations	 (0.25,	 0.5	 and	 1	 mg/mL)	 for	 bioconjugation	 to	 the	 MPs,	 and	 the	
effect	 of	 two	 scAb-MP	 conjugate	 concentrations	 (0.1	 and	 0.2	 mg/mL)	 for	 fPSA	
immumagnetic	separation,	by	magneto	ELISA	(m-ELISA).	The	optimisation	steps	were	
carried	out	by	m-ELISA	because	this	method	enables	high-throughput	simultaneous	
processing	of	multiple	samples.	Use	of	higher	concentrations	(>0.5	mg/mL))	of	scAb	
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for	 bioconjugation	 lead	 to	 significantly	 higher	 absorbance	 m-ELISA	 signals	 and,	
therefore,	1	mg/mL	of	antibody	concentration	(equivalent	to	20	μg	of	antibody	per	
mg	 of	 MPs)	 was	 selected	 as	 optimal	 for	 bioconjugation.	 The	 resulting	 magneto-
immunoassay	showed	a	limit	of	detection	of	0.3	ng/mL	with	a	dynamic	range	up	to	5	
ng/mL	of	 fPSA.	Once	the	assay	conditions	were	 fully	characterized	by	m-ELISA,	 the	
development	 of	 the	 electrochemical	 readout	 for	 the	 implementation	 of	 the	
amperometric	 magneto	 immunosensor	 was	 addressed.	 The	 electrochemical	
behavior	of	the	screen-printed	electrodes	was	evaluated	by	Dr.	Liébana	though	the	
hydroquinone/benzoquinone	 (HQ/BQ)	 redox	 couple.	 Cyclic	 voltammetry	 was	 used	
for	 electrode	 characterisation.	 For	 the	 electrochemical	 measurements,	 an	
amperometric	 method	 was	 selected,	 in	 which	 a	 constant	 potential	 (-0.15	 V)	 was	
applied	to	the	working	electrode	and	the	current	was	measured	as	a	function	of	time	
(Section	 1.6.2.1).	 The	 initial	 amperometric	 assay	 format	 had	 two	 incubation	 steps	
(one	 for	 fPSA	 binding	 to	 the	 MPs	 and	 the	 other	 for	 fPSA	 recognition	 by	 the	
secondary	antibody)	of	40	minutes	each,	with	a	washing	step	in	between.	As	a	result,	
the	total	assay	time	was	more	than	90	minutes.		In	order	to	further	reduce	the	assay	
time	 to	make	 the	 biosensor	 suitable	 for	 on-site	 testing,	 a	 ‘one-step’	 protocol	was	
implemented,	 which	 allowed	 to	 eliminate	 one	 incubation	 and	 washing	 step,	 thus	
reducing	 the	 assay	 time	 to	 less	 than	 an	 hour.	 The	 limit	 of	 detection	 for	 the	
amperometric	magneto-immunoassay	using	the	‘one-step’	protocol	was	found	to	be	
0.5	 ng/mL	with	 a	 dynamic	 range	 up	 to	 10	 ng/mL	 of	 fPSA.	 Although	 a	 similar	MP-
based	 electrochemical	 immunoassay	 for	 fPSA	 detection	 has	 been	 previously	
reported	 	 (Sarkar	 et	 al.,	 2008),	 this	 new	 design	 not	 only	 overcomes	 linearity	
limitations	present	 in	 the	previous	 system	 (with	 a	 linear	 range	of	 0–1	ng/mL),	 but	
also	 drastically	 reduces	 the	 assay	 time	 (from	 more	 than	 12h	 to	 less	 than	 1h).	 In	
addition	 to	 this,	 the	 platform	 was	 tested	 for	 a	 number	 of	 potential	 interferants	
(human	serum	albumin,	human	kallikrein	2	and	ACT-complexed	PSA)	and	little	or	no	
interferance	was	found.	
	
Some	 high-throughput	 devices	 manufactured	 by	 big	 pharmaceutical	 companies	
(Siemens,	Abbot,	 Roche)	 are	 able	 to	detect	 fPSA	at	 lower	 concentrations	 than	 the	
described	platform,	at	levels	as	low	as	0.008	ng/mL	(Sharma	et	al.,	2016).	However,	
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they	 rely	 on	 expensive	 analysers	 and	 there	 is	 a	 requirement	 for	 centralised	
laboratories	 for	 performance	 of	 tests.	 The	 magneto-immunosensing	 strategy	
described	 in	 this	 chapter	 could	 be	 easily	 incorporated	 in	 the	 portable	 Handi-Lab	
instrument	 (Gwent	 Group	 Ltd.),	 allowing	 low-cost	 on-site	 testing	 in	 medical	
practitioners’	 surgeries.	 Future	 work	 will	 entail	 the	 evaluation	 of	 the	 analytical	
performance	 of	 this	 platform	 using	 prostate	 cancer	 serum	 samples	 to	 support	 its	
clinical	utility.	
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Chapter	6	
	
Overall	Conclusions	
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6.1	OVERALL	CONCLUSIONS		
The	research	presented	in	this	thesis	describes	the	development	and	application	of	
recombinant	 antibody	 fragments	 (scFv	 and	 scAb)	 for	 the	 detection	 of	 prostate	
cancer	biomarkers		(fPSA	and	HER2).		
	
Chapter	 3	 focuses	 on	 generation	 and	 characterisation	 of	 scFv	 antibodies	 to	 HER2.		
Firstly,	 RNA	 was	 extracted	 from	 avian	 immune	 donor	 spleen	 and	 cDNA	 was	
synthesised	 by	 reverse	 transcription.	 This	 cDNA	 was	 used	 as	 a	 template	 for	 the	
amplification	 of	 the	 antibody	 variable	 heavy	 and	 variable	 light	 chains,	which	were	
then	bound	together	for	the	formation	of	the	scFv	product.	Phage	display	screening	
allowed	the	selection	of	antibodies	against	HER2,	as	confirmed	by	polyclonal	phage	
ELISA.	 Individual	HER2-specific	clones	were	 identified	by	soluble	monoclonal	ELISA,	
and	clone	A4	was	selected	for	IMAC	purification	and	further	characterisation	by	SDS-
PAGE,	 Western	 Blotting	 and	 ELISA.	 The	 purified	 antibody	 was	 utilised	 for	 the	
development	of	a	 competitive	ELISA,	which	was	not	 sufficiently	 sensitive	 to	detect	
HER2	in	the	clinically	relevant	ranges.	In	an	attempt	to	improve	the	assay	sensitivity,	
fluorescence-based	detection	was	investigated,	but	it	did	not	show	any	comparative	
advantage	 over	 colorimetric	 methods.	 In	 the	 second	 part	 of	 this	 chapter,	 an	
electrochemical	 approach	 for	 detection	 of	 HER2	 at	 the	 desired	 levels	 (<15	 ng/mL)	
was	 explored.	 A	 scFv	 antibody	 was	 incorporated	 on	 a	 gold	 nanoparticle-based	
impedimetric	 biosensor	 in	 collaboration	 with	 the	 Jaypee	 Institute	 of	 Information	
Technology,	 India.	The	 resulting	biosensor	was	able	 to	detect	HER2	 from	serum	at	
concentrations	 as	 low	 as	 0.01	 ng/mL,	 representing	 a	 45-fold	 improvement,	
compared	with	 the	colorimetric	ELISA	and,	 thus,	overcoming	sensitivity	 issues.	The	
dynamic	range	of	the	biosensor	was	from	0.01	to	100	ng/mL	for	HER2.	Since	HER2	is	
overexpressed/amplified	 in	 a	 range	 of	 tumours	 (e.g.	 breast,	 prostate	 and	 lung	
cancer),	 the	 study	of	 serum	concentrations	of	 this	biomarker	could	provide	a	non-
invasive	method	to	elucidate	the	clinical	use	of	serum	HER2	detection	in	a	variety	of	
diseases.	The	developed	antibody	and	biosensor	could	potentially	provide	the	means	
to	do	this.		
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The	incorporation	of	the	generated	anti-HER2	scFv	antibody	and	an	anti-fPSA	scFv		in	
a	 ‘lab-on-a-disc’	device	was	demonstrated	 in	Chapter	4.	 In	a	collaboration	with	the	
Physiscs	group	in	DCU,	a	novel	centrifugal	microfluidic	CD-like	platform	was	designed	
for	the	simultaneous	detection	of	a	panel	of	biomarkers	from	blood.	Sandwich	and	
competitive	ELISAs	for	the	detection	of	fPSA	and	HER2,	respectively,	were	optimised	
to	 allow	 the	 incorporation	 in	 the	 microfluidic	 platform.	 Washing	 steps	 and	
incubation	 times	 were	 reduced.	 The	 disc	 design	 was	 then	 used,	 as	 a	 proof-of-
concept	 strategy	 for	multi-step	 immunoassay,	 to	 detect	 HER2	 and	 fPSA.	Once	 the	
blood	 sample	 and	 reagents	 were	 loaded	 in	 the	 CD	 cartridge,	 all	 the	 assays	 steps	
were	implemented	by	the	use	of	a	spindle	rotor	with	simple	variations	in	rotational	
speed.	 The	 novelty	 of	 this	 platform	 relies	 on	 its	 capacity	 to	 simultaneously	 run	
different	 assay	 formats	 (sandwich	 and	 competitive	 ELISA)	 for	 the	 detection	 of	
multiple	 biomarkers	 (HER2	 and	 fPSA,	 with	 the	 potential	 to	 incorporate	 a	 third	
biomarker	on	the	panel).	 	The	easy-to-use,	 low-cost	(discs	are	made	of	plastic)	and	
rapid	 result	 delivery,	 characteristic	 of	 this	 platform,	has	potential	 for	point-of-care	
diagnosis.	 Future	 work	 will	 focus	 on	 the	 study	 of	 new	 antibody	 immobilisation	
techniques	for	improved	assay	reproducibility,	and	the	development	of	a	hand-held	
rotor	incorporating	an	optical	reader	to	record	results.		
	
Chapter	 5	 described	 the	 use	 of	 an	 ‘in-house’	 generated	 recombinant	 antibody	 for	
measurement	of	 free	PSA	 (fPSA).	 In	 this	 case,	 scAb	antibodies	were	 conjugated	 to	
paramagnetic	 particles	 for	 the	 detection	 of	 fPSA	 by	 magneto-immunoassay.	
Immunomagnetic	 separation	 was	 combined	 with	 optical	 (magneto-ELISA)	 and	
electrochemical	(amperometric)	approaches,	in	collaboration	with	The	Gwent	Group	
Ltd.,	 UK.	 Following	 optimisation	 of	 assay	 conditions,	 a	 screen-printed	 electrode	
(SPE)-based	 electrochemical	 magneto-immunosensor	 was	 developed.	 Further	
optimisation	 resulted	 in	 the	 reduction	 of	 the	 number	 of	 assay	 steps,	 while	
maintaining	good	analytical	performance	in	which	fPSA	was	detectable	at	a	limit	of	
0.5	 ng/mL	 (with	 a	 dynamic	 range	 up	 to	 10	 ng/mL)	 in	 less	 than	 one	 hour.		
Furthermore,	 interference	from	potential	serum	interfering	proteins	was	evaluated	
and	little	or	no	effect	was	found	on	the	testing	precision.	Due	to	time	constrains	and	
company	changes,	fPSA	detection	from	serum	samples	could	not	be	evaluated.		
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In	 addition	 various	 collaborative	 projects	 with	 other	 members	 of	 the	 Prosense	
community	are	ongoing	with	reagents	developed	as	part	of	this	Ph.D.	The	group	in	
Switzerland	 is	 investigating	 the	 effect	 of	 the	 size	 of	 different	 antibody	 fragments	
coated	on	silicon	nanowires,	on	the	memristive	signal	registered	upon	ligand	binding	
(Carrara	et	al.,	2012).	The	Slovak	Academy	of	Sciences	 is	using	a	scAb	antibody	for	
PSA	 capture	 prior	 to	 glycoprofiling.	 Because	 changes	 in	 a	 glycan	 structure	 can	 be	
indicators	not	only	of	disease	presence,	but	also	of	its	stage,	glycan	analysis	may	lead	
to	 the	 development	 of	 more	 reliable	 diagnostic	 tests	 (Belicky	 and	 Tkac,	 2015).	
Furthermore,	INESC	and	University	Lisbon	Veterinary	School	hope	to	investigate	the	
application	 of	 the	 generated	 scFv	 for	 the	 detection	 of	 HER2	 in	 cats	 using	 a	
microfluidic	platform.		
	
In	 conclusion,	 this	work	 describes	 the	 production	 of	 novel	 	 antibody	 fragments	 to	
HER2	 (scFv)	 and	 PSA	 (scAb),	 their	 use	 	 for	 assay	 development,	 and	 recombinant	
antibody-based	 biosensor	 development.	 It	 is	 expected	 that	 the	 results	 presented	
here	will	be	translated	into	publications	that	will	help	to	elucidate	the	utility	of	HER2	
and	 free	 PSA,	 as	members	 of	 a	 panel	 of	 biomarkers	 for	 improved	prostate	 cancer	
detection.	
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APPENDIX	1		
Single-chain	fragment	variable	(scFv)	antibody	A4	sequencing	chromatogram:	
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Clone	A4	DNA	sequence	analysis	was	performed	using	ExPASy	translation	tool	and,	
according	to	Kabat	definition,	the	following	antibody	regions	were	identified:	
	
        L1	 	 	 	 	 L2	
AALTQPSSVSANPGETVKITCSGGNNYYGWYQQKSPGSAPVTVIYWNDKRPSNIPSRFSGS	
	 	 	 	 										L3	 	 	 	 Linker	
ASGSTGTLTITGVQADDEAVYYCGSYGSSTNSGIFGAGTTLTVLGQSSRSSGGGGSSGGGGSAV	
	 	 	 	 	 H1	 	 	 	 	 							H2	
TLDESGGGLQTPGGALSLVCKASGFNFRDYAMetVWVRQAPGKGLAWVGVISSSIDGETVYGA	
	 	 	 	 	 	 	 							H3	
AVDGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKSAVTWCVGGCYGGLIDTWGHGTEVIVS	
	 								6X	His-tag												HA-tag	
STSGQAGQHHHHHHGAYPYDVPDYASX 
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